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GENERAL INTRODUCTION AND OUTLINE
Adapted from:
• Sympathetic nervous system control of triglyceride metabolism: 
novel concepts derived from recent studies. J Lipid Res (2014) 55:180-9
• Brown fat as a novel target to attenuate hyperlipidemia and atherosclerosis. 
Circ Res (2015) in press
• Regulation of brown fat by AMP-activated protein kinase. Trends Mol Med (2015) 
in press
• Hypothalamic regulation of brown fat activity. Trends Endocrinol Metab (2015) 
in press
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Cardiovascular disease (CVD) is currently the leading cause of death worldwide (1). 
While mortality rates are declining in high-income countries, CVD morbidity and 
mortality rapidly increase in low- and middle-income countries. Although CVD usually 
affects the elderly, the antecedents of CVD including atherosclerosis, begin in early 
life. CVD may be prevented by behavioral adjustments including exercise, healthy 
eating and avoidance of smoking, thereby reducing the development of dyslipidemia 
and inflammation, the two main risk factors for atherosclerotic lesion development. 
Current pharmaceutical approaches in the treatment of atherosclerosis mainly aim 
at correcting dyslipidemia through reduction of plasma cholesterol levels. However, 
although statins effectively reduce low-density lipoprotein-cholesterol (LDL-C), 
only about 25-30% of all cardiovascular events are prevented by this treatment (2). 
Accumulating evidence indicates a prominent role of the autonomic nervous 
system (ANS) in the regulation of lipid metabolism as well as inflammation, but the 
consequences for atherosclerosis development and the potential for novel treatment 
strategies are still unclear (Figure 1).
Autonomic nervous system control of homeostatic activity
From reports describing the effects of lesioning discrete brain nuclei, through to 
studies of genetically engineered animal models and human genetic disorders, 
the primacy of the central nervous system (CNS) in the control and coordination 
of homeostasis is clear. The hypothalamus in particular is critical in sensing and 
inammation
dyslipidemia
Figure 1 – Dysregulation of the inflammatory response and lipid metabolism by the 
autonomic nervous system may result in atherosclerotic lesion development.






















Figure 2 – Hypothalamic projection onto the autonomic nervous system. See text for details. 
In purple sympathetic pathways, in blue parasympathetic pathways. Ach, acetyl choline; ARC, 
arcuate nucleus; DMV, dorsal motor nucleus of the vagus; IML intermediolateral column of the 
thoracic spinal cord; NE, norepinephrine; PVN, paraventricular nucleus; SCN, suprachiasmatic 
nucleus.
integrating signals from the periphery and effecting appropriate physiological 
changes to maintain homeostasis. Classically, this has been viewed in terms of the 
neuroendocrine control system resulting from processing of hypothalamic signals 
projected to the pituitary. More recently, the hypothalamic control over the ANS 
has been increasingly recognized as a potent modulator of homeostatic activity in 
peripheral tissues.
Separate populations of pre-autonomic nerve fi bers residing from hypothalamic 
nuclei relay to either parasympathetic or sympathetic nuclei in the brain stem and 
spinal cord, respectively (Figure 2). The efferent parasympathetic signal is conveyed 
via preganglionic cells in the dorsal motor nucleus of the vagus (DMV). The DMV 
is directly connected by the vagal nerve to ganglion cells, without involvement 
of the spinal cord. Postganglionic parasympathetic nerves project on target 
organs and use acetylcholine (ACh) as their main neurotransmitter, which acts on 
muscarinic and nicotinic cholinergic receptors. On the other hand, sympathetic 
nerve fi bers arise from the intermediolateral (IML) column of the thoracic spinal 
cord and project onto the chain of sympathetic ganglia located just outside of the 
spinal cord. In turn, sympathetic ganglia give rise to postsynaptic sympathetic 
nerve fi bers that subsequently innervate the target organ. In general, sympathetic 
Kooijman.indd   10 30-9-2015   10:53:47
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neurons transmit their signal by releasing norepinephrine (NE) from their nerve 
endings. NE subsequently binds to adrenergic receptors located at the postsynaptic 
membrane on the target organ. At least nine subtypes of adrenergic receptors, 
divided into three major classes, have been identified: α1(A/B/D) -adrenergic receptors, 
α2(A/B/C)-adrenergic receptors, and β(1/2/3)-adrenergic receptors.
In addition to the hypothalamic control of both the sympathetic and parasympathetic 
nervous system, the ANS regulation of homeostatic activity involves certain reflexes, 
including the cholinergic anti-inflammatory reflex. Changes in homeostasis, e.g. the 
release of pro-inflammatory cytokines, are sensed by afferent peripheral nerve 
fibers that project directly onto efferent nerve fibers within the spinal cord or DMV, 
resulting in direct (de-)activation of efferent nerve signaling, without involvement of 
the hypothalamus or other brain regions.
Hypothalamic control of energy homeostasis
Before the ANS regulation of lipid metabolism can be discussed in more detail, I first 
have to elaborate on the role of the hypothalamus in energy homeostasis, which is 
a balance between energy intake and energy expenditure. It should be noted that 
several hypothalamic nuclei control both energy intake as well as peripheral energy 
expenditure, indicating the close interplay between these processes.
The arcuate nucleus (ARC) of the hypothalamus, in particular, plays an important 
role in energy metabolism. Within the ARC, two neuronal populations, cocaine- 
and amphetamine-regulated transcript (CART)/pro-opiomelanocortin (POMC)-
expressing neurons and neuropeptide Y (NPY)/Agouti-related protein (AgRP)-
expressing neurons, oppositely regulate energy balance (3). Activation of CART/POMC 
neurons leads to the production of α-melanocyte-stimulating hormone (α-MSH), 
which in turn stimulates the melanocortin (MC) receptors within the paraventricular 
nucleus (PVN) to promote satiety and induce a catabolic state of the body. In contrast, 
activation of NPY/AgRP neurons promotes food intake and an anabolic state, partly 
because AgRP acts as an endogenous antagonist for the melanocortin receptors and 
hereby directly inhibits the actions of CART/POMC-expressing neurons. Mutations 
and polymorphism within genes involved in this central melanocortin system are 
associated with the development of obesity and related metabolic disorders (4). 
Interestingly, variants in and near the melanocortin 4 receptor gene are not only 
associated with obesity, but also with reduced energy expenditure, suggesting that 
the melanocortin system directly regulates energy metabolism in peripheral organs. 
However, the exact mechanism remains unknown.
A second example and probably underappreciated regulator of energy balance 
is the central biological clock, located in the suprachiasmatic nucleus (SCN), 
which orchestrates diurnal and seasonal rhythms. Neuronal firing within the SCN 
is synchronized by light exposure, resulting in a high electrical activity during 
Kooijman.indd   11 30-9-2015   10:53:47
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the day and low activity during the night. The SCN subsequently signals to other 
hypothalamic nuclei and peripheral organs via regulation of hormonal output, e.g. 
rhythmic secretion of pituitary hormones and melatonin output, and via the ANS (5), 
together resulting in diurnal rhythms in metabolic processes. Disturbances in 
circadian rhythmicity, e.g. by shift-work or light pollution, are associated with 
obesity and related disorders including cancer and CVD (6). Causality in many of 
these associations still remain to be confirmed in animal studies or randomized-
controlled clinical trials.
Hypothalamic control of lipid metabolism via the autonomic nervous 
system
Energy balance comprises energy intake and expenditure of mainly glucose and 
lipids (triglycerides; TG). The role of the ANS in the regulation of glucose metabolism 
has been firmly established (reviewed in (7)), however, considerably fewer studies 
have focused on its role in TG metabolism.
Important players in TG metabolism include the liver and intestines (production), 
white adipose tissue (WAT) (storage), heart and skeletal muscle (combustion to 
generate ATP), and brown adipose tissue (BAT) (combustion towards heat), the 
collective action of which determine plasma TG levels. While all of these organs are 
innervated by sympathetic nerve fibers (8), the role for parasympathetic nerves in 
WAT is less clear (9) and even appear to be absent in BAT (10).
Hepatic sympathetic innervation stimulates very low-density lipoprotein (VLDL)-
triglyceride (TG) production (reviewed in (11)), while sympathetic denervation reduces 
VLDL-TG secretion (12). This reduction in VLDL-TG secretion upon sympathetic 
denervation was only observed in fasted rats, a situation in which lipids become the 
key substrate for energy metabolism. Conversely, neuropeptides that are increased 
upon positive energy balance reduce hepatic VLDL-TG production and hepatic 
parasympathetic denervation in obese Zucker rats results in elevated plasma 
cholesterol levels (reviewed in (13)).
Just as in liver, sympathetic innervation of WAT results in secretion of lipids 
to be used as substrate for energy metabolism. β2-adrenergic signaling induces 
phosphorylation of adipose tissue TG lipase (ATGL), hormone-sensitive lipase (HSL), 
and perilipins, ultimately resulting in lipolysis of stored TG and subsequent secretion 
of fatty acids into the circulation (reviewed in (14)). Long-term adrenergic stimulation 
of WAT additionally results in transdifferentiation of white adipocytes into beige/
bright adipocytes (15).
In general, increased sympathetic outflow toward BAT (e.g., following a cold 
stimulus) results in increased clearance and combustion of TG into heat (16). 
As BAT is an important topic of this thesis, I will provide a detailed description of 
BAT physiology. Upon sympathetic nerve fiber activity, NE is released and binds to 



































































Figure 3 – Sympathetic innervation of brown adipose tissue and subsequent combustion of 
TG into heat. See text for details.
β-adrenergic receptors on brown adipocytes (Figure 3; step 1). Of the three subtypes 
of β-adrenergic receptors, the β3-adrenergic receptor is the most signifi cant 
in mature brown adipocytes from at least rodents. Binding of norepinephrine 
(i.e. noradrenalin) to the β3-adrenergic receptor results in activation of its coupled 
stimulatory G-protein, after which adenylyl cyclase stimulates the formation of 
cyclic adenosine monophosphate (cAMP). cAMP activates protein kinase A (PKA), 
resulting in two important downstream effects (Figure 3; step 2). First, PKA 
stimulates phosphorylation of transcription factors that enhance expression and 
synthesis of uncoupling protein-1 (UCP-1) (Figure 3; step 3). Furthermore, PKA 
phosphorylates and activates intracellular HSL, resulting in increased intracellular 
lipolysis and, consequently, an increased fl ux of FAs toward the m itochondria to be 
combusted (Figure 3; step 4). In addition, FAs may bind to a hydrophobic binding 
pocket on the UCP-1 protein, resulting in its conformational change. This results 
in uncoupling between the respiratory chain and ATP synthase by proton leakage 
from the mitochondrial innermembrane space into the matrix leading to heat 
production instead of ATP (Figure 3; step 5). Finally, intracellular lipid stores need to 
be replenished by the uptake of glucose, FAs and triglyceride (TG)-derived FAs from 
plasma (Figure 3; step 6).
Kooijman.indd   13 30-9-2015   10:53:53
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Because of its ability to combust large amounts of TG into heat, BAT is an appealing 
target for treatment of obesity, dyslipidemia and related disorders. Cold exposure 
and β3-adrenergic receptor agonists were found to activate human BAT resulting 
in lower plasma TG and increased energy expenditure (17,18). Unfortunately, to my 
knowledge, until now no sympathomimetic drugs have been developed that stimulate 
human BAT without marked effects on the cardiovascular system, indicating the 
need for alternative pharmaceutical targets.
Control of inflammatory responses by reflexes of the autonomic 
nervous system
The hypothalamus-pituitary-adrenal (HPA) axis, which controls glucocorticoid 
release, is probably the most well-established neuroimmunomodulatory pathway. 
While the systemic control exerted by the HPA axis takes place over hours, 
inflammatory control by the ANS can control peripheral inflammation more rapidly 
and directly. Stimulation of peripheral C-afferent fibers, upon acute peripheral 
inflammation, releases excitatory amino acids (e.g. glutamate) in the spinal cord, 
which then binds to N-methyl-D-aspartate (NMDA) receptors to decrease adenosine 
release by efferent fibers (reviewed in (19)). Adenosine has an anti-inflammatory 
effect in the periphery by binding to A2A-receptors on neutrophils and to A1-receptors 
on nerve fibers within the spinal cord that inhibit NMDA receptor activation (20). Thus, 
acute inflammation results in further amplification of pro-inflammatory responses 
via the so-called dorsal root reflexes (Figure 4; item 1).
Subsequently, cytokines released at the inflammatory site may activate afferent 
fibers of the vagus nerve, resulting in an anti-inflammatory reflex. The afferent arm 
of the cholinergic reflex routes through the DMV to finally stimulate the release of 
ACh, the main neurotransmitter released by terminal vagal fibers, which activates 
nicotinic receptors composed of the α7 subunit on immune cells (reviewed in (21)). 
Interruption of this homeostatic mechanism in vagotomized animals aggravates 
inflammation (22). In animals with an intact vagal nerve, this reflex operates to reduce 
the release of pro-inflammatory cytokines in the periphery, thereby contributing to 
the homeostasis of the system by reducing inflammation (Figure 4; item 2).
The sympathetic nervous system (SNS) also exerts complex control on 
inflammation. The sympathetic neurotransmitter NE directly influences activation 
of CD4+  T cells during initial stages of inflammation (23). In later phases, the net 
effect of the SNS is anti-inflammatory and can be enhanced by the β-adrenergic 
agonists (24).
The development of atherosclerosis is considered as a chronic low-grade 
inflammatory disease. In particular serum concentrations of pro-inflammatory 
cytokines IL-1β, TNFα and IL-6 have been proposed as predictors for future 
cardiovascular events (reviewed in (25)). Large clinical trials are now underway with 






















Figure 4 – Autonomic nervous system regulation of infl ammatory responses; dorsal root 
refl ex (1) and cholinergic anti-infl ammatory refl ex (2). See text for details.
agents that lead to reduced infl ammation, investigating the effect on cardiovascular 
events as clinical end-point. Despite the clear primacy and big attention for the 
infl ammatory status during atherosclerotic lesion development and cardiovascular 
events, little is known about the consequences of interfering with the infl ammatory 
refl exes of the autonomic nervous system.
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Interplay between lipid metabolism and inflammation; potential 
consequences for atherosclerosis development
Dyslipidemia is often accompanied by low-grade systemic inflammation, which is 
characterized by increased presence of cytokines and other markers of inflammation 
in the circulation. Cholesterol, fatty acids and modified lipids can directly activate 
inflammatory pathways. In addition, circulating (modified) lipoproteins modulate the 
activity of leukocytes. Vice versa, pro-inflammatory signaling (i.e. cytokines) in pre-
clinical models directly affects lipid metabolism. Whereas the main lipid-lowering 
drugs including statins, fibrates and niacin all have potent anti-inflammatory 
actions, the lipid-modulating actions of anti-inflammatory agents appear to be less 
straightforward (reviewed in (26)).
Another compound with a dual mode of action is adenosine. As mentioned before 
adenosine has an anti-inflammatory effect in the periphery by binding to A2A-receptors 
on neutrophils. Additionally, adenosine is released upon sympathetic innervation 
of BAT and WAT, resulting in activation of brown adipocytes and browning of white 
adipocytes, respectively. Treatment of mice with A2A agonists prevents diet-induced 
obesity (DIO) and improves glucose tolerance (27). Yet, the possible beneficial effects 
of A2A agonists on CVD remain to be determined.
Interactions between lipid metabolism and inflammatory pathways do have 
direct consequences for the development of atherosclerosis as seen for example 
with salicylates. Salicylates belong to the NSAIDs (non-steroidal anti-inflammatory 
drugs) and are frequently used for prevention and treatment CVD, due to their 
anti-inflammatory activity by inhibiting the pro-inflammatory transcription factor 
NF-κB function through activation of 5’ AMP-activated protein kinase (AMPK) (28). 
Interestingly, besides its role in the control of inflammation, AMPK is crucial in 
maintaining cellular energy homeostasis. The net effect of AMPK activation is uptake 
and combustion of nutrients to increase cellular energy availability. Controversially, 
activation of AMPK by e.g. metformin (29) or salsalate (30) in BAT also enhances 
uncoupled respiration, resulting in a loss of energy. Taken together, salicylate 
drugs may potentiate a dual action in the treatment of both type II diabetes and 
atherosclerosis as they not only reduce inflammation (31), but also improve glucose 
tolerance, whole-body energy expenditure (32) and induce an anti-atherogenic 
lipoprotein profile (31).
Outline of this thesis
The aim of the present thesis is to gain more insight in the ANS regulation of lipid 
metabolism and inflammation, and the potential consequences for the development 
of atherosclerosis. Part I of this thesis focuses on regulation of lipid metabolism by 
the ANS, with special attention for BAT as an emerging pharmacological target for 
therapy.
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Since the melanocortin system has been linked to energy expenditure in addition 
to the regulation of food intake, and the underlying mechanism is as yet unknown, in 
Chapter 2, the direct effects of inhibition of the central melanocortin system on lipid 
metabolism were evaluated. Next we determined in Chapter 3 the potential beneficial 
effects of activating the central melanocortin system by intracerebroventricular 
(ICV) infusion of glucagon-like peptide-1 (GLP-1) on the activation of BAT, restoration 
of dyslipidemia and the reduction of DIO.
Interestingly, many genes involved in lipid metabolism and inflammation are 
expressed in a circadian manner. Disturbances in circadian rhythmicity by e.g. light 
pollution or shiftwork are associated with human obesity and CVD. The aim of the 
study described in Chapter 4 was to specifically determine the potentially harming 
effects of prolonged daily light exposure, as perceived by the SCN, on lipid metabolism 
and adiposity in mice. Subsequently, in Chapter 5, we determined the daily rhythm in 
lipid metabolism and the differences that may occur between seasons considering 
the change in daily light exposure.
The endocannabinoid system is a group of neuromodulatory lipids and their 
receptors in the brain that are involved in a variety of metabolic processes including 
appetite and energy expenditure. Interestingly, the cannabinoid receptors are not 
only expressed in CNS, but also on peripheral tissues, including BAT. In Chapter 6, 
we determined the effects of cannabinoid 1 receptor (CB1R) blockade on brown fat 
activation, reversal of dyslipidemia and DIO. Additionally, we discriminated between 
direct peripheral and indirect central effects of CB1R antagonism.
Part II of this thesis describes studies on the regulation of inflammation by the 
ANS, with focus on the anti-inflammatory reflex. During this reflex, binding of Ach to 
α7nAChR and subsequent intracellular signaling results in transcriptional repression 
of pro-inflammatory genes. In Chapter 7, we investigated the consequences of 
hematopoietic α7nAChR deficiency on the development of inflammation, platelet 
reactivity and atherosclerosis. Since the nerves involved in the anti-inflammatory 
reflex mainly project towards the spleen, in Chapter 8, we investigated the effects 
of selective parasympathetic and sympathetic denervation of the spleen on 
inflammation and atherosclerotic plaque development.
Finally, the results from these studies and their therapeutic implications are 
discussed in Chapter 9.
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INHIBITION OF THE CENTRAL 
MELANOCORTIN SYSTEM DECREASES 
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The melanocortin system is an important regulator of energy balance and MC4R 
deficiency is the most common monogenic cause of obesity. We investigated whether 
the relationship between melanocortin system activity and energy expenditure 
is mediated by brown adipose tissue (BAT) activity. Therefore, female APOE*3-
Leiden.CETP transgenic mice were fed a Western-type diet for 4 weeks and infused 
intracerebroventricularly with the MC3/4R antagonist SHU9119 or vehicle for 
2  weeks. SHU9119 increased food intake (+30%), body fat (+50%) and decreased 
energy expenditure by reduction in fat oxidation (-42%). In addition, SHU9119 
impaired the uptake of VLDL-TG by BAT. In line with this, SHU9119 decreased 
uncoupling protein-1 levels in BAT (-60%) and induced large intracellular lipid 
droplets, indicative of severely disturbed BAT activity. Finally, SHU9119-treated mice 
pair-fed to the vehicle-treated group still exhibited these effects, indicating that 
MC4R inhibition impairs BAT activity independent of food intake. These effects were 
not specific to the APOE*3-Leiden.CETP background as SHU9119 also inhibited BAT 
activity in wild-type mice We conclude that inhibition of central MC3/4R signaling 
impairs BAT function, which is accompanied by reduced energy expenditure thereby 
promoting adiposity. We anticipate that activation of MC4R is a promising strategy to 
combat obesity by increasing BAT activity.




The hypothalamus is important in the regulation of energy balance. Activation 
of pro-opiomelanocortin neurons, e.g. by insulin or leptin, induces secretion of 
α-melanocyte-stimulating hormone, which in turn stimulates melanocortin -3 and 
-4 receptors (MC3R/MC4R) within the paraventricular nucleus to cause a negative 
energy balance (1). Accordingly, activation of central MC4R in rodent models results 
in anorexia and weight loss (2), whereas blockade or targeted gene disruption 
induces hyperphagia and obesity, even on regular chow diet (3,4). Loss-of-function 
mutations in MC4R are the most common monogenic form of obesity in humans 
and are associated with severe obesity in childhood (5). In addition, recent meta-
analyses of genome-wide association studies identified common variants near 
MC4R to influence fat mass, obesity and obesity risk (6,7). These observations 
support an essential role for the melanocortin system in the regulation of 
energy homeostasis across mammalian species.
In addition to the effects of the melanocortin system on food intake, this system also 
affects energy balance via other pathways. This notion is supported by the observation 
that pharmacological inhibition of central MC4R by intracerebroventricular (i.c.v.) 
administration of the synthetic MC3/4R antagonist SHU9119 still increases body fat 
in pair-fed rats (8). Moreover, the peripheral effects of the central melanocortin 
system involves alterations in the activity of the sympathetic nervous system (SNS), 
as i.c.v. administration of the MC3/4R agonist MTII dose-dependently increases 
renal sympathetic activity in mice (9). Furthermore, ablation of neurons that produce 
agouti-related protein (AgRP), the endogenous antagonist for MC4R, in mice changes 
autonomic output into metabolic organs, accompanied by a changed respiratory 
exchange ratio (RER) indicating altered nutrient combustion (10). Additionally, 
chronic i.c.v. SHU9119 treatment in rats increases the RER (8), indicative of reduced 
lipid utilization. Interestingly, variants near and in the MC4R gene in humans are 
not only associated with an increased RER (8), but also with reduced total energy 
expenditure (EE) (11,12), underscoring the importance of the melanocortin system in 
the regulation of EE.
A recently discovered and highly important contributor to EE is brown adipose 
tissue (BAT). BAT contributes to EE by combusting high amounts of TG into heat, 
a process mediated by uncoupling protein-1 (UCP-1) (13). Interestingly, MC4R 
expressing neurons project onto BAT (14), indicating that BAT may mediate the 
association between MC4R signaling and EE. Therefore, the aim of this study was 
to evaluate the role of the melanocortin system in BAT activity. For this purpose, 
we inhibited melanocortin receptor signaling using the MC3/4R antagonist SHU9119 
in APOE*3-Leiden.CETP transgenic mice, a well-established model for human-like 
lipoprotein metabolism.





Female APOE*3-Leiden.CETP mice on a C57Bl/6J background (15) were bred at our 
institutional animal facility and housed under standard conditions with a 12-12 h 
light-dark cycle with ad libitum access to food and water unless stated otherwise. 
From 12-22 weeks after birth, mice were fed a Western-type diet containing 15% 
(w/w) cacao butter and 0.1% cholesterol (AB Diets, Woerden, The Netherlands) for 
the duration of the study, to increase plasma levels of apoB-containing lipoproteins 
thereby inducing a more human-like lipoprotein profile. After 4 weeks of run-in diet, 
mice were randomized into groups that received i.c.v. administration of artificial 
cerebrospinal fluid (vehicle) or SHU9119 (5 nmol/day; Bachem, Bubendorf, Germany) 
in vehicle during 14-17 days. Since SHU9119 induces hyperphagia (3), the effect of 
SHU9119 on BAT activity independent of food intake was also investigated by using 
an additional SHU9119-treated group that was pair-fed (SHU9119-pf) to the vehicle-
treated group. To achieve pair-feeding, food intake of the ad libitum fed mice was 
monitored daily and pair-fed mice received surgery one day behind the control mice. 
The pair-feeding regimen consisted of giving the mice the average daily consumed 
food amount by the control mice, just before onset of darkness. To investigate the 
effect of SHU9119 independent of dyslipidemia induced by Western-type feeding of 
APOE*3-Leiden.CETP mice, a second experiment was performed using 15-week old 
male wild-type C57Bl/6J mice (Charles River, USA) that were housed under similar 
conditions, while being fed a regular chow diet. After 2 weeks of acclimatization, 
mice  were randomized into three groups receiving, e.g. vehicle, SHU9119 and 
SHU9119-pf for 15 days. All animal experiments were approved by the institutional 
ethics committee on animal care and experimentation at Leiden University Medical 
Center.
Surgical procedure
For continuous i.c.v. administration of SHU9119 vs. vehicle, mice were sedated 
using a mixture of dexmedetomidine (0.5 mg/kg), midazolam (5 mg/kg) and fentanyl 
(0.05 mg/kg), and cannulas (Brain Infusion Kit 3, ALZET Cupertino, CA, USA) were 
stereotactically placed in the left lateral ventricle of the brain (coordinates: -0.45 mm 
anteroposterior, -1.00 mm lateral and 2.50 mm dorsoventral from bregma). Osmotic 
mini-pumps (Model 1004, Alzet, CA) attached to the cannula via a catheter were 
implanted subcutaneously on the back slightly posterior to the scapulae. The skin 
was sutured and the sedation was antagonized with a mixture of antiparnezol 
(2.5 mg/kg), flumanezil (0.5 mg/kg) and naloxon (1.2 mg/kg). Buprenorphine (0.9 µg) 
was used as pain killer. After the surgery, mice were housed individually and food 
intake and body weight were monitored on a daily basis. By filling the catheters with 
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vehicle, mice were allowed to recover for four days before actually receiving the 
assigned treatment for 17 days (collection of organs or VLDL production) or 14 days 
(indirect calorimetry and VLDL clearance).
Body composition
After 17 days of treatment, body composition (lean mass and fat mass) was 
determined in conscious mice using an EchoMRI-100 (EchoMRI, Houston, Texas).
Indirect calorimetry
During the first 5 days of treatment, oxygen uptake (V˙ O2), carbon dioxide production 
(V˙ CO2) and physical activity were measured in fully automatic metabolic cages 
(LabMaster System, TSE Systems, Bad Homburg, Germany). The average RER, EE, 
carbohydrate and fat oxidation rates were calculated as described previously (16).
Liver lipid staining and content
Liver samples were perfused with PBS, collected, snap frozen and stored at -80°C. 
Sections of 10 µm were cut, fixed in 4% paraformaldehyde and stained with Oil-red-O 
and Mayer’s hematoxylin. Lipids were extracted according to a modified protocol 
from Bligh and Dyer (17). In short, small liver pieces were homogenized in ice-cold 
methanol (10 µL/mg tissue). 1.8 mL of CH3OH: CHCl3 (3:1, vol/vol) was added to 45 μL 
of homogenate. After vigorous mixing and centrifugation, the supernatant was dried 
and suspended in 2% Triton X-100. Concentrations of hepatic TG, total cholesterol (TC) 
and phospholipids (PL) were measured using commercially available enzymatic kits 
for TG (11488872, Roche Diagnostics, Germany), TC (11489232, Roche Diagnostics, 
Mannheim, Germany) and PL (3009, Instruchemie, Delfzijl, the Netherlands). Liver 
lipids were expressed per milligram of protein, which was determined using the BCA 
protein assay kit (Thermo Scientific, Rockford, IL, USA).
VLDL production
After 17 days of treatment, after 4 h of fasting (from 8.00 h to 12.00 h), the VLDL 
production rate was assessed. Mice were sedated using a mixture of ventranquil 
(6.25 mg/kg), dormicum (6.25 mg/kg), and fentanyl (0.31 mg/kg). Subsequently, 
mice were injected intravenously (i.v.) with 100 µL PBS containing 150 µCi Tran35S 
label to measure de novo apoB synthesis and blood samples were taken via tail 
bleeding (t=0). 30 min after injection of the Tran35S label, the mice received an i.v. 
injection of 500 mg of tyloxapol (Triton WR-1339, Sigma Aldrich, Germany) per kg 
body weight as 10% (w/w) solution in PBS, to block VLDL-TG clearance by lipoprotein 
lipase (LPL)-mediated TG hydrolysis. Additional blood samples were taken at t=15, 
30, 60 and 90  min after tyloxapol injection and used for determination of plasma 
TG concentration. After 120 min, the mice were exsanguinated via the retro-orbital 
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plexus. VLDL was isolated from serum after density gradient ultracentrifugation 
and counted for incorporated 35S-activity. VLDL particle size was determined using 
a Zetasizer (Malvern Instruments, Malvern, UK) and VLDL lipid composition was 
determined as described above.
VLDL clearance experiment
Glycerol tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) double-labeled 
VLDL-like emulsion particles (80 nm) were prepared as previously described (18). 
After 14 days of i.c.v. SHU9119 or vehicle treatment, mice were fasted for 4 h (from 
8.00 h to 12.00 h) and injected i.v. with the radiolabeled emulsion particles (1.0 mg TG 
in 200 µL PBS) via the tail vein. At time points t=2, 5, 10 and 15 min after injection, 
blood was taken from the tail vein to determine the serum decay of both radiolabels. 
Immediately after the last blood withdrawal, mice were euthanized by cervical 
dislocation and perfused with ice-cold PBS for 5 min. Organs were harvested, 
weighed, and the uptake of 3H and 14C radioactivity was determined.
BAT histology
After 17 days of SHU9119 treatment, a part of interscapular BAT (iBAT) was fixed in 
4% paraformaldehyde in PBS (pH 7.4) for 24 h, dehydrated and embedded in paraffin. 
10 µm sections were cut, rehydrated and stained with Mayer’s hematoxylin and eosin. 
To determine sympathetic activation of BAT a tyrosine hydroxylase (TH) staining was 
performed. To this end, sections were rehydrated and incubated 15 min with 10 mM 
citrate buffer (pH 6.0) at 120°C for antigen retrieval. Sections were cooled on ice, 
washed in PBS and PBS 0.1% Tween and incubated with 5% BSA/PBS for 60 min 
at room temperature. This was followed by overnight incubation with 1:2000 anti-
TH (Abcam) primary antibody at 4°C. Next, sections were incubation with secondary 
antibody (anti-rabbit antibody, DAKO enVision TM) and stained with Nova Red. Nuclei 
were counterstained with Mayer’s haematoxylin and sections were mounted on 
glass slides. Percentage of area positive for TH staining was quantified using Image 
J software.
BAT Western blot analysis
Another part of BAT was snap frozen and stored at -80°C. These BAT samples were 
homogenized in RIPA buffer, centrifuged and protein concentration was determined 
using the BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Samples were 
diluted and denatured for 5 min at 95°C after adding Laemmli Sample Buffer (1:1, 
vol/vol; Serva, Heidelberg, Germany). Proteins within homogenates (1 μg protein for 
UCP1 and 15 μg for p-CREB) were separated on a 10% SDS-page gel and subsequently 
transferred onto blotting membrane. The blotting membranes were then washed 
with PBS+0.1% Tween (PBS+T), blocked with 5% milk powder in PBS+T and incubated 
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O/N at 4°C with the first antibody (anti-UCP-1 rabbit polyclonal; Ab U6382, Sigma 
Aldrich or anti-p-CREB; Cell). After washing (PBS-T) the second antibody (anti-
rabbit IgG HRP conjugate; 1:5,000; Promega, Madison, WI, USA) was added. After 
another wash with PBS-T and PBS, SuperSignal Western Blot Enhancer  (Thermo 
Scientific, Rockford, IL, USA) was added to the blotting membranes after which they 
were analyzed with Bio-Rad Quantity One.
BAT gene expression analysis
A part of iBAT from wild-type C57Bl/6J mice treated with vehicle or SHU9119, 
was snap frozen and stored at -80°C for gene expression analysis and protein 
analysis (see above). Total RNA was isolated using TriPure (Roche) according to 
the manufacturer’s instructions. 1 μg of total RNA was reverse-transcribed using 
M-MLV reverse transcriptase (Promega, Madison, WI, USA). Real-time PCR was 
carried out on a CFX96 PCR machine (Bio-Rad) using IQ SYBR-Green Supermix (Bio-
Rad). Melt curve analysis was included to assure a single PCR product was formed. 
Expression levels were normalized using β2-microglobulin as housekeeping gene.
Body temperature
In four wild-type C57Bl/6J mice per group, temperature transponders (IPTT-300, 
BMDS) were implanted subcutaneously in the clavicular region. Every three days 
body temperature was recorded using a compatible Smart Probe (BMDS).
Statistical analysis
Differences between groups were determined using independent sample T-tests 
for normally distributed data and Mann-Whitney U tests for non-normal distributed 
data. Serum decay in the VLDL clearance experiment was analyzed using repeated 
measurements ANOVA with a Tukey’s Post-Hoc test. Probability values less than 
0.05 were considered statistically significant. Data are presented as means ± SEM.
Results
SHU9119 increases body weight and fat mass independent of food 
intake
APOE*3-Leiden.CETP mice were treated i.c.v. with SHU9119 or vehicle for 17 days. 
In ad libitum fed mice, throughout the treatment period, SHU9119 consistently 
increased food intake (on average 4.04±0.21 vs. 3.18±0.13 g/day, p<0.01) (Figure 1A), 
concomitantly with an increased body weight gain (after 17 days: 6.68±0.58 vs. 
0.70±0.14 g, p<0.001). Obviously, SHU9119 also increased body weight in pair-fed 
mice when compared to vehicle-treated mice (4.14±0.45 vs. 0.70±0.14 g, p<0.01) 
(Figure 1B) indicating that the SHU9119-induced weight gain is independent of food 
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Figure 1 – SHU9119 increases body weight and fat mass independent of food intake. APOE*3-
Leiden.CETP mice were treated intracerebroventricularly with vehicle (n=21) or SHU9119 
(5 nmol/day) while being fed ad libitum (n=21) or being pair-fed (pf) to the vehicle-treated group 
(n=22). Food intake (A) and body weight gain (B) were monitored on a daily basis. After 17 days 
of treatment, lean and fat mass were measured in a random selection of the mice (n=3-4 per 
group) using EchoMRI (C). Part of the mice were used for the collection of organs, and weight 
of gonadal white adipose tissue was determined (n=10-11 per group) (D). Values are means 
± SEM. *p<0.05, **p<0.01, ***p<0.001 compared to control.
intake. Determination of body composition using EchoMRI revealed that SHU9119 
increased body weight under both ad libitum feeding and pair-fed conditions due to a 
selective increase in fat mass (10.6±1.2 and 9.6±1.0 vs. 4.9±1.1 g, p<0.05) (Figure 1C). 
The SHU9119-induced increase in body weight and fat mass was accompanied by an 
increase in gonadal white adipose tissue (gWAT) weight, both in ad libitum feeding 
conditions (+124%; 1.32±0.13 vs. 0.59±0.12 g, p<0.001) and pair-fed conditions (+124%; 
1.32±0.16 vs. 0.59±0.12 g, p<0.01) (Figure 1D). SHU9119 increased plasma TG levels in 
pair-fed mice, while it decreased total cholesterol levels in both ad libitum and pair-
fed mice (Supplemental Figure 1).
In a first experiment, we did observe a large increase in plasma TG levels upon 
17 days of SHU9119 treatment under ad libitum conditions (Supplemental Figure 1A), 
which would be consistent with reduced uptake of TG by BAT. However, in a subsequent 
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study the SHU9119-induced increase in plasma TG only reached significance under 
pair-fed conditions (Supplemental Figure 1B).
SHU9119 reduces whole body fat oxidation independent of food 
intake
Since SHU9119 induced fat accumulation independent of food intake, we reasoned 
that SHU9119 likely affected EE. Therefore, we next assessed the effect of SHU9119 
on energy metabolism. Fully automated metabolic cages were used during the first 
5 days of treatment in order to prevent a potential confounding effect of differences 
in body weight. Indeed, in ad libitum fed mice, SHU9119 decreased EE (-10%; 23.7±0.3 
vs. 26.4±0.2 cal/h/g fat-free mass [FFM], p<0.05) (Figure 2A) and increased RER 
(0.92±0.01 vs. 0.88±0.00 p<0.01) (Figure 2B). These effects were not caused by an 
effect on carbohydrate oxidation (Figure 2C) but rather by a large reduction in fat 
oxidation (-43%; 5.1±1.0 vs. 8.9±0.3 cal/h/g FFM, p<0.001) (Figure 2D). SHU9119 
also reduced activity of the animals (-46%; 67±6 vs. 123±5 A.U., p<0.05; Figure 2E). 
Strikingly, the effects of SHU9119 in pair-fed mice, as compared to the control group, 
were essentially similar as in ad libitum fed mice with respect to EE (23.9±0.1 cal/
h/g FFM; p<0.01), RER (0.91±0.01; p<0.01), fatty acid oxidation (5.3±0.5 cal/h/g FFM; 
p<0.001) and activity (75±3 A.U.; p<0.05). Apparently, SHU9119 reduced EE, because 
of reduced fat oxidation and independent of food intake, as well as a lower locomotor 
activity.
SHU9119 induces hepatic steatosis due to increased food intake
Since the liver is an important player in TG storage and secretion, we evaluated 
the effect of SHU9119 on liver weight and TG content as well as on hepatic VLDL-
TG secretion. SHU9119 induced hepatomegaly as evidenced by increased liver 
weight (+85%; 2.17±0.11 vs. 1.17±0.06 g, p<0.001) (Figure 3A) and aggravated hepatic 
steatosis, as shown by a selective increase in liver TG (+57%; 689±33 vs. 439±37 nmol/
mg protein, p<0.001) (Figure 3B) and neutral lipid staining (Figure 3C). However, the 
effects of SHU9119 on the liver were fully attributed to the induction of hyperphagia, 
as hepatomegaly and hepatic steatosis were not induced under pair-fed conditions 
(Figure 3A-D). SHU9119 did not affect the VLDL-TG production rate in mice that 
were either fed ad libitum (3.39±0.14 mmol/L/h) or pair-fed (3.61±0.37 mmol/L/h) 
as compared to control mice (3.59±0.29 mmol/L/h) (Figure 3D,E). The VLDL-apoB 
production rate was slightly decreased in SHU9119-treated mice, but not in pair-
fed SHU9119-treated mice (Figure 3F). In line with these observations, SHU9119 did 
not affect VLDL particle size (Figure 3G), VLDL composition (Figure 3H), or hepatic 
expression of the genes Apob, Mttp, Dgat2 involved in VLDL synthesis (not shown). 
Taken together, SHU9119 induced hepatic steatosis secondary to its induction of 
hyperphagia and without affecting VLDL-TG secretion.








































































































Figure 2 – SHU9119 lowers energy expenditure by reducing fat oxidation independent of food 
intake. APOE*3-Leiden.CETP mice were treated intracerebroventricularly with vehicle (n=9) 
or SHU9119 (5 nmol/day) while being fed ad libitum (n=6) or being pair-fed (pf) to the vehicle-
treated group (n=9). During the first 5 days of treatment, mice were housed in fully automated 
metabolic cages. Energy expenditure (A), respiratory exchange ratio (B), carbohydrate 
oxidation (C) and fat oxidation (D) were calculated from O2 uptake and CO2 excretion. Values are 
means ± SEM. *p<0.05, **p<0.01, ***p<0.001 compared to control.
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Figure 3 – SHU9119 induces hepatomegaly and steatosis only in ad libitum fed mice. APOE*3-
Leiden.CETP mice were treated intracerebroventricularly with vehicle (n=21) or SHU9119 
(5 nmol/day) while being fed ad libitum (n=21) or being pair-fed (pf) to the vehicle-treated group 
(n=20). After 17 days of treatment, part of the mice were sacrificed (n=10-11 per group) to 
collect organs and determine liver weight (A), and to determine liver content of triglycerides 
(TG), total cholesterol (TC) and phospholipids (PL) (B). Frozen liver samples were sectioned 
and stained with a neutral lipid staining (Oil-red-O) and hematoxylin, and representative 
pictures are shown (C). The remaining mice (n=8-10 per group) were 4 h fasted, consecutively 
injected with Trans35S label and tyloxapol, and blood samples were drawn up to 90 min after 
tyloxapol injection. Plasma TG concentration was determined and plotted as the increase in 
plasma TG relative to t=0 (D). The rate of TG production was calculated from the slopes of 
the curves from the individual mice (E). After 120 min, the total VLDL fraction was isolated 
by ultracentrifugation and the rate of newly synthesized VLDL-ApoB was determined (F). 
The VLDL fractions were assayed for particle size (G) and lipid content (H). Values are means 
± SEM. *p<0.05, ***p<0.001 compared to control.
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SHU9119 induces brown adipose tissue dysfunction independent of 
food intake
Since BAT strongly contributes to fat oxidation and total energy expenditure, we 
subsequently determined the effect of SHU9119 treatment on BAT function. SHU9119 
treatment increased BAT weight in ad libitum fed mice (+50%; 0.15±0.01 vs. 0.10±0.01 g, 
p<0.01) and tended to increase BAT weight in pair-fed animals (+24%; 0.13±0.01 g, 
p=0.06) (Figure 4A). Strikingly, SHU9119 dramatically increased intracellular 
lipid droplet size in BAT in both ad libitum fed and pair-fed mice (Figure 4B), along 
with reduced sympathetic innervation of BAT as evidenced by reduced tyrosine 
hydroxylase (i.e. the rate-limiting enzyme in norepinephrine synthesis) (-53%; 
p<0.001 and -43%; p<0.001) (Figure 4C-D) and reduced phosphorylation of CREB 
(-22%; p<0.05 and -15%; n.s.) (Figure 4E), a downstream target of β3-adrenergic 
signaling. Accordingly, largely reduced UCP-1 protein levels in BAT (-61%; p<0.001 
and -61%, p<0.001) were observed (Figure 4F). These data imply that SHU9119 
decreases BAT activity independent of food intake, likely due to lower sympathetic 
innervation of BAT, and this may result in decreased burning of intracellulary stored 
TG and, as a consequence, larger intracellular lipid droplet size.
To assess the capacity of BAT to take up VLDL-TG, we next determined the effect 
of SHU9119 on the kinetics of i.v. injected [3H]TO and [14C]CO double-labeled VLDL-
like emulsion particles after 14 days of treatment. SHU9119 impaired the plasma 
decay of [3H]TO (Figure 4G) and [14C]CO (Figure 4I) under ad libitum fed conditions, 
and that of [14C]CO under pair-fed conditions (Figure 4I). At 15 min after injection, 
the distribution of radiolabels over the organs was assessed. In control mice, the 
uptake of [3H]TO-derived activity by BAT (31.6±8.0%/g) was much higher than the 
uptake by liver (~4-fold), muscle (~25-fold) and WAT (~25-fold), indicating that BAT is 
highly metabolically active compared to other organs. Interestingly, SHU9119 tended 
to selectively decrease the uptake of [3H]TO by BAT in the ad libitum fed group, and 
significantly did so in mice pair-fed to the control group (-57%; 13.7±1.9% of injected 
dose/g; p<0.05) (Figure 4H), most likely as a consequence of reduced hydrolysis of 
VLDL-TG. Indeed, in the control group, as compared to the 3H-label, the uptake of 
the 14C-label was much lower in BAT (~10-fold), muscle (~4-fold), heart (~3-fold) 
and WAT (~3-fold), while the uptake of 14C-label was higher in liver (~3-fold). This 
pattern is compatible with selective delipidation of the VLDL-like emulsion particles 
in plasma by the LPL-expressing tissues (i.e. uptake of 3H activity), with subsequent 
uptake of the core remnant by the liver (i.e. uptake of 14C activity). SHU9119 treatment 
tended to reduce the uptake of [14C]CO in the liver of both ad libitum fed mice (-20%; 
20.8±3.6 %/g; p=0.11) and pair-fed mice (-11%; 23.1±1.5 %/g; p=0.25) as compared to 
the control group (26.1±2.1 %/g), whereas it decreased the uptake of [14C]CO by BAT 
(ad libitum fed: -39%; p=0.24 ; pair-fed: -57%; p<0.01) (Figure 4J).
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Figure 4 – SHU9119 causes malfunction of brown adipose tissue. APOE*3-Leiden.CETP mice 
were treated intracerebroventricularly with vehicle (n=21) or SHU9119 (5 nmol/day) while 
being fed ad libitum (n=21) or being pair-fed (pf) to the vehicle-treated group (n=22). After 
17 days of treatment, part of the mice were sacrificed (n=10-11 per group) and interscapular 
brown adipose tissue (iBAT) was quantitatively removed. iBAT was examined for weight  (A), 
morphology, as assessed by hematoxylin and eosin (H&E) staining, (B) and tyrosine hydroxylase 
(TH) content (C,D). In iBAT, protein content of phosphorylated CREB (E) and UCP-1 (F) were 
determined. In a second experiment, after 14 days of i.c.v. treatment with vehicle (n=8) or 
SHU9119 (5 nmol/day) while being fed ad libitum (n=5) or being pf to the vehicle-treated group 
(n=9), mice were 4h fasted and consecutively injected with [3H]TO and [14C]CO-labeled VLDL-
like emulsion particles. Plasma [3H]TO (G) and [14C]CO (H) were determined at the indicated 
time points and plotted relative to the dosage at t=2 min. At 15 min after injection, organs were 
isolated and uptake of the 3H-activity (I) and 14C-activity (J) was determined. Values are means 
± SEM. #p<0.05, *p<0.05. **p<0.01, ***p<0.001 compared to control.
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SHU9119 also induces brown adipose tissue dysfunction independent 
of dyslipidemia
To investigate the inhibitory effects of SHU9119 on BAT activity independent of 
dyslipidemia induced by Western-type diet feeding in APOE*3-Leiden.CETP mice, 
we next repeated experiments in wild-type mice that were fed a regular chow 
diet. Again, SHU9119 consistently increased food intake (on average 4.97±0.29 vs. 
4.10±0.26 g/day, p<0.05) (Figure 5A) accompanied by an increase in body weight gain 
(5.43±0.58 vs. 0.21±0.24 g, p<0.001) (Figure 5B). As with the APOE*3-Leiden.CETP 
mice, administration of SHU9119 in wild-type mice increased body weight gain in 
pair-fed animals (1.29±0.32 g, p<0.05) (Figure 5B), due to a selective increase in fat 
mass (Figure 5C). Histological analysis revealed increased lipid accumulation in 
BAT upon SHU9119 treatment (Figure 5D), especially in the ad libitum fed mice in 
which 51±14% of the total area consisted of lipids (p<0.001) (Figure 5E). In addition, 
SHU9119 tended to reduce tyrosine hydroxylase content in BAT in both ad libitum and 
pair-fed mice (-32% and -42%, respectively) (Figure 5F), accompanied by reduced 
phosphorylation of CREB (-32%, p<0.01 and -52%, p<0.001 respectively) (Figure 5G), 
supporting reduced sympathethic innervation of BAT. Again, SHU9119 markedly 
reduced UCP-1 protein content in BAT in both ad libitum and pair-fed mice (-54%, 
p<0.001 and -64%, p<0.001 respectively) (Figure 5H). SHU9119 resulted in lower body 
temperature in both ad libitum (35.9±0.32 °C, p<0.01), and pair-fed (35.6±0.47  °C, 
p<0.05) animals as compared to vehicle treated mice (36.7±0.46 °C) (Figure 5I-J), 
which is in line with reduced BAT thermogenesis. We next assessed the capacity of 
BAT to take up VLDL-TG upon SHU9119 treatment. Again, SHU9119 lowered uptake 
of [3H]TO-derived activity from VLDL-like emulsion particles by BAT In ad libitum fed 
mice compared to vehicle treated animals (-80%; p<0.001). Interestingly, in pair fed 
animals this effect was not observed (Figure 5K). Accordingly, gene expression of 
the lipolytic enzyme Lpl was decreased in ad libitum fed mice (-70%; p<0.001), but not 
in pair fed mice (Figure 5L). These data suggest that lower local hydrolysis of TG-
rich lipoprotein like particles may well underlie the lower uptake of TG by BAT upon 
SHU9119 treatment. Altogether, SHU9119 inhibits BAT activity in both hyperlipidemic 
APOE*3-Leiden.CETP mice and normolipidemic wild-type mice.
Discussion
The melanocortin system is an important regulator of energy balance and MC4R 
deficiency is the most common monogenic cause of obesity. BAT recently emerged 
as an important player in energy expenditure by combusting high amounts of TG 
towards heat. In addition, MC4R expressing neurons project onto BAT (14). Hence, 
the association between MC4R and energy expenditure may be mediated by BAT. In 
the current study we aimed to evaluate the direct effect of the melanocortin system 
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Figure 5 – SHU9119 induces brown adipose tissue dysfunction independent of dyslipidemia. 
Wild-type C57Bl/6J mice were treated intracerebroventricularly with vehicle (n=9) or SHU9119 
(5 nmol/day) while being fed ad libitum (n=10) or being pair-fed (pf) to the vehicle-treated group 
(n=9). Food intake (A) and body weight (B) were monitored on a daily basis. After 15 days, body 
composition was determined using echo-MRI (C). Core body temperature was measured 
every 3 days using subcutaneously implanted temperature transponder (D) and average 
core body temperature was calculated (E). On histological level tyrosine hydroxylase (TH) 
immunoreactivity was determined (F) and BAT protein levels of phosphorylated CREB (G) 
and UCP-1 (H) were measured using Western blots. Before scarification, after 4h of fasting, 
mice were injected with 3H]TO-labeled VLDL-like emulsion particles and organs were isolated 
15 min after injection. Uptake of the 3H-activity (I) was determined. On BAT, an H&E staining (J) 
was performed to quantify lipid content (K) and on frozen sections were used to determine 
gene expression (L). Values are means ± SEM. *p<0.05, **p<0.05, ***p<0.001 compared to 
control.
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on BAT activity. For this purpose, we inhibited the central melanocortin system using 
the MC3/4R synthetic antagonist SHU9119 in APOE*3-Leiden.CETP mice. We found 
that i.c.v. administration of SHU9119 decreased EE and BAT activity, concomitant with 
selectively impaired uptake of TG from plasma by BAT, independent of food intake.
Both in ad libitum as well in pair-fed conditions, SHU9119 treatment increased 
body weight and WAT mass. These data are in line with those of Nogueiras et al. (8), 
who attributed weight gain and adiposity upon SHU9119 treatment to an increase in 
both lipid uptake as well as TG synthesis for storage in WAT. Accordingly, we found 
enhanced uptake of TG by gWAT after a bolus injection of double-labeled VLDL-like 
emulsion particles. Though the increase in TG uptake by gWAT may have seemed 
small when expressed per gram tissue, the total depot of gWAT may contribute 
to a marked absolute TG uptake by the tissue. We also showed that in ad libitum 
fed conditions, SHU9119 induced ectopic lipid deposition in the liver, manifested 
by hepatomegaly and hepatic steatosis. Hepatic steatosis did not develop in pair-
fed mice, indicating that this effect is a direct consequence of SHU9119-induced 
hyperphagia. Similar effects on the liver are observed after 4 days of i.c.v. SHU9119 
treatment in rats (19) and in MC4R deficient mice, which in addition develop 
steatohepatitis when fed a high-fat diet and have therefore been proposed as a 
novel mouse model for non-alcoholic steatohepatitis (NASH) (20). Although hepatic 
steatosis could promote the secretion of hepatic lipid as VLDL (21), SHU9119 did not 
increase the VLDL-TG production, VLDL-size or composition of newly synthesized 
VLDL. Our data corroborate those of Stafford et al.(22) who showed that a single 
i.c.v. injection of 15 µg SHU9119 does not affect VLDL-TG production in rats. Of note, 
ApoB production was decreased in ad libitum fed SHU9119 treated animals, which 
may be the consequence of the hepatic steatosis. These data corroborate previous 
observations that steatosis, by inducing ER stress, inhibits the hepatic production of 
apoB100 (23), which can result in production of large lipid-rich VLDL particles (24).
Because SHU9119 was able to increase body adiposity independent of a change 
in food intake, we reasoned that SHU9119 reduced EE. Indeed, by performing studies 
with metabolic cages we confirmed that inhibition of the central melanocortin 
system reduced EE. Besides decreasing locomotor activity, SHU9119 selectively 
reduced fat oxidation, whereas carbohydrate oxidation remained unaffected. This 
reduction in fat oxidation and total EE occurred independently of food intake and 
before changes in body weight were observed, indicative of a causal relation between 
reduced energy expenditure and the induction of obesity. Likewise, a previous study 
has shown that 7 days of i.c.v. injections with SHU9119 in rats increased the RER and 
thereby decreased fat utilization independent of food intake (8). As locomotor activity 
was not affected in that study, reduced fat oxidation may be dominant over the effect 
of decreased locomotor activity in the decrease in EE. In addition, MC4R-deficient 
humans also display an increase in RER (8). Taken together, we suggest that, in 
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general, inhibition of the melanocortin system results in a shift towards decreased 
metabolic use of lipids leading to elevated fat deposition in WAT.
Since BAT is a highly active metabolic tissue involved in EE and regulation of 
weight gain, we next proposed that the reduction in fat oxidation could be largely 
attributed to decreased activity of BAT. Indeed, in both ad libitum and pair-fed 
conditions in Western-type diet fed APOE*3-Leiden.CETP mice, analysis of BAT 
revealed that SHU9119 largely increased intracellular lipid stores and decreased 
the protein level of the UCP-1, both indicative of reduced BAT activity (25). These 
data corroborate previous findings showing that chronic i.c.v. treatment of ad libitum 
fed rats with SHU9119 lowered BAT temperature during the night (26). Moreover, 7 
daily i.c.v. injections of AgRP, the endogenous antagonist for MC4R, decreased Ucp1 
gene expression in pair-fed rats (27), while acute i.c.v. injections of GLP-1, which 
indirectly stimulates MC4R, increased BAT thermogenesis by increasing activity 
of the sympathetic fibers towards BAT (28). Accordingly, since the activity of BAT 
is dependent on SNS outflow from the hypothalamus (29,30), reduced sympathetic 
output from the hypothalamus towards BAT is the likely mechanism by which 
inhibition of the central melanocortin system reduced BAT activity. We observed 
reduced sympathetic output towards BAT as evidenced by decreased levels of tyrosine 
hydroxylase, the rate limiting enzyme in norepinephrine synthesis, and decreased 
phosphorylation of CREB, a downstream target of β3-adrenergic signaling, in BAT 
upon SHU9119 treatment. Thus, these data support a major role for BAT in the 
reduced EE and enhanced weight gain of central MC4R inhibition. However, based 
on these data, we cannot exclude the involvement of other metabolic tissues such 
as liver and WAT in the development of the disadvantageous metabolic phenotype.
Interestingly, in the Western type diet-fed APOE*3-Leiden.CETP mice we provided 
evidence that SHU9119 lowered both β-oxidation and VLDL-TG uptake by BAT, while 
lipid accumulation was markedly enhanced. This suggests that the lower β-oxidation 
upon SHU9119 treatment was more pronounced than the reduced VLDL-TG uptake 
by the tissue. It would make physiological sense if the reduction in VLDL-TG uptake 
by BAT occurred as a secondary mechanism to compensate for the diminished TG 
combustion by the tissue. Indeed, this is supported by the study performed in chow-
fed wild-type C57Bl/6J mice. While both the ad libitum fed and pair-fed animals 
developed marked lipid accumulation in BAT upon SHU9119 treatment, only the ad 
libitum fed mice exhibited lower TG uptake by BAT. Of note, the lipid accumulation in 
BAT was less pronounced in the chow pair-fed C57Bl6/J mice as compared to the 
Western-type diet pair-fed APOE*3-Leiden.CETP mice, perhaps due to the lower fat 
content of the chow diet. It is, therefore, likely that especially brown adipocytes that 
become saturated with lipids lower their TG uptake as a secondary mechanism, for 
instance by downregulation of Lpl expression resulting in lower VLDL-TG hydrolysis. 
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Indeed, in the study with C57Bl6/J mice Lpl was downregulated only in the SHU9119 
mice that were fed ad libitum.
Recently, Bartelt et al. (13) identified BAT as a major organ involved in plasma VLDL-
TG clearance, with 24 hours of cold induction resulting in normalisation of plasma 
TG levels in hypertriglyceridemic mice. To investigate the effects of decreased BAT 
activity on plasma lipid levels, dyslipidemic APOE*3-Leiden.CETP mice were used 
in the first set of experiments. In a first experiment, we did observe a large increase 
in plasma TG levels upon 17 days of SHU9119 treatment under ad libitum conditions 
(Supplemental Figure 1A), which would be consistent with reduced uptake of TG by 
BAT. However, in a subsequent study the SHU9119-induced increase in plasma TG only 
reached significance under pair-fed conditions (Supplemental Figure 1B). Likewise, 
i.c.v. infusion of the MC4R synthetic antagonist HS104 also failed to increase plasma 
TG levels in pair-fed rats (31). It should be noted that MC4R deficient mice have only 
modestly increased plasma TG levels compared to control mice (+30%) (32), implying 
that partial inhibition of MC4R by SHU9119 may be insufficient to significantly increase 
plasma TG levels. In heterozygous MC4R-deficient subjects, plasma TG levels are 
increased (1.7 vs. 1.3 mmol/L) (33), indicating that the melanocortin system does play 
a role in the regulation of plasma VLDL-TG levels in humans.
Recently, Perez-Tilve et al. (34) demonstrated that inhibition of the central 
melanocortin neurons by either ghrelin or SHU9119 in wild-type mice increased 
circulating cholesterol, related to a decreased hepatic expression of SR-BI involved 
in the selective hepatic uptake of HDL-cholesteryl esters. In our study in APOE*3-
Leiden.CETP mice with a human-like lipoprotein metabolism, SHU9119 did not rather 
decrease total cholesterol levels (Supplemental Figure 1) despite decreased hepatic 
SR-BI expression (Supplemental Figure 2). This is likely due to the expression 
of human CETP that provides an alternative route for the clearance of HDL-
cholesterol, as CETP expression in SR-BI-deficient mice also precludes an increase 
in HDL-cholesterol (35). In addition, this could be related to an increased output of 
cholesterol in the feces as well as a somewhat reduced output of cholesterol from 
the liver within VLDL. Likewise, humans with heterozygous MC4R deficiency also do 
not have increased cholesterol levels (33), pointing to a species-dependent effect of 
MC4R function on HDL-cholesterol levels.
In conclusion, inhibition of central MC3/4R signaling by SHU9119 reduces BAT 
activity thereby reducing the uptake and combustion of VLDL-TG by BAT. As a 
consequence, excess lipids are stored in WAT (Figure 6). We anticipate that MC4R 
agonists that are currently in development to combat obesity, increase energy 
expenditure through activation of BAT.
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Figure 6 – Proposed model of the effect of SHU9119 on peripheral triglyceride metabolism. 
Under physiological conditions MC3/4R signalling is required for basal combustion of VLDL-
derived triglycerides (TG) in brown adipose tissue (BAT), preventing storage of excess TG in 
WAT (A). Inhibition of central MC3/4R signaling by SHU9119 reduces BAT activity, thereby 
reducing the uptake and combustion of VLDL-TG by BAT. As a consequence, excess TG is stored 
in WAT, independent of SHU9119-induced hyperphagia (B).
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Supplemental Figure 1 – Effect of SHU9119 on plasma lipid levels. (A) In a first experiment, 
APOE*3-Leiden.CETP mice were treated intracerebroventricularly with vehicle (n=10) or 
SHU9119 (5 nmol/day) (n=7). After 17 days of treatment, blood was drawn after a 4 h fast (from 
8.00 h to 12.00 h) via tail vein bleeding in paraoxon-coated capillary tubes to prevent ex vivo 
lipolysis and assayed for triglycerides (TG), total cholesterol (TC) and phospholipids (PL) 
using commercially available enzymatic kits for TG (11488872, Roche Diagnostics, Germany), 
TC (11489232, Roche Diagnostics, Mannheim, Germany) and PL (3009, Instruchemie, Delfzijl, 
the Netherlands). (B) In a second experiment, mice were treated i.c.v. with vehicle (n=21) or 
SHU9119 (5 nmol/day) while being fed ad libitum (n=21) or being pair-fed (pf) to the vehicle-
treated group (n=22). Plasma lipids were determined after 4 h of fasting. Values are means 
± SEM. *p<0.05, **p<0.01 compared to control.





























Supplemental Figure 2 – Effect of SHU9119 on hepatic SR-BI protein levels. APOE*3-Leiden.
CETP mice were treated intracerebroventricularly with vehicle (n=21) or SHU9119 (5 nmol/
day) while being fed ad libitum (n=21) or being pair-fed (pf) to the vehicle-treated group (n=20). 
After 17 days of treatment, part of the mouse groups were sacrificed (n=10-11 per group) to 
collect organs and determine hepatic SR-BI protein levels. Values are means ± SEM. **p<0.01 
compared to control.
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CENTRAL GLP-1 RECEPTOR 
SIGNALLING ACCELERATES 
CLEARANCE OF TRIACYLGLYCEROL 
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Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonism, used in the treatment 
of type 2 diabetes, has recently been shown to increase thermogenesis via the 
brain. As brown adipose tissue (BAT) produces heat by burning triacylglycerol (TG) 
and takes up glucose for de novo lipogenesis, the aim of this study was to evaluate 
the potential of chronic central GLP-1R activation by exendin-4 to facilitate 
clearance of lipids and glucose from the circulation by activating BAT. Lean and 
diet-induced obese (DIO) C57Bl/6J mice were used to explore the effect of a 5 day 
intracerebroventricular infusion of the GLP-1 analogue exendin-4 or vehicle on lipid 
and glucose uptake by BAT in both insulin-sensitive and insulin-resistant conditions. 
Central administration of exendin-4 in lean mice increased sympathetic outflow 
towards BAT and white adipose tissue (WAT), resulting in increased thermogenesis 
as evidenced by increased uncoupling protein 1 (UCP-1) protein levels and decreased 
lipid content, while the uptake of TG-derived fatty acids was increased in both BAT 
and WAT. Interestingly, in DIO mice, the effects on WAT were blunted, while exendin-4 
still increased sympathetic outflow towards BAT and increased the uptake of plasma 
TG-derived fatty acids and glucose by BAT. These effects were accompanied by 
increased fat oxidation, lower plasma TG and glucose concentrations, and reduced 
body weight. Collectively, our results suggest that BAT activation may be a major 
contributor to the glucose- and TG-lowering effects of GLP-1R agonism.




Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists, such as exendin-4, have 
been used in the treatment of type 2 diabetes; they increase glucose-dependent insulin 
secretion, regulate gastric emptying and reduce food intake and body weight  (1). 
At least some of these actions are mediated through neuroendocrine mechanisms, 
as shown by rodent studies, consistent with the notion that GLP-1R is highly 
expressed in the hypothalamus. Intracerebroventricular (i.c.v.) administration  of 
GLP-1 reduces food intake and body weight (2,3). Moreover, the central GLP-1R 
signalling system is linked to the control of peripheral glucose metabolism by 
inhibiting non-insulin-mediated glucose uptake by muscle and increasing insulin 
secretion from the pancreas (4,5). Previously, we have shown that subcutaneous 
GLP-1 treatment reduces hepatic glucose production in mice, partly through central 
GLP-1R signalling (6). Hence, one of the functions of the central GLP-1R system is 
the modulation of the metabolic activity in peripheral organs that are crucial for the 
maintenance of energy homeostasis.
Brown adipose tissue (BAT) is a regulator of overall energy homeostasis 
by combusting triacylglycerol (TG) and glucose into heat. Enhancement of the 
thermogenic capacity of BAT induces weight loss through increased energy 
expenditure (7,8) and lowers the plasma levels of TG and glucose. In fact, BAT 
activation can correct hyperlipidaemia (9) and hyperglycemia (10) by increased 
uptake of TG-derived fatty acids (11) and glucose from plasma. Recently, it has 
been shown that activation of central GLP-1R increases thermogenesis in BAT and 
induces browning within white adipose tissue (WAT), and that this correlates with 
increased expression of genes required for thermogenesis, including uncoupling 
protein-1  (12,13). While these findings suggest an important role of the central 
GLP-1R system in BAT activation, the effect of central GLP-1R activation on lipid 
and glucose control by BAT has not yet been investigated. Furthermore, although 
GLP-1R agonists are implemented to treat type 2 diabetes, the responsiveness of the 
central GLP-1R system to activate BAT to take up TG-derived fatty acids and glucose 
under central insulin resistance (14), is unknown.
The aim of this study was to evaluate the potential of activating central GLP-1R 
by exendin-4 to facilitate clearance of lipids and glucose from the circulation by 
activating BAT, under both insulin-sensitive and insulin-resistant conditions in diet-
induced obese (DIO) C57Bl/6J mice.





For all experiments, 20-week-old male C57Bl/6J mice (Charles River, Saint-
Germain-Nuelles, France) were used, housed with a regular 12:12 h light/dark cycle 
in a temperature- and humidity-controlled environment, with free access to food 
and water unless noted otherwise. For diet-induced obesity, mice were fed a high-fat 
diet (44% energy derived from bovine fat; Hope Farms, Woerden, the Netherlands) 
for 12 weeks, starting at 8 weeks of age. All animal experiments were performed 
in accordance with the regulations of the Dutch law on animal welfare, and the 
Institutional Ethics Committee for Animal Procedures, Leiden University Medical 
Center, Leiden, the Netherlands, approved the protocol.
Intracerebroventricular surgery and treatment
Mice were randomised based on body weight, anaesthetised and cannulas (Brain 
Infusion Kit 3, ALZET Cupertino, CA, USA) were stereotactically implanted into the 
left lateral ventricle of the brain (coordinates −0.45 mm anteroposterior, −1.00 mm 
lateral and 2.50 mm dorsoventral from bregma). Osmotic minipumps (Model 1004, 
Alzet, CA, USA) attached to the cannula via a catheter were implanted subcutaneously 
on the back, slightly posterior to the scapulae. The catheter connected to the osmotic 
minipump was filled with artificial cerebrospinal fluid (aCSF; Harvard Apparatus, 
Holliston, MA, USA) to delay the start of drug delivery by 2 days. The minipump assured 
continuous delivery of 0.75 nmol/day exendin-4 (Bachem, Weil am Rhein, Germany) 
dissolved in aCSF or aCSF only. The dose of exendin-4 was expected to suppress food 
intake. Therefore, an aCSF-receiving pair-fed control group (restricted to the same 
amount of food each day as consumed by the i.c.v. exendin-4-infused mice) was also 
included. Because of the inclusion of a pair-fed group, blinding to group assignment 
was not feasible. Body weight and food intake were measured daily. One lean mouse 
(assigned to exendin-4 group) and three obese mice (assigned to control group) were 
excluded from the study because of complications after surgery. After 5  days of 
intervention, TG and glucose clearance was determined as described below.
Triacylglycerol and glucose clearance
Triacylglycerol-rich lipoprotein (TRL)-like particles were prepared from 100 mg of 
total lipid including glycerol trioleate (triolein; 70 mg), egg yolk phosphatidylcholine 
(22.7 mg), lysophosphatidylcholine (2.3 mg), cholesteryl oleate (3.0 mg) and cholesterol 
(2.0 mg), with addition of glycerol tri[3H]oleate ([3H]TO) (3.7 MBq). The emulsion was 
sonicated and fractionated by consecutive density gradient ultracentrifugation 
steps (15). The emulsion fraction containing TRL-like particles with an average size 
80 nm was isolated and mixed with 2-[1-14C]deoxy-D-glucose ([14C]DG) in a 3:1 ratio 
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based on radioactive count. Emulsions were stored at 4°C under argon and used for 
in vivo kinetic experiments within 5 days following preparation. Animals were fasted 
for 4 h. At t=0, blood was drawn via the tail vein to determine, via enzymatic assays, 
basal plasma TG (Roche Molecular Biochemicals, Indianapolis, IN, USA) and glucose 
(Instruchemie, Delfzijl, the Netherlands). Mice then received an i.v. injection of TRL-
like particles (1 mg TG) and [14C]DG. Blood samples were taken from the tail vein at 2, 
5, 10 and 15 min after injection, and plasma 3H and 14C activities were counted. After 
the last blood sample, the mice were killed, perfused via the heart with ice-cold PBS 
and various organs were collected. Organs were dissolved overnight at 60°C in Tissue 
Solubilizer (Amersham Biosciences, Roosendaal, the Netherlands), and 3Hand 14C 
activities were counted. Uptake of [3H]TO- and [14C]DG-derived radioactivity by the 
organs was calculated from the 3H and 14C activities in each organ and expressed 
as percentage of injected dose per g wet tissue weight.
Body composition
After the treatment period, body composition (lean and fat mass) was determined in 
conscious DIO mice using an EchoMRI-100 (EchoMRI, Houston, TX, USA).
Indirect calorimetry
During the treatment period of the DIO mice, oxygen uptake (V˙O2), carbon dioxide 
production (V˙CO2) and physical activity were measured in metabolic cages 
(LabMaster System, TSE Systems, Bad Homburg, Germany). The average respiratory 
exchange ratio (RER), energy expenditure, carbohydrate and fat oxidation rates were 
calculated from day 1 to day 4 of treatment, as described previously (16).
Histology
Formalin-fixed paraffin-embedded interscapular BAT (iBAT) and subcutaneous WAT 
(sWAT) tissue sections (5 μm) were stained with haematoxylin and eosin (H&E) using 
standard protocols. For staining of UCP-1 and tyrosine hydroxylase (TH), sections 
were dewaxed, rehydrated and treated with peroxidase. Antigen retrieval was 
accomplished in 10 mmol/l citrate buffer (pH=6.0). Slides were blocked with normal 
goat serum (UCP-1) or BSA (TH) and incubated overnight at 4°C with anti-UCP-1 
antibodies (1:4,000; Ab10983; Abcam, Cambridge, UK) or anti-TH antibodies (1:2,000; 
Ab112; Abcam). Next, sections were incubated for 30 min with biotinylated goat 
α-rabbit secondary antibodies (UCP-1; 1:600; Vector Labs, Burlingame, CA, USA) or 
DAKO EnVision anti-rabbit antibodies (DAKO, Glostrup, Denmark). Immunostaining 
was amplified and visualised using the Elite ABC Nova Red kit (Vector Labs). 
Counterstaining was performed with Mayer’s haematoxylin (1:4). The areas occupied 
by intracellular lipid vacuoles, UCP-1 and TH protein were quantified using ImageJ.




Differences between groups were determined with the Kruskal–Wallis non-
parametric test. When significant differences were found, the Mann–Whitney 
nonparametric test was used as a post hoc test to determine differences between 
two independent groups. Serum decay in the clearance experiment was analysed 
using repeated measurements ANOVA with Tukey’s post hoc test. A p value of <0.05 
was considered statistically significant. Data are presented as mean ±SD.
Results
Central GLP-1R activation decreases body weight and induces BAT 
activation in lean C57Bl/6J mice
Intracerebroventricular infusion of exendin-4 in lean C57Bl/6J mice decreased 
body weight as compared with controls (Figure 1A,B) this was accompanied by a 
reduced food intake (Figure 1C), both of which are well-known effects of activation 
of the central GLP-1R system (3,17). Reduction of food intake per se, as shown by the 
control mice that were pair fed with the exendin-4-treated mice (Figure 1C), resulted 
in a reduction in body weight compared with controls that was delayed compared 
with that evoked by exendin-4 (Figure 1A).
As central GLP-1 infusion increases sympathetic outflow towards BAT and WAT 
and subsequently stimulates thermogenesis (12,13,18), we analysed the expression 
of TH, a marker for activity of noradrenergic (norepiphrenergic) nerve fibres (19). 
Exendin-4 increased the TH content in both iBAT (+103%; p<0.01) and sWAT (+331%; 
p<0.05) as compared to controls (Figure 1D,E). This increased sympathetic nervous 
system (SNS) signalling was accompanied by enhanced thermogenic capacity, as 
exendin-4 increased UCP-1 protein content in iBAT (+44%, p<0.01) and sWAT (+142%, 
p<0.05) compared with the control group (Figure 1F,G), indicating more active BAT 
as well as browning of WAT. Reduction of food intake per se evoked similar increases 
in UCP-1 protein content in both BAT and WAT, but it was apparently independent of 
sympathetic input, which suggests the involvement of other pathways. The effects of 
exendin-4 on UCP-1 content were accompanied by a decreased lipid droplet content 
in iBAT (−67%, p<0.001) and sWAT (−53%, p<0.05) (Figure 1H,I), probably as activation 
of BAT results in combustion of intracellular lipid stores as well as browning of WAT. 
The lipid content in iBAT was reduced to a greater extent in exendin-4-treated mice 
than in food-restricted mice (−46%, p<0.05), which coincided with a higher level of 
TH, reflecting higher SNS activity towards BAT induced by exendin-4.
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Figure 1 – Central GLP-1R activation decreases body weight and food intake and induces 
activation of BAT in lean mice. Mice were treated for 5 days with i.c.v. exendin-4 (n=8) or 
vehicle (control n=9, pair-fed n=6). On a daily basis, body weight (A,B) and food intake (C) 
were monitored. Samples of BAT and WAT were collected and stained for TH and UCP-1. 
Representative pictures and quantification of TH (D,E), UCP-1 (F,G) and lipid droplet content 
with H&E staining (H,I) are shown. Values are mean ±SD. *p<0.05, **p<0.01 and ***p<0.001 
compared with control; †p<0.01 compared with pair-fed control. White bars, control; black 
bars, exendin-4; grey bars, pair-fed control.
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Figure 2 – Central GLP-1R activation increases uptake of plasma TG-derived fatty acids and 
glucose by BAT in lean mice. Mice were treated for 5 days via i.c.v. (A-D) or i.v. (E-F) routes with 
exendin-4 (n=8) or vehicle (control n=9, pair-fed n=6). After treatment, mice were injected with 
[3H]TO-labelled particles and [14C]DG. Plasma 3H activity (A) and 14C activity (C) were plotted 
relative to the injected dose. At 15 min after injection, organs were isolated and uptake of 3H 
activity (B,E) and 14C activity (D,F) was determined. Values are mean ±SD. *p<0.05, **p<0.01 
and ***p<0.001 compared with control. †p<0.05 and ††p<0.01 compared with pair-fed control. 
White bars/circles, control; black bars/circles, exendin-4; grey bars/circles, pair-fed control.
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Central GLP-1R activation enhances uptake of plasma TG-derived 
fatty acids and glucose by BAT and browns WAT in lean C57Bl/6J 
mice
Subsequently, we tested our hypothesis that BAT activated during chronic GLP-
1R activation is a major contributor to the plasma clearance of TG and glucose. To 
this end, mice were injected i.v. with [3H]TO-labelled TRL-like emulsion particles 
and [14C]DG. Indeed, exendin-4 accelerated the clearance of [3H]TO from plasma 
(Figure 2A). This enhanced clearance was the result of a greatly increased uptake 
of [3H]TO-derived activity by iBAT (+276%; p<0.001; Figure 2B). In addition, exendin-4 
enhanced the uptake of [3H]TO-derived activity by both sWAT (+111%, p<0.01) and 
gonadal (g)WAT (+138%, p<0.05) compared with the control group, corresponding to 
the browning observed in these WAT depots. The pair-fed animals showed similar 
results for [3H]TO kinetics as the exendin-4-treated group. Plasma clearance was 
increased (Figure 2A), relating to a marked increase in uptake of 3H-activity by iBAT 
as compared with control-infused animals (+314%; p<0.001; Figure 2B). In addition, 
the uptake by sWAT was increased (+194%; p<0.05), whereas there was no significant 
effect on uptake by gWAT (+109%; p=0.20) in pair fed conditions.
Similar to plasma [3H]TO clearance, chronic infusion of exendin-4 accelerated 
the clearance of [14C]DG from plasma (Figure 2C). This enhanced clearance from 
the circulation was the result of an increased uptake of [14C]DG by iBAT (+142%; 
p<0.01) and skeletal muscle (+40%; p<0.05) compared with controls (Figure 2D). 
Interestingly, while the uptake of [3H]TO-derived activity by BAT in pair-fed mice was 
increased to a similar extent as in exendin-4 treated animals, the uptake of [14C]DG 
by iBAT was not increased in the pair-fed control mice.
To rule out that the effects of i.c.v. administered exendin-4 on the uptake of TG-
derived fatty acids and glucose by BAT were caused by leakage of exendin-4 into 
the circulation, we next administered exendin-4 peripherally at the same dose as 
administered centrally. Peripheral exendin-4 treatment for 5 days delivered via 
subcutaneous minipumps did not enhance the uptake of [3H]TO-derived activity 
(Figure 2E) or [14C]DG (Figure 2F) by BAT. Peripheral exendin-4 only slightly increased 
the uptake of [3H]TO-derived activity by gWAT, possibly via a direct effect of GLP-1R 
signalling on white adipocyte formation (20).
Central GLP-1R activation decreases body weight, plasma TG and 
glucose levels, and shifts combustion from carbohydrates towards 
fat in DIO C57Bl/6J mice
Whether chronic i.c.v. exendin-4 infusion still leads to an increased uptake of plasma 
TG-derived fatty acids and glucose via BAT when obesity and insulin resistance have 
developed, we next explored the effects of central GLP-1R activation after 12 weeks of 
high-fat feeding. In DIO mice, continuous infusion of exendin-4 for 5 days decreased 
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body weight compared with control-infused mice (Figure 3A), which could only partly 
be attributed to reduced food intake (Figure 3B) as the reduction in body weight was 
greater than in pair-fed controls. Determination of body composition showed that 
exendin-4 and pair feeding decreased body weight because of a selective decrease in 
fat mass compared with controls (Figure 3C). Furthermore, plasma TG and glucose 
levels were both decreased from baseline values in the exendin-4-infused mice at 
the end of the treatment period (Table 1). In the pair-fed mice, plasma glucose levels 
were reduced from baseline values, but remained significantly higher than in the 
exendin-4-treated mice.
Indirect calorimetry showed that the decreased fat mass in the exendin-4-infused 
DIO mice was accompanied by an increased fat oxidation (Figure 3D) at the expense 
of carbohydrate oxidation (Figure 3E). This was also reflected by a decreased RER 
(Figure 3F) compared with controls, suggesting a shift in nutrient combustion. 
Of note, exendin-4 reduced total energy expenditure (Figure 3G) and decreased 
physical activity (Figure 3H). Pair feeding also increased fat oxidation and decreased 
carbohydrate oxidation compared with the controls, but these effects were less 
pronounced than those of exendin-4. This implies that the effects of exendin-4 on 
energy metabolism are only partly caused by reduced food intake in DIO mice.
Table 1 – Central GLP-1R activation decreases plasma TG and glucose levels in DIO mice
Control Exendin-4 Pair fed Control
TG
(mmol/l)
Start 0.7 ± 0.1 0.7 ± 0.1 0.6 ± 0.1
End 0.7 ± 0.5 0.5 ± 0.2* 0.6 ± 0.4
Glucose 
(mmol/l)
Start 11.3 ± 0.8 11.6 ± 1.1 11.4 ± 1.1
End 10.6 ± 0.9 4.5 ± 1.2*** ††† 7.4 ± 1.1***
After 12 weeks of high-fat feeding,mice were treated for 5 days with i.c.v. exendin-4 (n=10) 
or vehicle (control n=6, pair-fed n=9). Blood was collected before and after treatment by tail 
bleeding after 4 h of fasting and plasma TG and glucose were determined. Values are mean ±SD 
*p<0.05 and ***p<0.001 compared with baseline; †††p<0.001 compared with pair-fed control.
Central GLP-1R activation increases BAT thermogenesis, but does 
not induce browning of WAT in DIO C57Bl/6J mice
Under high-fat-fed conditions, i.c.v. exendin-4 treatment still increased SNS output 
towards BAT compared with controls, reflected by increased TH content (sBAT: 
+59%; p<0.05 [not shown], iBAT: +107%; p<0.01, Figure 4A,B) and increased UCP-1 
protein content (sBAT: +62%; p<0.001 [not shown], iBAT: +93%; p<0.01, Figure 4C,D), 
indicative of more active BAT. As a consequence, lipid droplet content was decreased 
in the exendin-4 treated animals compared with controls (sBAT: -49%; p<0.05, iBAT: 
-41%; p<0.01, Figure 4E,F). Pair fed feeding did not affect TH expression in BAT 
(Figure 4A,B), slightly increased UCP-1 protein content (Figure 4C,D) and slightly 
























































































































































Figure 3 – Central GLP-1R activation decreases body weight and shifts combustion from 
carbohydrates towards fat in DIO mice. After 12 weeks of high-fat feeding, mice were treated 
for 5 days with i.c.v. exendin-4 (n=10) or vehicle (control n=6, pair-fed n=9). Body weight 
gain  (A) and food intake (B) were determined. Lean (crossed area) and fat (no cross) mass 
were measured (C). During the treatment period, mice were housed in metabolic cages. 
Fatty acid oxidation (D), carbohydrate oxidation (E), RER (F) and energy expenditure (G) were 
calculated from O2 uptake and CO2 excretion. (H) Magnitude of physical activity in arbitrary 
units. Values are mean ±SD. *p<0.05, **p<0.01 and ***p<0.001 compared with control. †p<0.05 
and †††p<0.001 compared with pair-fed control. White bars/continuous lines, control; black 
bars/dotted lines, exendin- 4; grey bars/dashed lines, pair-fed controls. AU, arbitrary units; 
CH, carbohydrate; EE, energy expenditure; FA, fatty acid.
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Figure 4 – Central GLP-1R activation increases TH and UCP-1 protein levels and decreases 
lipid droplet content in BAT in DIO mice. After 12 weeks of high-fat feeding, mice were treated 
for 5 days with i.c.v. exendin-4 (n=10) or vehicle (control n=6, pair-fed n=9). After treatment, 
mice were killed and BAT and WAT were collected and stained for TH and UCP-1. Staining with 
H&E was performed for lipid droplet content. Representative pictures and quantification of 
TH (A,B), UCP-1 (C,D) and lipid droplet content (E,F) are shown. Values are mean ±SD. *p<0.05, 
**p<0.01 and ***p<0.001 compared with control. †p<0.01 compared with pair-fed control. 
White bars, control; black bars, exendin-4; grey bars, pair-fed control.
decreased lipid content (Figure 4E,F) compared with controls. In contrast to the lean 
mice, infusion of exendin-4 in DIO mice did not induce browning of WAT as evidenced 
by unaffected TH expression, UCP-1 protein and lipid content.
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Central GLP-1R activation enhances TG and glucose clearance by 
BAT in DIO C57Bl/6J mice
Similar to lean mice, chronic i.c.v. infusion of exendin-4 in DIO mice accelerated 
the plasma clearance of [3H]TO (Figure 5A) and [14C]DG (Figure 5C). This was 
accompanied by a selectively increased uptake of [3H]TO-derived activity and [14C]DG 
by iBAT (+291%; p<0.001 and +482%; p<0.001, respectively) and sBAT (+217%; p<0.01 
and +247%; p<0.001, respectively) (Fig 5B,D). Despite lack of evidence for browning 
of WAT, exendin-4 enhanced the uptake of both [3H]TO-derived activity and [14C]DG 
by both sWAT (+146%; p<0.05 and +93%; p<0.05) and gWAT (+69%; p<0.01 and +82%; 
p<0.01). To some extent, the pair fed animals showed similar results on [3H]TO and 



























































































































Figure 5 – Central GLP-1R activation increases uptake of plasma TG-derived fatty acids and 
glucose by BAT in DIO mice. After 12 weeks of high-fat feeding, mice were treated for 5 days 
with i.c.v. exendin-4 (n=10) or vehicle (control n=6, pair-fed n=9). After treatment, mice were 
injected with [3H]TO labelled particles and [14C]DG. Plasma 3H activity (A) and 14C activity (C) 
were plotted relative to the injected dose. At 15 min after injection, organs were isolated and 
uptake of the 3H activity (B) and 14C activity (D) was determined. Values are mean ±SD. *p<0.05, 
**p<0.01 and ***p<0.001 compared with control. †p<0.05 and ††p<0.01 compared with pair-
fed control. White bars, control; black bars, exendin-4; grey bars, pair-fed control.
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[14C]DG kinetics as the exendin-4 treated mice. Plasma clearance was increased 
(Figure 5A,C), associated with a marked increase in uptake of [3H]TO-derived activity 
and [14C]DG by iBAT (+170%; p<0.01 and +482%; p<0.001, respectively) and sBAT 
(+188%; p<0.001 and +247%; p<0.001 respectively) compared with control infused 
animals (Figure 5B,D). Interestingly, the uptake of [3H]TO-derived activity by iBAT 
and the uptake of [14C]DG by iBAT and sBAT were significantly lower compared with 
exendin-4 treated mice (-31%; p<0.05, -63%; p<0.01, and -43%; p<0.01 respectively), 
indicating that exendin-4 exerts its effects partly independent of lowering food 
intake.
Discussion
In the present study we show that central GLP-1R activation by exendin-4 increases 
the plasma clearance of TG and glucose in both lean and DIO C57Bl/6J mice via 
increased uptake of TG-derived fatty acids and glucose by BAT, accompanied by 
activation of BAT and browning of WAT.
First, we showed that continuous central infusion of the GLP-1R analogue 
exendin-4 (5 days, 0.75 nmol/day) evokes the well-known effect of reducing food 
intake and body weight (3,17). In addition, central administration of exendin-4 
increased SNS activity towards BAT and WAT, as evidenced by increased TH and 
UCP-1 protein content and lowered lipid content. This corroborates previous findings 
demonstrating the essential role of the SNS in BAT and WAT activation by central 
GLP-1R signalling (12,18). Exendin-4 also caused a robustly accelerated clearance 
of plasma TG and glucose, which likely contributed to reduced plasma TG and 
glucose concentrations observed in DIO mice. Strikingly, the uptake of TG-derived 
activity, presumably [3H]oleate liberated by lipoprotein lipase (LPL) (11), was not 
only increased by BAT but also by WAT, together with the increase in UCP-1 content 
indicative of so-called browning. Although activation of BAT and WAT are likely 
involved in the observed reduction of plasma TG and glucose by central exendin-4, 
further studies are warranted to investigate the quantitative contribution of GLP-1R 
signalling towards BAT and WAT to the overall metabolic improvements on GLP-1R 
agonism.
It has been reported that central GLP-1 infusion reduces the lipid content of WAT 
in lean mice but not DIO mice (18), suggesting that some resistance to the actions of 
central GLP-1 is induced in DIO mice. Clearly, this effect is not desirable for a drug to 
treat obesity. Therefore, we explored the effects of chronic central exendin-4 infusion 
after 12 weeks of high-fat feeding, sufficient to induce obesity and insulin resistance 
in this mouse model (21,22). Our results show that under these conditions, chronic 
central GLP-1R signalling still improves the clearance of plasma TG and glucose via 
a robustly increased uptake by BAT. However, central GLP-1R agonism did not alter 
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UCP-1 protein content or lipid droplet content in WAT in DIO mice, consistent with 
previous findings by Nogueiras et al (18). It is interesting to speculate on why, during 
obesity, WAT is not susceptible to browning on exendin-4 treatment. Previous studies 
reported a decreased sensitivity of white adipocytes to adrenergic stimulation in 
obese individuals (23). However, in our study we also describe the absence of exendin-
4-induced TH expression in WAT in DIO mice. It is possible that different brain areas 
modulate specific BAT and WAT functions. While multiple tissues are simultaneously 
sympathetically stimulated during cold exposure, there are many examples of 
treatments that result in differential sympathetic outflow to various types of tissues 
(e.g. WAT vs BAT) and even within a type of tissue (e.g. different WAT pads) (24). The 
GLP-1R is widely expressed through the hypothalamus (25), and exerts effects via 
different nuclei. For example, GLP-1R signalling in the arcuate nucleus regulates 
glucose metabolism, while it modulates feeding via the paraventricular nucleus (5). 
Altogether, it is likely that GLP-1R signalling and subsequent sympathetic outflow 
differ during obesity and lean conditions.
In apparent contrast to the notion that increased BAT activity is generally 
correlated with an enhanced total energy expenditure (26), central GLP-1R activation 
in fact reduced total energy expenditure, an effect we have observed before during 
chronic peripheral exendin-4 treatment (27). Possibly, the reduction in energy intake 
is compensated by a relative reduction in energy expenditure. In addition, it appears 
that chronic central GLP-1R activation results in a shift from using carbohydrates to 
fatty acids as an energy source, which is consistent with previous studies that showed 
that chronic i.c.v. GLP-1 treatment decreased the respiratory quotient, indicative of 
a higher level of fat oxidation by BAT (18,28). The exendin-4-induced decrease in 
physical activity, resulting from a diminished food-seeking behaviour  (29), is less 
likely to contribute to the change in total energy expenditure (30).
From a clinical perspective, the possibility that BAT activity in humans may be 
amenable to pharmacological manipulation by GLP-1R agonism to control insulin 
sensitivity and body weight is attractive but, as yet, undemonstrated. Drugs targeting 
the GLP-1R system are already widely prescribed for their incretin properties to 
treat type 2 diabetes, but they may be useful in a wider context related to energy 
balance. The resting energy expenditure of obese individuals with type 2 diabetes 
increases with 1 year of treatment with a combination of metformin and exenatide 
or liraglutide (13). It is tempting to speculate that BAT may be activated in these 
patients. Increasing our knowledge about the mechanism of action of exendin-4 may 
add to the (further) development of peptidomimetics in our battle against obesity and 
type 2 diabetes.
In conclusion, our results show that chronic central infusion of exendin-4 
increases SNS output to enhance BAT activity in both lean and DIO C57Bl/6J mice. Via 
highly active BAT, the plasma clearance of TG and glucose is accelerated and body fat 
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content is decreased, which, together with reduced food intake, leads to a decrease 
in body weight. Therefore, we suggest that GLP-1R agonists via BAT activation reduce 
both hyperlipidaemia and hyperglycaemia, and possibly even atherosclerosis (31), in 
addition to the effects of BAT activation on obesity.
Acknowledgements
We acknowledge the support from the Netherlands CardioVascular Research 
Initiative: ‘the Dutch Heart Foundation, Dutch Federation of University Medical 
Centers, the Netherlands Organisation for Health Research and Development and 
the Royal Netherlands Academy of Sciences’ for the GENIUS project ‘Generating the 
best evidence-based pharmaceutical targets for atherosclerosis’ (CVON2011 -19). 
MR Boon was supported by a grant from the Board of Directors of LUMC and is 
supported by a Rubicon grant from ZonMW (825.13.021). PCN Rensen is an Established 
Investigator of the Netherlands Heart Foundation (grant 2009T038).




1.  Gallwitz, B. (2011) Glucagon-like 
peptide-1 analogues for Type 2 diabetes 
mellitus: current and emerging agents. 
Drugs 71, 1675-1688.
2.  Hwa, J. J., Ghibaudi, L., Williams, P. 
et al. (1998) Differential effects of 
intracerebroventricular glucagon-
like peptide-1 on feeding and energy 
expenditure regulation. Peptides 19,  
869-875.
3.  Turton, M. D., O’Shea, D., Gunn, I. et al. 
(1996) A role for glucagon-like peptide-1 
in the central regulation of feeding. 
Nature 379, 69-72.
4.  Knauf, C., Cani, P. D., Perrin, C. et al. 
(2005) Brain glucagon-like peptide-1 
increases insulin secretion and muscle 
insulin resistance to favor hepatic 
glycogen storage. J Clin Invest 115, 3554-
3563.
5.  Sandoval, D. A., Bagnol, D., Woods, S. C. 
et al. (2008) Arcuate glucagon-like 
peptide 1 receptors regulate glucose 
homeostasis but not food intake. 
Diabetes 57, 2046-2054.
6.  Parlevliet, E. T., de Leeuw van 
Weenen JE, Romijn, J. A. et al. (2010) 
GLP-1 treatment reduces endogenous 
insulin resistance via activation of 
central GLP-1 receptors in mice fed a 
high-fat diet. Am J Physiol Endocrinol 
Metab 299, E318-E324.
7.  Boon, M. R., van den Berg, S. A., Wang, Y. 
et al. (2013) BMP7 activates brown 
adipose tissue and reduces diet-induced 
obesity only at subthermoneutrality. 
PLoS One 8, e74083.
8.  Geerling, J. J., Boon, M. R., van der 
Zon, G. C. et al. (2014) Metformin lowers 
plasma triglycerides by promoting VLDL-
triglyceride clearance by brown adipose 
tissue in mice. Diabetes 63, 880-891.
9.  Bartelt, A., Bruns, O. T., Reimer, R. et al. 
(2011) Brown adipose tissue activity 
controls triglyceride clearance. Nat Med 
17, 200-205.
10.  Emanuelli, B., Vienberg, S. G., Smyth, G. 
et al. (2014) Interplay between FGF21 
and insulin action in the liver regulates 
metabolism. J Clin Invest 124, 515-527.
11.  Khedoe, P. P., Hoeke, G., Kooijman, S. 
et al. (2015) Brown adipose tissue takes 
up plasma triglycerides mostly after 
lipolysis. J Lipid Res 56, 51-59.
12.  Lockie, S. H., Heppner, K. M., 
Chaudhary, N. et al. (2012) Direct control 
of brown adipose tissue thermogenesis 
by central nervous system glucagon-like 
Peptide-1 receptor signaling. Diabetes 61, 
2753-2762.
13.  Beiroa, D., Imbernon, M., Gallego, R. 
et al. (2014) GLP-1 Agonism Stimulates 
Brown Adipose Tissue Thermogenesis 
and Browning Through Hypothalamic 
AMPK. Diabetes 63, 3346-58.
14.  Coomans, C. P., Biermasz, N. R., 
Geerling, J. J. et al. (2011) Stimulatory 
effect of insulin on glucose uptake by 
muscle involves the central nervous 
system in insulin-sensitive mice. 
Diabetes 60, 3132-3140.
15.  Rensen, P. C., Herijgers, N., 
Netscher, M. H. et al. (1997) Particle 
size determines the specificity of 
apolipoprotein E-containing triglyceride-
rich emulsions for the LDL receptor 
versus hepatic remnant receptor in vivo. 
J Lipid Res 38, 1070-1084.
16.  Van Klinken, J. B., van den Berg, S. A., 
Havekes, L. M. et al. (2012) Estimation of 
activity related energy expenditure and 
resting metabolic rate in freely moving 
mice from indirect calorimetry data. 
PLoS One 7, e36162.
17.  Al-Barazanji, K. A., Arch, J. R., 
Buckingham, R. E. et al. (2000) Central 
exendin-4 infusion reduces body weight 
without altering plasma leptin in (fa/fa) 
Zucker rats. Obes Res 8, 317-323.
18.  Nogueiras, R., Perez-Tilve, D., Veyrat-
Durebex, C. et al. (2009) Direct control of 
peripheral lipid deposition by CNS GLP-1 
receptor signaling is mediated by the 
sympathetic nervous system and blunted 
in diet-induced obesity. J Neurosci 29, 
5916-5925.
19.  Giordano, A., Frontini, A., & Cinti, S. 
(2008) Adipose organ nerves revealed by 
immunohistochemistry. Methods Mol Biol 
456, 83-95.
20.  Challa, T. D., Beaton, N., Arnold, M. et al. 
(2012) Regulation of adipocyte formation 
by GLP-1/GLP-1R signaling. J Biol Chem 
287, 6421-6430.
21.  Korsheninnikova, E., van der Zon, G. C., 
Voshol, P. J. et al. (2006) Sustained 
activation of the mammalian target of 
rapamycin nutrient sensing pathway 
Kooijman.indd   63 30-9-2015   10:54:04
64
3
is associated with hepatic insulin 
resistance, but not with steatosis, in 
mice. Diabetologia 49, 3049-3057.
22.  Surwit, R. S., Kuhn, C. M., Cochrane, C. 
et al. (1988) Diet-induced type II diabetes 
in C57BL/6J mice. Diabetes 37, 1163-1167.
23.  van Baak, M. A. (2001) The peripheral 
sympathetic nervous system in human 
obesity. Obes Rev 2, 3-14.
24.  Bartness, T. J. & Song, C. K. (2007) 
Brain-adipose tissue neural crosstalk. 
Physiol Behav 91, 343-351.
25.  Goke, R., Larsen, P. J., Mikkelsen, J. D. 
et al. (1995) Distribution of GLP-1 binding 
sites in the rat brain: evidence that 
exendin-4 is a ligand of brain GLP-1 
binding sites. Eur J Neurosci 7, 2294-
2300.
26.  Cannon, B. & Nedergaard, J. (2004) 
Brown adipose tissue: function and 
physiological significance. Physiol Rev 84, 
277-359.
27.  Parlevliet, E. T., Wang, Y., Geerling, J. J. 
et al. (2012) GLP-1 Receptor Activation 
Inhibits VLDL Production and Reverses 
Hepatic Steatosis by Decreasing Hepatic 
Lipogenesis in High-Fat-Fed APOE*3-
Leiden Mice. PLoS One 7, e49152.
28.  Tachibana, T., Oikawa, D., Adachi, N. et al. 
(2007) Intracerebroventricular injection 
of glucagon-like peptide-1 changes lipid 
metabolism in chicks. Comp Biochem 
Physiol A Mol Integr Physiol 147, 1104-
1108.
29.  Dickson, S. L., Shirazi, R. H., Hansson, C. 
et al. (2012) The glucagon-like peptide 1 
(GLP-1) analogue, exendin-4, decreases 
the rewarding value of food: a new role 
for mesolimbic GLP-1 receptors. J 
Neurosci 32, 4812-4820.
30.  Virtue, S., Even, P., & Vidal-Puig, A. 
(2012) Below thermoneutrality, changes 
in activity do not drive changes in total 
daily energy expenditure between 
groups of mice. Cell Metab 16, 665-671.
31.  Berbee, J. F., Boon, M. R., Khedoe, P. P. 
et al. (2015) Brown fat activation reduces 
hypercholesterolaemia and protects 
from atherosclerosis development. 
Nat Commun 6, 6356.
Kooijman.indd   64 30-9-2015   10:54:04
4
PROLONGED DAILY LIGHT EXPOSURE 
INCREASES BODY FAT MASS 
THROUGH ATTENUATION OF 
BROWN ADIPOSE TISSUE ACTIVITY
Sander Kooijman*















†Authors share last authorship
Proc Natl Acad Sci USA (2015) 112: 6748-53




Disruption of circadian rhythmicity is associated with obesity and related disorders 
including type 2 diabetes and cardiovascular disease. Specifically, prolonged 
artificial light exposure associates with obesity in humans, although the underlying 
mechanism is unclear. Here, we report that increasing the daily hours of light 
exposure increases body adiposity through attenuation of brown adipose tissue (BAT) 
activity, a major contributor of energy expenditure. Mice exposed to a prolonged 
day length of 16 h and 24 h light, compared to regular 12 h light, showed increased 
adiposity without affecting food intake or locomotor activity. Mechanistically, we 
demonstrated that prolonged day length decreases sympathetic input into BAT 
and reduces β3-adrenergic intracellular signalling. Concomitantly, prolonging day 
length decreased the uptake of fatty acids from triglyceride-rich lipoproteins as well 
as of glucose from plasma selectively by BAT. We conclude that impaired BAT activity 
is an important mediator in the association between disturbed circadian rhythm and 
adiposity and anticipate that activation of BAT may overcome the adverse metabolic 
consequences of disturbed circadian rhythmicity.




Modern world society is subjected to disturbances of circadian rhythms by shift 
work, sleep deprivation and environmental light pollution. Importantly, increasing 
prevalence of obesity is associated with disrupted sleep-wake pattern in humans (1) 
and coincides with the availability of artificial light (2,3). Additionally, a recent study 
revealed a relationship between exposure to light at night and obesity in a cross-
sectional analysis of over 100,000 women (4). Light input is the most important cue 
for generation of circadian (~24 h) rhythms by the master clock. Both in rodents 
and humans the master clock is situated in the suprachiasmatic nucleus (SCN) of 
the hypothalamus. The SCN is responsible for synchronization of peripheral clocks 
throughout the body, which is mediated by endocrine and neuronal signals (5). 
A  causal role for a disturbed circadian rhythm in the development of obesity has 
been demonstrated by animal studies. Mice with genetically dysfunctional clock 
genes develop obesity and insulin resistance (6-9). Moreover, specific ablation of the 
SCN induces acute weight gain (10). These results indicate a crucial role for the SCN 
in the regulation of adiposity.
Interestingly, we previously showed that prolonged light exposure only is sufficient 
to enhance weight gain in mice. Constant light disrupts the central circadian clock, 
evidenced by an immediate reduction in the circadian amplitude of SCN electrical 
activity. Moreover, constant light induces body weight gain and insulin resistance, 
even faster than high-fat diet, which was not due to increased food intake or reduced 
locomotor activity (11). Therefore, disruption of the central biological clock likely 
induces weight gain by decreasing energy expenditure.
Recently, it has been recognized that brown adipose tissue (BAT) importantly 
contributes to energy expenditure. BAT combusts high amounts of triglycerides (TG) 
into heat, a process called thermogenesis that is mediated by uncoupling protein 1 
(UCP1). Interestingly, SCN neurons project onto BAT and injection of glutamate into 
the SCN increases BAT thermogenesis in rats (12,13). This indicates that BAT may 
mediate the association between circadian rhythmicity and energy expenditure. 
Therefore, the aim of this study was to shed light on the association between 
prolonged light exposure and obesity in humans by investigating the effect of day 
length on BAT activity in mice in relation to body fat gain, independent of ambient 
temperature. We demonstrate that daily light exposure negatively associates with 
the uptake of TG-derived fatty acids and glucose from plasma by BAT, pointing to 
decreased activity of the tissue. Furthermore, we show that increasing daily light 
exposure decreases BAT activity through reduced sympathetic stimulation.





All animal experiments were approved by the institutional ethics committee on 
animal care and experimentation at Leiden University Medical Center (LUMC), 
Leiden, The Netherlands. 9-12 week old male C57Bl/6J mice (Charles River) were 
single housed in clear plastic cages within light-tight cabinets at constant room 
temperature of 22°C. Stable temperature inside the light-tight cabinets was verified 
in 12 h vs. 24 h light conditions. The cages were illuminated with white fluorescent 
light with an intensity of approximately 85 µW/cm2. Before start of the experiment, 
mice were kept on a regular 12:12 light-dark cycle. Mice had ad libitum access to 
standard laboratory chow (Special Diets Services, UK) and water throughout 
experiments. Mice were matched on body weight and light intervention consisted 
of subjecting mice to either 12, 16 or 24 h light exposure per day (i.e. 24 h) for the 
duration of five weeks (n= 9).
In a second study, mice were randomized to either bilateral selective sympathetic 
denervation (n=17) of iBAT or sham surgery (n=6). Mice were anesthetized (isofluorane 
inhalation) and a midline incision of the skin was made, exposing both iBAT pads. 
Sympathetic branches were visualized and cut on both sides. Wounds were closed 
and mice received post-operative analgesia (0.03 mg/kg buprenorphine, Temgesic, 
Merck). Successful denervation was confirmed retrospectively by absence of TH 
in iBAT sections (see below). After four days of recovery, mice that underwent 
denervation were randomized based on body weight and exposed to 12, 16, or 24 h 
light per day for five weeks while sham operated mice were exposed to 12 h light per 
day and served as a reference group.
Body composition, food intake and locomotor activity
At the end of the experiment, body weight was measured and body composition (i.e., 
lean mass and fat mass) was determined in conscious mice using an EchoMRI-100 
(EchoMRI, Houston, Texas). Food intake was monitored by weighing food on lids 
either during last two weeks of light intervention or throughout the five weeks of 
light exposure (denervation experiment). Behavioural activity of mice was assessed 
with passive infrared detectors and recorded using Actimetrics software (Wilmette, 
IL, USA).
TG and glucose clearance
At the end of the experiments, the clearance of TG and glucose was assessed. 
Glycerol tri[3H]oleate ([3H]TO) labeled VLDL-like emulsion particles (80 nm) were 
prepared as previously described (14) and [14C]deoxyglucose ([14C]DG) was added 
(ratio 3H:14C = 6:1). After 5 weeks of light intervention, mice were fasted for 4 h (9AM 
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to 1PM clock time, corresponding to Zeitgeber time (ZT) 2-6 for 12 h group and ZT 4-8 
for 16 h group) and intravenously injected with the radiolabeled emulsion particles 
(1.0 mg TG in 200 µL PBS) and glucose via the tail vein. At time points t=2, 5, 10 and 
15 min after injection, blood was taken from the tail vein to determine the serum 
decay of both radiolabels. Immediately after the last blood withdrawal, mice were 
euthanized by cervical dislocation and perfused with ice-cold PBS for 5 min. Organs 
were harvested, weighed, and the uptake of 3H and 14C radioactivity was determined.
Histology
Formalin-fixed paraffin-embedded iBAT and gWAT sections were cut (5 µm). To 
determine gWAT cell size, sections were stained with Mayer’s haematoxylin and 
eosin. White adipocyte size was quantified using ImageJ software. To determine 
sympathetic activation of iBAT a TH staining was performed. Sections were 
rehydrated and incubated 15 min with 10 mM citrate buffer (pH 6.0) at 120°C for 
antigen retrieval. Sections were blocked with 5% BSA/PBS followed by overnight 
incubation with anti-TH antibody (1:2000, AB-112, Abcam) at 4°C. Next, sections were 
incubated with a secondary antibody (anti-rabbit antibody, DAKO enVision), stained 
with Nova Red and counterstained with Mayer’s haematoxylin. Percentage of area 
positive for TH staining was quantified using Image J software.
Gene expression analysis and mitochondrial assays
A part of iBAT and sBAT was snap frozen and stored at -80°C for gene expression 
analysis and protein analysis (see below). Total RNA was isolated using TriPure 
(Roche) according to the manufacturer’s instructions. 1 μg of total RNA was reverse-
transcribed using M-MLV reverse transcriptase (Promega, Madison, WI, USA). Real-
time PCR was carried out on a CFX96 PCR machine (Bio-Rad) using IQ SYBR-Green 
Supermix (Bio-Rad). Expression levels were normalized to 36B4 as housekeeping 
gene. Expression of mitochondrial genes was measured with quantitative PCR on 
a Roche Lightcycler 480 using Roche SYBR-green mastermix, using mitochondrial 
specific primers (Table S1). Mitochondrial DNA (mtDNA) abundance was quantified 
as described before (15). In short, total DNA was extracted from sBAT tissue, using 
the QIAamp DSP DNA Mini Kit (Qiagen). Citrate synthase activity was measured in 
sBAT tissue as described before (16).
Western blot analysis
The iBAT samples stored at -80°C were homogenized in lysis buffer. Samples 
were diluted and denatured for 5 min at 95°C after adding Laemmli Sample Buffer 
(1:1,  vol/vol; Serva, Heidelberg, Germany). Proteins within homogenates (15 μg) 
were separated on a 10% SDS-page gel and subsequently transferred onto blotting 
membranes. The blotting membranes were blocked with 5% milk powder and 
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incubated overnight at 4°C with the primary antibody β-actin, pCREB, pAMPK or 
pHSL S565 (Cell Signaling). Secondary antibody (anti-rabbit IgG HRP conjugate; 
1:5000; Promega, Madison, WI, USA) was added and SuperSignal Western Blot 
Enhancer (Thermo Scientific, Rockford, IL, USA) was used to visualize protein bands. 
Blots were analysed with Bio-Rad Quantity One and normalized to β-actin.
Statistical analysis
Data are presented as means ± SEM. Correlations between two dependent variables 
were made using Pearson’s correlation. Associations of variables with day length 
were assessed by linear regression analysis. Differences between groups were 
determined using T-tests for normally distributed data. Contribution of light exposure 
as a covariate to body weight gain was analysed by mixed model analysis using IBM 
SPSS Statistics version 20. To assess behavioural activity, actograms were analysed 
using Clock lab and rhythmicity F periodogram analysis was performed on activity 
bins of 10 minutes of the last 10 consecutively recorded days, based on the algorithm 
of Dörrscheidt and Beck (17). Differences at P values < 0.05 were considered 
statistically significant.
Results
Entrainment to light schedules
Male 12 week old C57Bl/6J mice, fed ad libitum a regular chow diet, were exposed 
to daily light exposure of either 12 h, 16 h or to 24 h during 5 weeks at a constant 
ambient temperature of 22°C. During the last 2 weeks of light intervention, circadian 
rhythm in behavioural activity was assessed in their home cages. As compared to a 
day length of 12 h (Supplemental Figure 1A), mice exposed to a day length of 16 h 
showed a retained circadian (24 h) rhythm in behavioural activity, with high activity 
during night-time (Supplemental Figure 1B). In contrast, circadian rhythmicity 
of behavioural activity was largely reduced in mice exposed to constant light 
(Supplemental Figure 1C).
Prolonged daily light exposure increases adiposity without increasing 
food intake
After 5 weeks of light intervention, body weight was determined and body composition 
was assessed by EchoMRI. Prolonged light exposure did not significantly increase 
total body weight (Figure 1A) or lean mass (Figure 1B). Interestingly, we observed a 
daily light exposure-dependent increase in fat mass which reached significance for 
24 h versus 12 h exposure (+57%; p=0.01; Figure 1C). In fact, duration of light exposure 
positively correlated with the body fat mass (β=0.053; r2=0.21; p=0.02) (Figure 1D). 
Mixed model analysis of weekly body weight development showed that light exposure 






























































































































Figure 1 – Mice were exposed to either 12, 16 or 24 h light (n = 9) for 5 weeks, and body weight 
(A), lean mass (B) and fat mass (C) were determined. Correlations are depicted between the 
light exposure period and total fat mass (D), gWAT weight (E) and adipocyte size in gWAT (G). 
Representative images of gWAT stained with haematoxylin and eosin are shown (F). Food 
intake of the last two weeks of light intervention was measured (H). Data are presented as 
means ± SEM. Dotted lines represent 95% confidence interval of the regression line. **p<0.01. 
significantly contributed to weight gain (p=0.028). After 5 weeks of light intervention, 
mice were sacrificed after a kinetic experiment with radioactive tracers (see below), 
and gonadal white adipose tissue (gWAT) was quantitatively weighed and examined 
histologically. A positive correlation was found between light exposure duration and 
gWAT weight (β=0.005; r2=0.20; p=0.02) (Figure 1E) as well as average adipocyte 
size (β=0.08; r2=0.20; p=0.04) (Figure 1F,G). The gWAT weight and adipocyte size 
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were significantly increased in mice exposed to 24 h light compared to 12 h (+21%; 
p=0.02 and +21%; p=0.04, respectively). Notably, food intake was not different in mice 
exposed to 16 h light, and even tended to be reduced in mice continuously exposed 
to light (-13%; p=0.08) compared to mice exposed to 12 h light per day, (Figure 1H). 
Therefore, the positive correlation between day length and adiposity is not explained 
by hyperphagia, consistent with our previous observations that exposure of mice to 
constant light decreases energy expenditure rather than increasing food intake (11).
Prolonged daily light exposure decreases the nutrient uptake by 
brown adipose tissue
To investigate whether prolonged daily light exposure reduces BAT activity, consistent 
with decreased energy expenditure, we determined the effect of light exposure 
duration on the ability of BAT to take up TG-derived free fatty acids and glucose from 
plasma. Hereto, we assessed the kinetics of intravenously injected glycerol tri[3H]
oleate ([3H]TO)-labeled VLDL-like emulsion particles and [14C]deoxyglucose ([14C]DG) 
and determined the distribution of radiolabels at 15 min after injection.
 Prolonged daily light exposure did not substantially alter the kinetics of plasma 
clearance of [3H]TO and [14C]DG (Supplemental Figure 2A,B). In mice exposed to a 
12 h light per day, the uptake of [3H]TO-derived radioactivity was much higher in 
the various BAT depots (interscapular BAT (iBAT), subscapular BAT (sBAT), and 
perivascular adipose tissue (pVAT)) as compared to liver (~3.5-fold), heart (~10-
fold), muscle (~15-fold) and white adipose tissue (WAT) (~25-650-fold) (Figure 2A). 
Interestingly, the uptake of [3H]TO-derived activity by iBAT, sBAT and pVAT 
decreased with prolonged light exposure reaching -47% (p=0.001), -34% (p=0.03) 
and -48% (p=0.01) for 24 h versus 12 h light exposure (Figure 2A). Accordingly, the 
day length negatively associated with the uptake of [3H]TO-derived activity by iBAT 
(β=-0.83; r2= 0.32; p=0.002) (Figure 2B), sBAT (β=-0.58; r2= 0.12; p=0.08) (Figure 2C) 
and pVAT (β=-0.90; r2=0.30; p=0.005) (Figure 2D). Prolonged light exposure did not 
alter the uptake of [3H]TO-derived radioactivity by organs other than BAT. Consistent 
with reduced TG-derived free fatty acid uptake by BAT, we found that prolonged light 
exposure associated to increased plasma free fatty acid levels (β= 0.03; r2=0.45; 
p<0.001) (Supplemental Figure 2C).
Prolonged daily light exposure also decreased the uptake of [14C]DG by BAT. As 
compared to 12 h light exposure, 24 h light exposure decreased the uptake of [14C]DG 
by iBAT (-54%; p=0.002), sBAT (-48%; p=0.02) and pVAT (-57%; p=0.001) (Figure 2F). 
Additionally, 16 h of light a day significantly decreased glucose uptake in pVAT 
(-32%; p=0.04) compared to 12 h (Figure 2E). Similar to the uptake of [3H]TO-derived 
radioactivity, day length negatively associated with the uptake of glucose by iBAT 
(β=-0.02; r2=0.26; p=0.007) (Figure 2F), sBAT (β= -0.13; r2=0.18; p=0.03) (Figure 2G) 
and pVAT (β=-0.03; r2=0.42; p=0.0005) (Figure 2H).
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Figure 2 – Mice were exposed to either 12, 16 or 24 h light (n = 8-9) for 5 weeks, and the 
VLDL-TG and glucose kinetics were assessed by injection of glycerol tri[3H]oleate ([3H]TO)-
labeled emulsion particles and [14C]deoxyglucose ([14C]DG). Uptake of [3H]TO-derived activity 
by the various organs was determined (A), and correlations were determined between light 
exposure and [3H]TO-derived activity in iBAT (B), sBAT (C) and pVAT (D). Concomitantly, the 
uptake of [14C]DG by the various organs was determined (E), and correlations were determined 
between light exposure and the uptake of [14C]DG by iBAT (F), sBAT (G) and pVAT (H). Data are 
presented as means ±SEM. Dotted lines represent 95% confidence interval of the regression 
line.*p<0.05, **p<0.01, *** p<0.001. Abbreviations of organs: iBAT, interscapular BAT; sBAT, 
subscapular BAT; pVAT, perivascular adipose tissue; vWAT, visceral WAT; sWAT, subcutaneous 
WAT; gWAT, gonadal WAT.
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12 h  16 h  24 h
Figure 3 – Mice were exposed to either 12, 16, or 24 h light (n = 9) for 5 weeks, and 
interscapular BAT was isolated. Histological sections were stained for tyrosine hydroxylase 
(TH), representative images are shown (A; arrows indicate TH staining), and quantified (B). 
Correlation was determined between TH staining and uptake of [3H]TO-derived activity (C) 
and [14C]DG (D). Also, correlations were determined between light exposure and protein 
levels of pCREB (E), pAMPK (F), and pHSL S565 (G). Protein levels were normalized to β-actin 
levels. Representative blots for β-actin, pCREB, pAMPK and pHSL S565 are shown (H). Gene 
expression of Pgc1α (I) and Ucp1 (J) were determined and normalized to 36B4 expression. 
Data are presented as means ± SEM. Dotted lines represent 95% confidence interval of the 
regression line. *p<0.05.
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These data imply that prolonged daily light exposure decreases the uptake of 
nutrients from plasma quite specifically by the various BAT depots, indicating that 
prolonged daily light exposure decreases the activity of brown adipocytes.
Prolonged daily light exposure decreases intracellular adrenergic 
signalling in BAT
As the SCN is directly connected to BAT via the sympathetic nervous system, we 
reasoned that prolonged daily light exposure decreases sympathetic activation 
of BAT. Indeed, immunohistochemical analysis of iBAT showed that the amount of 
tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of noradrenalin 
tended to decrease with increasing day length, up to -42% in 24 h compared to 12 h 
(p=0.10) (Figure 3A,B). Additionally, the amount of TH detected in BAT correlated 
with the uptake of [3H]TO-derived activity by BAT (r2=0.17; p=0.056) (Figure 3C) as 
well as with the uptake of [14C]DG by BAT (r2=0.43; p=0.001) (Figure 3D).
Since activation of the β3-adrenergic receptor by noradrenalin increases 
intracellular levels of cyclic AMP (cAMP) which activates protein kinase A (PKA), 
resulting in phosphorylation of cAMP response-binding element (CREB) and activates 
AMP-activated protein kinase (AMPK), we next determined the phosphorylation status 
of these proteins involved in thermogenesis in iBAT. Phosphorylated CREB (pCREB) 
was decreased in 24 h light exposure compared to 12 h (-27%; p=0.009) (Figure 3E). 
Phosphorylated AMPK (pAMPK) was decreased in mice on a day length of 16 h (-14%; 
p=0.05) and 24 h (-32%; p=0.002) (Figure 3F,H) compared to 12 h of light exposure 
per day, independent of total AMPK levels (Supplemental Figure 3A,B). Daily light 
duration negatively associated with levels of both pCREB (β= -0.03, r2=0.29, p=0.006) 
(Figure 3E, H) and pAMPK (β= -0.04, r2=0.47, p=0.0003) (Figure 3F,H). Both pAMPK 
and pCREB induce phosphorylation of the lipolytic enzyme hormone-sensitive 
lipase (HSL). While day length did not affect PKA-mediated phosphorylation of HSL 
on serine 563 position (pHSL S563) (Supplemental Figure 3A,C), it reduced AMPK-
mediated phosphorylation of HSL on serine 565 (pHSL S565). A day length of 24 h 
decreased pHSL S565 compared to a day length of 12 h (-39%; p=0.009) and day length 
negatively correlated with pHSL S565 (β= -0.04, r2=0.33, p=0.0031) (Figure 3G,H).
Gene targets of pCREB include peroxisome proliferator-activated receptor 1α 
(PPARGC1α or PGC1α) that drives transcription of genes involved in mitochondrial 
biogenesis, and UCP1, which is essential for BAT thermogenesis. Prolonged daily 
light exposure (24 h vs. 12 h) decreased gene expression of Pgc1α (-55%; p<0.05) 
(Figure 3I) and tended to decrease gene expression of Ucp1 (-37%; p=0.08) 
(Figure 3J). Increasing day length negatively associated with expression of Ucp1 (β= 
-0.03, r2=0.39, p=0.0005) (Figure 3J).
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Next, we examined the possibility that prolonged light exposure reduces 
BAT thermogenic capacity by decreasing mitochondrial function. Prolonged 
light exposure did not affect gene expression of genes involved in mitochondrial 
biogenesis (Tfam, Cox7a1, Cyc1, Atp5g1), fatty acid oxidation enzymes (Acadvl, Acadl, 
Acadm) or mitochondrial fusion (Mfn2) (Supplemental Figure 4A). Additionally, the 
amount of mitochondrial DNA (Supplemental Figure 4B) as well as citrate synthase 
activity (Supplemental Figure 4C) was similar between the different light exposure 
groups. In line with this finding, total BAT amount was not different upon prolonged 
light exposure (Supplemental Figure 4D).
Together, these data indicate that prolonged daily light exposure reduces 
sympathetic signalling in BAT that is not accompanied by a decrease in mitochondrial 
capacity, but does result in reduced uptake of TG-derived fatty acids and glucose.
Sympathetic denervation of iBAT largely reduces nutrient uptake 
and abolishes effects of prolonged light exposure
To confirm that sympathetic outflow is crucial for the observed effects of prolonged 
daily light exposure, we performed selective, bilateral denervation of the iBAT 
prior to exposing mice to 12, 16 or 24 h light per day. A reference group of mice 
underwent sham surgery and were exposed to 12 h light per day. Denervation 
completely abolished sympathetic input into iBAT, as evidenced by absence of TH 
(Figure 4A). In line with the previous experiment, light exposure did not affect food 
intake (Figure 4B). Additionally, spontaneous locomotor activity was similar between 
all groups (Figure 4C). Interestingly, body weight gain only increased in mice that 
were subjected to 24 h light exposure (Figure 4D). This increase was likely due to 
increased fat mass gain in these animals (Figure 4E).
Next, iBAT and sBAT activity was investigated by determining the ability to take up 
TG-derived fatty acids and glucose from plasma by injection of radiolabeled particles 
as described above. While the uptake of [3H]TO and [14C]DG by non-denervated sBAT 
remained high (Figure 4F and Figure 4G resp.), specific iBAT denervation lowered 
the uptake of [3H]TO-derived activity (Figure 4H) and [14C]DG (Figure 4I) by iBAT with 
approximately 70-80% compared to sham operated animals (p<0.001), indicating 
the importance of noradrenergic input in BAT activity. Importantly, prolonged daily 
light exposure did not further decrease the uptake of [3H]TO and [14C]DG. These 
data indicate the reduction in adrenergic signalling may be causal in the negative 
correlations of hours of light exposure and BAT activity.










































































































































































Figure 4 – Mice underwent bilateral sympathetic denervation of iBAT or sham surgery. 
Denervated mice were exposed to either 12, 16 or 24 h light (n = 5-6) while sham mice were 
exposed to 12 h light exposure (n=6). After 5 weeks, iBAT was isolated and histologically 
stained for tyrosine hydroxylase (TH). Representative images are shown (A). Total food 
intake (B), locomotor activity (C), body weight gain (D) and fat mass gain (E) were determined. 
VLDL-TG and glucose kinetics were assessed by injection of glycerol tri[3H]oleate ([3H]TO)-
labeled emulsion particles and [14C]deoxyglucose ([14C]DG). Uptake of [3H]TO-derived and 
[14C]DG activity by sBAT (F,G) and by iBAT was determined (H,I). Data are presented as means 
±SEM. ns. = not significant, *p<0.05, **p<0.01, *** p<0.001.




This study addressed the effect of daily light exposure (12, 16 and 24 h) on energy 
metabolism in chow-fed C57Bl/6J mice. We show that prolonging the daily light 
exposure increases adiposity and reduces the uptake of TG-derived fatty acids and 
glucose specifically by BAT, accompanied by decreased ß-adrenergic signalling in BAT 
and decreased phosphorylation of intracellular proteins involved in thermogenesis.
Daily light exposure duration positively associated with body fat mass and white 
adipocyte hypertrophy. These data are in line with observations in field voles, 
switching the day length from 8 h to 16 h increased body weight by 24% in 4 weeks 
compared to animals that remained on a day length of 8 h (18). Accordingly, we 
previously showed that prolonging day length from 12 h to 24 h decreases energy 
expenditure in mice without increasing food intake or locomotor activity  (11). 
Although acute light exposure at night can reduce locomotor activity (19) and 
prolonged light exposure affects wheel running activity (20,21), our present study 
confirms previous reports from us (11) and others (22) that prolonged light exposure 
does not decrease spontaneous locomotor activity. Together, these studies support 
the idea that prolonged daily light exposure increases body fat mass through a 
decrease in energy expenditure rather than to an increase in food intake or decrease 
of locomotor activity.
The present study strongly suggests that prolonged daily light exposure increases 
adiposity due to attenuation of BAT activity as reflected by the negative association 
between daily light exposure and the uptake of fatty acids and glucose by several 
BAT depots. Of note, prolonged daily light exposure did not affect uptake of nutrients 
by other metabolic organs, such as WAT. These data are consistent with our recent 
findings that attenuating BAT activity by inhibiting the central melanocortin system 
also reduces the influx of nutrients into BAT (23). In fact, activation of BAT, e.g. by 
cold exposure, increases expression of genes involved in fatty acid oxidation, glucose 
uptake and lipogenesis (24) and strongly increases the uptake of TG-derived fatty 
acids (25) and glucose (24).
Our data are consistent with the hypothesis that prolonged daily light exposure 
decreases BAT activity through reduction of the sympathetic outflow towards BAT. 
Tyrosine hydroxylase (TH), the rate limiting enzyme in noradrenalin production, 
correlates with nutrient uptake by BAT and we observed a decrease in sympathetic 
signalling pathways in BAT. Prolonged light exposure decreased phosphorylation of 
CREB and AMPK, two main targets of β3-adrenergic signalling in the brown adipocyte. 
AMPK not only modulates intracellular lipolysis by phosphorylation of HSL, but also 
regulates uptake of lipids and glucose by inducing translocation of CD36, LPL and 
GLUT4 to the plasma membrane (26,27), which may explain the reduced nutrient 
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uptake by BAT. Moreover, we showed that in the absence of sympathetic input, BAT 
activity is equal among the various light exposure groups.
We propose that the SCN directly mediates the decrease in sympathetic outflow 
upon prolonging daily light exposure. In previous studies we demonstrated that 
prolonged light exposure dampens the amplitude of electrical activity in the SCN 
in vitro (28) and in vivo (10). Interestingly, the amplitude of electrical activity in the SCN 
is linked to sympathetic outflow towards multiple organs (29). This mechanism also 
explains previous findings that exposure of mice to dim light (5 lux) during 10 h nights 
for 4 weeks already results in an increase in body weight, which was accompanied 
by an attenuated amplitude of circadian gene expression in the hypothalamus (30). 
Also, sympathetic outflow towards BAT depots other than interscapular BAT would 
explain our observations that denervation of iBAT does not increase body weight. 
Only 24 h light exposure decreases sympathetic outflow to such an extent, that 
mice increase significantly in body weight. Of note, the effects of light exposure on 
BAT are independent of melatonin secretion, since C57Bl/6J mice are genetically 
melatonin deficient (31). However, we cannot exclude the possibility that in humans 
melatonin does play a role in the association between light pollution and adiposity 
as administration of melatonin increases BAT growth (32) and activity (33,34) in 
hamsters and rats.
Based on our collective data, we thus propose the following mechanism by which 
prolonging daily light exposure increases adiposity: prolonged day length dampens 
the SCN amplitude thereby lowering sympathetic outflow towards BAT resulting in 
decreased β3-adrenergic signalling and thermogenesis in brown adipocytes. As 
a consequence, the uptake of VLDL-TG derived fatty acids and glucose by BAT is 
reduced. The decreased combustion of fatty acids by BAT at equal energy intake thus 
results in a positive energy balance and therefore storage of lipids in WAT (Figure 5).
Recent evidence suggests that BAT activity in humans is physiologically 
regulated by the biological clock. The detectability of BAT by [18F]fluorodeoxyglucose 
(FDG)-PET-CT imaging at room temperature follows a circannual cycle, both in the 
northern and southern hemisphere (35-37), with low detectability of BAT in summer 
(i.e., short day) as compared to winter (i.e., long day). Although differences in outside 
temperature over the year would be a likely explanation for this phenomenon, the 
detectability of BAT showed a stronger correlation with day length than with outside 
temperature (35). Based on our present data, the daily light exposure may thus well 
explain the circannual cycle of BAT detectability. Likewise, impaired BAT activity may 
also explain, at least partly, the relationship between obesity and disturbances in 
circadian rhythmicity in humans by light pollution (2,3,38), and possibly also by shift 
work (39-41) and sleep curtailment (1,42,43). Additionally, our data may provide the 
link in the relationship between exposure to light in the bedroom and obesity  (4). 
The  suggested causal relationship has clear implications for the prevention of 
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Figure 5 – Proposed model on how light exposure modulates body fat mass through brown 
adipose tissue activity. Daily light exposure duration is perceived by the suprachiasmatic 
nucleus, that signals towards BAT via the sympathetic nervous system. At normal day length 
uptake of nutrients by BAT and WAT is in balance, while increasing daily light exposure result 
in reduced BAT activation and subsequent storage of excess energy in WAT. The decrease in 
noradrenaline (NA) availability for stimulation of the β3-adrenergic receptor (B3-AR) leads 
1) reduced phosphorylation of CREB, which decreases transcription of UCP1; 2) reduced 
phosphorylation of AMPK resulting in decreased phosphorylation of HSL and thus decreased 
lipolysis.
obesity in humans. Although the association between light in the bedroom and BAT 
activity in humans remains to be investigated, future lifestyle advice could include 
instructing people to darken their bedroom.
In conclusion, our study provides evidence that prolonged daily light exposure 
increases body fat mass through reduction of BAT activity. The present findings 
support the hypothesis that the relationship between disturbed circadian rhythmicity 
and adiposity in humans is mediated by impaired BAT activity.
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Supplemental Figure 1 – Prolonged daily light exposure affects behavioural rhythms in 
mice. Mice were exposed to either 12, 16 or 24 h light (n = 9) for 5 weeks, and behavioural activity 
was monitored by passive infrared detectors. Representative actograms (left panels) and the 
pertaining F periodogram (right panels) are shown of a mouse exposed to 12 (A), 16 (B) and 
24 h (C) of light. The double-plotted actograms show consecutive days on successive lines and 
the vertical black upticks indicate behavioural activity measured by passive infrared detectors. 
The light regimes are plotted on top of the actograms; white areas represent light and black 
areas represent darkness. Periodogram analysis visualizes the strength of behavioural 
rhythmicity. The dotted lines in the periodograms indicate the 0.05 level of significance.
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Supplemental Figure 2 – Effect of light exposure on TG and glucose plasma clearance. 
Prolonged daily light exposure does not affect TG and glucose plasma clearance. Mice were 
exposed to either 12, 16 or 24 h light for 5 weeks, and the VLDL-TG and glucose kinetics were 
assessed by injection of glycerol tri[3H]oleate ([3H]TO)-labeled emulsion particles and [14C]
deoxyglucose ([14C]DG). Blood was drawn 2, 5, 10 and 15 min after injection. [3H]TO (n=8-9) (A) 
and [14C]DG (n=6-7) (B) derived activity was assessed in plasma samples by liquid oscillation 
counting. Data are represented as means ±SEM. Statistical significance was determined by 
unpaired two-tailed Student’s t-test.















































12 h  16 h  24 h
Supplemental Figure 3 – Prolonged daily light exposure does not affect AMPK and pHSL S563 
in BAT. Prolonged daily light exposure does not affect AMPK and pHSL S563 in BAT. Mice 
exposed to either 12, 16, or 24 h light (n= 9) for 5 weeks, and interscapular BAT was isolated 
for protein quantification. Representative western blots are shown for β-actin, total AMPK 
and pHSL S563 (A). Correlation was determined between hours of light exposure and protein 
levels of AMPK (B) and pHSL S563 (C). Protein levels were normalized to β-actin levels. Data 
are represented as means ± SEM. Statistical significance between groups was determined by 
unpaired two-tailed Student’s t-test, linear regression analysis was performed to analyse the 
association of gene expression with light exposure.


















































































































Supplemental Figure 4 – Effects of prolonged light exposure on mitochondrial function. 
Prolonged daily light exposure does not decrease structural mitochondrial function in BAT 
and quantity of BAT. Mice were exposed to either 12, 16, or 24 h light (n= 9) for 5 weeks, and 
interscapular and subscapular BAT was isolated for gene expression and mitochondrial 
function analysis. Expression of genes involved in mitochondrial biogenesis, fatty acid 
oxidation and fusion genes did not change upon prolonged light exposure (A). The same is true 
for relative mitochondrial DNA quantity (B) and mitochondrial citrate synthase activity (C). iBAT 
was removed quantitatively and weighed (D). Gene expression levels were normalized to 36B4 
levels. Mitochondrial DNA quantity is expressed as ratio of mitochondrial gene expression 
relative to nuclear gene expression (genes indicated below) Data are represented as means 
± SEM. Abbreviations: Tfam, transcription factor A, mitochondrial; Cox7a1, cytochrome c oxidase 
subunit VIIa 1; Cyc1, cytochrome C-1; Atp5g1, ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit C1; Acadvl, acyl-Coenzyme A dehydrogenase, very long chain; Acadl, acyl-
Coenzyme A dehydrogenase, long-chain; Acadm, acyl-Coenzyme A dehydrogenase, medium 
chain; Mfn2, mitofusin 2; mtCo2, cytochrome c oxidase II, mitochondrial; mt-Rnr2, 16S rRNA, 
mitochondrial; Ucp2, uncoupling protein 2; Hk2, hexokinase 2.
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Brown adipose tissue (BAT) contributes importantly to non-shivering thermogenesis 
by its ability to combust large amount of triglycerides (TG) into heat. Interestingly, BAT 
is not only connected through the sympathetic nervous system to the hypothalamic 
temperature center but also to the suprachiasmatic nucleus (SCN). The SCN drives 
circadian (i.e. 24h) rhythms and activity of the SCN is known to adapt to seasonal 
changes in photoperiod. However, the effects of SCN on circadian and seasonal 
rhythms of BAT activity are largely unknown. Therefore, the aim of this study was to 
identify circadian and seasonal rhythms in BAT activity. Hereto, C57Bl/6J male mice 
were subjected to a short photoperiod of 8h (reflecting winter), a regular photoperiod 
of 12h or a long photoperiod of 16h (reflecting summer) per day. After 5 weeks, we 
assessed the uptake of TG-derived fatty acids from the circulation by BAT and other 
metabolically active tissues along the day. Under regular photoperiod, the various 
BAT depots showed a strong circadian rhythm in the uptake of fatty acids with a 
peak at ZT (Zeitgeber time) 12, just before the onset of the dark period. Strikingly, 
exposure to short photoperiod advanced the peak to ZT8 and increased the average 
diurnal fatty acid uptake, compared to long photoperiod that both delayed the peak 
and reduced the average fatty acid uptake. Similarly, short photoperiod resulted in 
an advanced onset of sympathetic outflow and expression of key thermogenic genes. 
Interestingly, this strong diurnal rhythm in fatty acid uptake as well as the adaptation 
to long and short photoperiod did not occur in other metabolically active tissues, 
including white adipose tissue, muscle and heart. In dyslipidemic APOE*3-Leiden.
CETP mice exposed to a 10h photoperiod, at ZT10 compared to ZT0, the plasma 
half-life of TG-derived fatty acids was 1.6-fold lower, while the uptake of fatty acids 
by BAT was 4-fold higher, and plasma TG levels were 2.4-fold lower. In conclusion, 
our findings show that BAT activity is strongly regulated by the biological clock, 
incorporating both seasonal (i.e. photoperiod) and circadian information, which may 
contribute to circadian rhythms in plasma lipid levels.




While the main function of white adipose tissue (WAT) is the storage of surplus energy 
in the form of triglycerides (TG), brown adipose tissue (BAT) combusts large amounts 
of TG into heat, a process called non-shivering thermogenesis. The thermogenic 
capacity of BAT arises from uncoupled respiration through expression of uncoupling 
protein-1 (UCP-1) and is initiated by sympathetic nervous system activity upon 
exposure to cold. Interestingly, retrograde tracing has not only identified direct 
neuronal connections between the hypothalamic temperature center and BAT, but 
also direct connections between the suprachiasmatic nucleus (SCN) and BAT (1).
The SCN is the central biological clock, responsible for the regulation of daily 
(i.e. circadian) rhythms in e.g. sleep-wake activity, endocrine function and body 
temperature. Administration of the excitatory neurotransmitter glutamate directly 
into the SCN increases BAT temperature (2), suggesting that an increased neuronal 
activity in the SCN may directly increase BAT activity. Accordingly, the expression of 
several nuclear receptors as well as the key thermogenic protein UCP-1 follows a 
circadian rhythm in BAT (3), and mice have a lower cold tolerance in the light phase 
than during the dark phase (4). Collectively, these data indicate functional differences 
in BAT reactivity throughout the circadian cycle.
The SCN also functions as a seasonal clock through adaptation to seasonal 
changes in daily photoperiod (5). This sophisticated timing system evolved in order 
to anticipate cyclic challenges, such as changes in food availability and temperature. 
Interestingly, detectability of human BAT by [18F]fluorodeoxyglucose (FDG) PET-CT 
scans at room temperature follows a circannual cycle, with low detectability of BAT in 
summer as compared to winter (6). Although differences in outside temperature over 
the year would be a likely explanation for this phenomenon, the detectability of BAT 
showed a stronger correlation with photoperiod than with outside temperature (6).
We recently demonstrated in mice that prolonged daily light exposure (i.e. 16h 
and 24h of light per day compared to 12h of light per day) decreases sympathetic 
outflow towards BAT and reduces BAT activity (7). Since the effects of the SCN on 
more refined rhythms in BAT function are largely unknown, the aim of this study was 
to identify daily and seasonal rhythms in BAT activity. Thereto, we examined the daily 
rhythms in BAT with respect to changes in histology, gene expression and fatty acid 
uptake, and identified the effects of short photoperiod (reflecting winter) and long 
photoperiod (reflecting summer) on rhythmicity of BAT activity.





All animal experiments were approved by the institutional ethics committee on 
animal care and experimentation at Leiden University Medical Centre (LUMC), 
Leiden, The Netherlands. 12 week old male C57Bl/6J mice (Charles River) were 
single housed in clear plastic cages within light-tight cabinets at constant room 
temperature of 22°C. The cages were illuminated with white fluorescent light with 
an intensity of approximately 85 µW/cm2. Before start of the experiment, mice were 
kept on a regular 12h:12h light-dark cycle. Mice were matched on body weight. 
Light intervention consisted of subjecting mice to a photoperiod of either 8, 12 or 
16h of light per day (i.e. 24h) for the duration of five weeks (n=24 per group). Mice 
had ad libitum access to standard laboratory chow (Special Diets Services, UK) and 
water throughout the experiment. After being exposed to a specific photoperiod for 
five weeks, a TG-derived fatty acid uptake experiment (see below) was performed 
at time points ZT (Zeitgeber Time, time after lights on) 0, 4, 6, 8, 12 and 18 (n=4 
per specific photoperiod per time point). At the end of this experiment, mice were 
sacrificed via cervical dislocation and organs were collected for further gene 
expression and histological analysis (see below).
Homozygous human cholesteryl ester transfer protein (CETP) transgenic mice 
were crossbred with hemizygous APOE*3-Leiden mice at our Institutional Animal 
Facility to obtain female APOE*3-Leiden.CETP mice on a C57Bl/6J background (8). 
Before start of the experiment, mice were kept on a regular 12h:12h light-dark cycle 
and matched on body weight and plasma TG. Mice were single housed on a photoperiod 
of 10h per day and had ad libitum access to Western-type diet (containing 16% fat 
and 0.1% cholesterol; AB diet, Woerden, the Netherlands) and water throughout the 
experiment. After 4 weeks, a TG-derived fatty acid uptake experiment (see below) 
was performed both at the onset of light (ZT0) and the onset of darkness (ZT10).
TG-derived fatty acid uptake
After 5 weeks of exposure to a specific photoperiod, the uptake of TG-derived 
fatty acids was assessed. Glycerol tri[3H]oleate-labeled lipoprotein-like emulsion 
particles (80 nm) were prepared as previously described (9). Mice were fasted for 
4h and intravenously injected with the radiolabeled emulsion particles (1.0 mg TG in 
200 µL PBS) via the tail vein. Two mice could not be injected (12h ZT6 and ZT18). Blood 
was collected after 2, 5, 10 and 15 min to determine plasma decay of the radiolabel. 
After 15 minutes, mice were euthanized by cervical dislocation and perfused with ice-
cold PBS for 5 min. Organs were harvested, weighed, and the uptake of 3H-derived 
activity was determined.




Formalin-fixed paraffin-embedded iBAT sections were cut (5 µm). To determine 
sympathetic activation of iBAT a TH staining was performed. Sections were 
rehydrated and incubated 15 min with 10 mM citrate buffer (pH 6.0) at 120°C for 
antigen retrieval. Sections were blocked with 5% BSA/PBS followed by overnight 
incubation with anti-TH antibody (1:2000, AB-112, Abcam) at 4°C. Next, sections were 
incubated with a secondary antibody (anti-rabbit antibody, DAKO enVision), stained 
with Nova Red and counterstained with Mayer’s haematoxylin. Percentage of area 
positive for TH staining was quantified using Image J software.
Gene expression analysis
A part of iBAT was snap frozen and stored at -80°C for gene expression analysis. 
Total RNA was isolated using TriPure (Roche) according to the manufacturer’s 
instructions. 1 μg of total RNA was reverse-transcribed using M-MLV reverse 
transcriptase (Promega, Madison, WI, USA). Real-time PCR was carried out on a 
CFX96 PCR machine (Bio-Rad) using IQ SYBR-Green Supermix (Bio-Rad). Melt curve 
analysis was included to assure a single PCR product was formed. Expression levels 
were normalized to 36B4 and Hprt housekeeping gene expression. Data were plotted 
as relative expression to expression in 12h light group at ZT0. Primer sequences are 
shown in Table S1.
Plasma TG concentration
After 5 weeks, blood was collected from the tail vein of 4h fasted mice. Plasma was 
assayed for TG using a commercially available enzymatic kit (Roche, Mannheim, 
Germany).
Statistical analysis
Data are presented as means ± SEM. Contribution of Zeitgeber time and photoperiod 
to TG-derived FA uptake was analysed by two-way ANOVA. Differences between 
groups were determined by T-tests (for two groups) or using one-way ANOVA (more 
than two groups). Graph Pad Prism v6.0 was used for all calculations. Associations of 
variables with day length exposure as independent variable were assessed by linear 
regression analysis. Differences at p values < 0.05 were considered statistically 
significant.




TG-derived fatty acid uptake shows circadian rhythm in metabolic 
organs, most pronounced in BAT
To study the daily and seasonal rhythms in BAT activity, C57Bl/6J male mice were 
exposed to a photoperiod of 8h (short), 12h (regular) or 16h (long) per day. After 
5 weeks, we determined the ability of BAT and other metabolic organs to take up 
TG-derived fatty acids at 6 different Zeitgeber time (ZT) points (0, 4, 6, 8, 12 and 18).
First, we identified daily rhythms in the uptake of [3H]oleate from glycerol 
tri[3H]oleate-labeled lipoprotein-like emulsion particles under the standard 
laboratory photoperiod of 12h. Zeitgeber time determined the uptake of [3H]oleate in 
liver, subcutaneous WAT (sWAT), gonadal WAT (gWAT), heart, muscle, interscapular 
BAT (iBAT), subscapular BAT (sBAT) and perivascular adipose tissue (PVAT) (all 
p-values for ZT, pZT≤ 0.01; Figure 1A-H). The peak in uptake of 
3H-activity was found 
at ZT18 for liver (Figure 1A), sWAT (Figure 1B) and gWAT (Figure 1C), corresponding 
with the active phase of the animals, when energy intake is usually high and available 
for storage. The peak in uptake of 3H-activity for heart (Figure 1D) and muscle 
(Figure 1E) was found at ZT4, corresponding to the period of low energy intake and a 
required shift towards fat oxidation. For the BAT depots the [3H]oleate uptake peaked 
just before onset of the active dark phase at ZT12, and was 17±4 % dose/g for iBAT 
(Figure 1F) and 28±19 % dose/g sBAT (Figure 1G), respectively. The uptake at this 
peak was 1.7-15 fold higher than the maximum uptake by other organs, indicating that 
BAT is highly metabolically active. Additionally, the difference between the minimum 
and maximum [3H]oleate uptake by iBAT (4.3-fold) and sBAT (12.0-fold) was higher 
than the difference observed in liver (1.7-fold), sWAT (2.0-fold), gWAT (3.3-fold), heart 
(1.9-fold) and muscle (2.3-fold). The maximum uptake of [3H]oleate by PVAT was 15.3-
fold higher than its minimum and, therefore, comparable to other BAT depots, albeit 
that the peak in uptake (i.e. ZT18) was similar to WAT depots (Figure 1H). Most likely 
this discrepancy is explained by the fact that PVAT is a composed of a mixture of 
brown and white adipocytes.
Circadian rhythm of TG-derived fatty acid uptake adapts to 
photoperiod, only in BAT
Next, we assessed the ability of the various tissues to adapt the circadian rhythm of 
[3H]oleate uptake to either a short (8h) or long (16h) photoperiod. Interestingly, the 
photoperiod changed the circadian [3H]oleate uptake pattern only by brown adipocyte 
depots. Light exposure (LE) duration significantly determined [3H]oleate uptake by 
iBAT (p-value for LE, pLE=0.0034; Figure 1F), sBAT (pLE =0.0085; Figure 1G) and PVAT 
(pLE = 0.014; Figure 1H), but not by liver (pLE = 0.141; Figure 1A), sWAT (pLE = 0.75; 
Figure 1B), gWAT (pLE = 0.3040; Figure 1C), heart (pLE = 0.1765; Figure 1D) and muscle 
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(pLE = 0.3232; Figure 1E). Short photoperiod increased the amplitude (i.e. difference 
between maximum and minimum uptake) of [3H]oleate uptake by iBAT (264%) and 
sBAT (226%) compared to a photoperiod of 12h. Notably, photoperiod did not only 
determine amplitude, but also the timing of the maximum [3H]oleate uptake by 
BAT. Long photoperiod delayed maximum [3H]oleate uptake by iBAT from ZT12 to 
ZT18. Likewise, short photoperiod advanced and increased the maximum [3H]oleate 
uptake by both iBAT and sBAT depots from ZT12 to ZT8. Strikingly, short photoperiod 
resulted in an increased area under the curve for [3H]oleate uptake (Figure 2A) and 
increased the average [3H]oleate uptake of all time points by iBAT (+190%; p<0.05), 
sBAT (+207%; p<0.05) and pVAT (+230%; p<0.05) compared to long photoperiod 
(Figure 2B). The light exposure period (h) negatively correlated with [3H]oleate uptake 
by iBAT (R2 = 0.107, p=0.006; Figure 2C), sBAT (R2 = 0.099, p=0.010; Figure 2D) and 
PVAT (R2 = 0.096, p=0.011; Figure 2E) and not by other metabolic organs (not shown).
Because changes in photoperiod specifically affected the circadian pattern of 
fatty acid uptake by the various brown adipocyte depots, we further investigated 
on the effect of photoperiod on BAT function. Since BAT activation decreases the 
lipid content of BAT (10) whereas BAT inactivation increases its lipid content (11), we 
histologically determined the daily rhythm of lipid content in BAT, and the effect of 
photoperiod thereon. A short photoperiod resulted in a maximum intracellular lipid 
depletion at time point ZT8 (Figure 2F) corresponding with the period of maximum 
uptake of [3H]oleate by iBAT (Figure 1F). A long photoperiod delayed maximum lipid 
depletion to ZT18 (Figure 2F) at which a maximum uptake of [3H]oleate by iBAT was 
observed (Figure 1F). Previously, we proposed that the SCN regulates BAT activity 
via the sympathetic nervous system (7). Since tyrosine hydroxylase (TH) is the 
rate-limiting enzyme in norepinephrine production and, therefore, a measure of 
sympathetic activity we next quantified TH content in BAT. The dip in lipid content at 
ZT8 during short photoperiod coincided with a peak in TH content in BAT (Figure 2G). 
Long photoperiod shifted the peak in TH to ZT18, corresponding to the maximum lipid 
depletion of BAT (Figure 2F) and maximum uptake of [3H]oleate by iBAT (Figure 1F). 
These data indicate that the daily and seasonal rhythms in BAT activity indeed may 
depend on sympathetic outflow.
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Figure 1 – Daily and seasonal rhythms in TG-derived fatty acid uptake in wild-type mice. 
Wild-type mice were exposed to photoperiods of 8, 12 or 16h of light per day for five weeks and 
injected with glycerol tri[3H]oleate-labeled lipoprotein-like particles at six time points (n=3-4/
group). Mice were sacrificed and uptake of [3H]oleate was determined for liver (A), sWAT (B), 
gWAT (C), heart (D), muscle (E), iBAT (F), sBAT (G) and PVAT (H). Data are presented as means 
±SEM and ZT0/ZT24 was double plotted for visualization purposes. PZT and PLE represent 
p-values for the factors Zeitgeber Time (i.e. time point) and light exposure, respectively 
(two-way ANOVA). Abbreviations: iBAT, interscapular BAT; sBAT, subscapular BAT; pVAT, 
perivascular adipose tissue; sWAT, subcutaneous white adipose tissue; gWAT, gonadal white 
adipose tissue.











































































































































































































Figure 2 – Photoperiodic regulation of TG-derived fatty acid uptake by BAT of wild-type 
mice. Wild-type mice were exposed to photoperiods of 8, 12 or 16h of light per day for five 
weeks and injected with glycerol tri[3H]oleate-labeled lipoprotein-like particles (n=24/group). 
Mice were sacrificed at six time points (ZT 0, 4, 6, 8, 12, 18) and the area under the curve (A) 
and average daily uptake of [3H]oleate derived activity was determined (B). Interscapular 
BAT (iBAT) was collected for histological purposes. Intracellular lipid content was quantified 
from H&E stained sections (A) and tyrosine hydroxylase (TH) content was determined by 
immunohistochemistry  (B). Data are presented as means ±SEM and ZT0/ZT24 was double 
plotted for visualization purposes. Correlations were made between photoperiod and uptake 
of [3H]oleate by iBAT (C), sBAT (D) and pVAT (E). Interscapular BAT (iBAT) was collected for 
histological purposes. Intracellular lipid content was quantified from H&E stained sections (F) 
and tyrosine hydroxylase (TH) content was determined by immunohistochemistry (G). * p<0.05 
(one-way ANOVA, Tukey’s post-hoc test). Correlations were analyzed by linear regression. 
Abbreviations: iBAT, interscapular BAT; sBAT, subscapular BAT; pVAT, perivascular adipose 
tissue; sWAT, subcutaneous white adipose tissue; gWAT, gonadal white adipose tissue.
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The daily and seasonal rhythms of BAT activity coincide with 
expression of thermogenic genes.
Next, we determined expression patterns of key genes involved in BAT thermogenesis 
(Figure 3). Zeitgeber Time did not significantly determine expression of Cd36 
(Figure  3A), lipoprotein lipase (Lpl; Figure 3B) and uncoupling protein 1 (Ucp1; 
Figure 3C), but did determine gene expression of deiodinase type II (Dio2; Figure 3D), 
Prdm16 (Figure 3E), peroxisome proliferator-activated receptor gamma coactivator 
1-alpha (Pgc1α; Figure 3F) and clock genes Rev-erbα (Figure 3G) and period 2 (Per2; 
Figure 3H) in iBAT. When mice were exposed to a regular photoperiod of 12h, gene 
expression of Ucp1, Dio2, Prdm16 and Pgc1α were highest at ZT12 and lowest at ZT18 
(1.9-fold, 5.1-fold, 2.4-fold and 4.6-fold difference, respectively). Gene expression of 
Rev-erbα was highest at ZT6 and lowest at ZT18 (4.6-fold difference), while expression 
of Per2 was highest at ZT12 and lowest at ZT4 (5.7-fold difference).
Light exposure duration significantly determined expression of Per2 (pLE=0.0126), 
as both long and short photoperiod shifted the rhythmic pattern. Long photoperiod 
only shifted the peak of Pgc1α expression from ZT8 to ZT12, and that of the clock 
genes Rev-erbα from ZT6 to ZT8 and Per2 from ZT12 to ZT18, while the maximum gene 
expression of the other genes remained at ZT12. Interestingly, short photoperiod 
resulted in a phase advance of the peaks in gene expression to ZT8 for Lpl, Dio2 and 
Prdm16, and to ZT6 for Ucp1 and Pgc1α, indicating adaptation the circadian expression 
of all these genes to the photoperiod.
► Figure 3 – Daily and seasonal rhythms in gene expression in BAT of wild-type mice. Wild-
type mice were exposed to photoperiods of 8, 12 or 16h of light per day for five weeks and 
sacrificed at six time points (n=4/group). Interscapular BAT (iBAT) was collected for gene 
expression analysis. Normalized gene expression was calculated for Cd36 (A), Lpl (B), Ucp1 (C), 
Dio2 (D), Prdm16 (E), Pgc1a (F) and clock genes Rev-erba (G) and Per2 (H). Data are presented as 
means ±SEM and ZT0/ZT24 was double plotted for visualization purposes.
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Circadian rhythm in BAT activity determines diurnal variation in 
plasma TG levels
Since activation of BAT importantly contributes to lowering of plasma TG levels in 
hyperlipidemic mice (12), we next investigated the consequences of the circadian 
rhythm in BAT activity on plasma TG levels in hyperlipidemic APOE*3-Leiden.CETP 
mice. Mice were exposed to a photoperiod of 10h and after 5 weeks we determined 
the uptake of TG-derived fatty acids by BAT and other metabolic organs at the onset 
of light- and dark phase. The uptake of glycerol tri[3H]oleate-derived [3H]oleate was 
higher at ZT10 compared to ZT0 for iBAT (4.2-fold; p<0.01), sBAT (3.8-fold; p<0.05) 
and sWAT (2.2-fold; p<0.01), and lower for heart (1.6-fold; p<0.01) (Figure 4A). The 
increase in [3H]oleate uptake at ZT10 compared to ZT0 by iBAT (up to 34±6 % of 
injected dose/g organ) and sBAT (up to 33±10 % of injected dose/g organ) resulted in 
an enhanced clearance of the radiolabel from the circulation (Figure 4B) reflected 
by a 1.6-fold shorter half-life (2.8±0.2 min vs 4.5±1.0 min; p<0.01; Figure 4C), and 
was accompanied by lower plasma TG levels (7.2±1.6 mM vs 3.0±0.6 mM; p<0.05; 
Figure 4D). These data indicate that the endogenous high activity of BAT at the start 
of the dark phase leads to increased TG clearance and lowering of plasma TG in 
hyperlipidemic mice.
Discussion
In the present study we investigated daily and seasonal rhythms in BAT. We show 
that circadian timing as well as photoperiodic seasonal information are important 
for BAT activity, as demonstrated by studies evaluating TG-derived fatty acid uptake 
from plasma, lipid content and expression of thermogenic genes. We found that 
BAT activity is the highest at the onset of the active, dark period. Strikingly, short 
photoperiod advanced the peak in BAT activity and resulted in an increased total 
capacity to take up circulating lipids, while long photoperiod reduced the uptake of 
fatty acids by BAT. Metabolic organs other than BAT, including liver, WAT, muscle and 
heart, also displayed a circadian pattern in their metabolic activity but did not adapt 
to photoperiodic changes.
While the daily peaks in TG-derived fatty acid uptake by WAT and liver corresponded 
with periods of excessive energy availability (i.e. active period at dark phase) and the 
uptake by heart and muscle with the period of low carbohydrates (i.e. inactive period 
during light phase), the uptake of BAT depots reached it maximum at the onset of 
the dark phase. In addition, we observed high TH content, lipid depletion and high 
expression of key thermogenic genes at the same time, overall indicating increased 
BAT activity just before wakening. These patterns are in line with a previous report 
on circadian rhythm in glucose uptake by BAT using [18F]FDG-PET-CT scanning (6) 
and correspond with the known rhythm in core temperature for mice, which declines 
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Figure 4 – Daily rhythms in TG metabolism in hyperlipidemic APOE*3-Leiden.CETP mice. 
APOE*3-Leiden.CETP mice were exposed to a photoperiod of 10h of light per day. After 5 weeks, 
mice were injected with glycerol tri[3H]oleate-labeled lipoprotein-like particles at ZT0 and 
ZT10 (n=6/ time point). Uptake of [3H]oleate by various metabolic organs was determined (A). 
[3H]oleate was quantified in plasma at several time points after injection and expressed as 
percentage of the injected dose (B), and the plasma half-life of [3H]oleate was calculated (C). 
Triglycerides were measured in plasma at the onset and light phase (ZT0) and dark phase 
(ZT10) (D). Data are presented as means ±SEM. *p<0.05, **p<0.01 (T-test). Abbreviations: 
iBAT, interscapular BAT; sBAT, subscapular BAT; pVAT, perivascular adipose tissue; sWAT, 
subcutaneous white adipose tissue; gWAT, gonadal white adipose tissue.
during sleep and rises before wake (13). The pronounced gene in Pgc1α, Ucp1, 
Prdm16 and Dio2 are in line with previous reports of gene expression under normal 
photoperiod regimes (3,14,15). The rhythmicity of Ucp1 seems less consistent as 
one study found a high amplitude (3) while others reported weaker rhythmicity (15) 
similar to the present data. A possible explanation for this discordance is that Ucp1 
expression may be more influenced by fasting or feeding of the mice, since the 
feeding state varies across the different studies.
We found large differences in uptake of TG-derived fatty acids and expression 
of genes involved in thermogenesis, including Prdm16 and Pgc1α, by BAT along the 
day, indicating that disturbed circadian rhythmicity may have considerable effects on 
BAT function and adiposity. Indeed, genetic mouse models of circadian dysfunction, 
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among others Clockmt/mt mice (16) and Per2-/- mice (17), are prone to develop obesity. 
In addition lesioning of the SCN and continuous light exposure result in disturbed 
circadian behavior and acute weight gain (7,18,19). However, these severe models 
for disturbed circadian rhythmicity can be considered as a pathophysiological 
condition. In the current study, exposure to a photoperiod of 16h was sufficient to 
severely diminish the uptake of TG-derived fatty acids by BAT when compared to 
short photoperiod, which most likely corresponded with lower energy expenditure. 
Comparable, hibernating animals typically increase their food intake and decrease 
energy expenditure during summer, resulting in lipid deposition in WAT (20). 
Conversely, during winter hibernating animals almost exclusively rely on lipid 
oxidation. These changes in energy expenditure can partly be mimicked by exposing 
animals to different photoperiods under laboratory conditions (20). Interestingly, this 
regulation of energy balance by photoperiod is not limited to hibernating animals. 
Switching photoperiod in field voles to a length of 16h increases body weight by 24% 
in 4 weeks compared to animals that remained on a photoperiod of 8h (21). Further, 
it has been reported that overweight and obese children experience accelerated 
weight gain during the summer (22), suggesting that photoperiodic regulation of 
energy expenditure may apply to humans as well.
It is tempting to speculate why especially BAT is sensitive to changes in 
photoperiod, reflecting seasonal regulation, with respect to TG uptake, compared to 
other metabolic organs such as white adipose tissue, liver, muscle and heart. Heat 
production by BAT is activated whenever the animal is in need of extra heat, e.g. 
during arousal from hibernation or upon wakening, so a possible explanation is the 
adaptation to photoperiodic changes in sleep-wake pattern (23). However, this does 
probably not explain the change in overall daily capacity of BAT to take up TG-derived 
fatty acids as observed within our study. As noted before, detectability of human 
BAT by [18F]FDG PET-CET scans at room temperature displays a stronger correlation 
with photoperiod than ambient temperature (6), and changes in photoperiod and BAT 
detectability seem to occur before changes in outside temperature. Therefore, a 
change in photoperiod likely signals to BAT to be prepared for upcoming seasonal 
changes, as in general, changes in photoperiod precede changes in ambient 
temperature.
Despite the increasing interest in circadian clock research, the exact mechanism 
how light information is perceived by the eye and transmitted to the periphery is 
not fully understood. Lesioning of the SCN does not lead to loss of cyclic activity 
in metabolic organs, but does prevent synchronization of peripheral clocks to the 
environment (24). As synchronization of peripheral clocks occurs during seasonal 
adaptation, the SCN is likely crucial for the regulation of seasonal adaptation. Studies 
reported that the SCN communicates to the periphery via the autonomic nervous 
system, via hormonal cues such as corticosterone and melatonin, and via rhythmic 
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behavior (25). Considering the importance of the sympathetic activity for cold-
induced thermogenesis (1,26) and the direct neuronal connection between the SCN 
and BAT (1), it is likely that the autonomic nervous system regulates circadian and 
seasonal rhythmicity in BAT. Compatible with this hypothesis, in this study we found 
peaks in TH content of BAT occurring simultaneously with lipid depletion in BAT, 
uptake of TG-derived fatty acids by BAT and expression of thermogenic genes in BAT. 
In addition, we recently demonstrated that prolonged daily light exposure diminishes 
BAT activity, an effect that was abolished by surgical sympathetic denervation of the 
tissue (7).
In summary, we identified circadian and seasonal rhythms in BAT activity, 
contributing to diurnal rhythmicity in TG plasma levels in dyslipidemic mice. Future 
studies should reveal to what extent these data can be extrapolated to humans. 
At least in light of pre-clinical research on BAT activity, but potentially also in clinical 
research, timing of experiments clearly is a crucial factor that should be carefully 
considered.
Acknowledgements
This work was supported by the Netherlands Organization for Scientific Research 
(NWO-VENI grant 016.136.125 to NR Biermasz), the European Foundation for the 
Study of Diabetes and the Programme Partner Novo Nordisk (grant 94802 to CP 
Coomans, JH Meijer and PCN Rensen) and the Dutch Diabetes Research Foundation 
(grant 2013.81.1663 to CP Coomans). PCN Rensen is an Established Investigator of 
the Netherlands Heart Foundation (grant 2009T038). The authors declare no conflict 
of interest.




1.  Bamshad, M., Song, C. K., & 
Bartness, T. J. (1999) CNS origins of the 
sympathetic nervous system outflow to 
brown adipose tissue. Am J Physiol 276, 
R1569-R1578.
2.  Amir, S., Shizgal, P., & Rompre, P. P. 
(1989) Glutamate injection into the 
suprachiasmatic nucleus stimulates 
brown fat thermogenesis in the rat. 
Brain Res 498, 140-144.
3.  Yang, X., Downes, M., Yu, R. T. et al. 
(2006) Nuclear receptor expression links 
the circadian clock to metabolism. Cell 
126, 801-810.
4.  Gerhart-Hines, Z., Feng, D., 
Emmett, M. J. et al. (2013) The nuclear 
receptor Rev-erbalpha controls 
circadian thermogenic plasticity. Nature 
503, 410-413.
5.  VanderLeest, H. T., Houben, T., Michel, S. 
et al. (2007) Seasonal encoding by the 
circadian pacemaker of the SCN. Curr 
Biol 17, 468-473.
6.  van der Veen, D. R., Shao, J., 
Chapman, S. et al. (2012) A diurnal 
rhythm in glucose uptake in brown 
adipose tissue revealed by in vivo PET-
FDG imaging. Obesity (Silver Spring) 20, 
1527-1529.
7.  Kooijman, S., van den Berg, R., 
Ramkisoensing, A. et al. (2015) 
Prolonged daily light exposure increases 
body fat mass through attenuation of 
brown adipose tissue activity. Proc Natl 
Acad Sci USA.
8.  Westerterp, M., van der Hoogt, C. C., 
de, H. W. et al. (2006) Cholesteryl ester 
transfer protein decreases high-density 
lipoprotein and severely aggravates 
atherosclerosis in APOE*3-Leiden mice. 
Arterioscler Thromb Vasc Biol 26, 2552-
2559.
9.  Rensen, P. C., Herijgers, N., 
Netscher, M. H. et al. (1997) Particle 
size determines the specificity of 
apolipoprotein E-containing triglyceride-
rich emulsions for the LDL receptor 
versus hepatic remnant receptor in vivo. 
J Lipid Res 38, 1070-1084.
10.  Berbee, J. F., Boon, M. R., Khedoe, P. P. 
et al. (2015) Brown fat activation reduces 
hypercholesterolaemia and protects 
from atherosclerosis development. 
Nat Commun 6, 6356.
11.  Kooijman, S., Boon, M. R., 
Parlevliet, E. T. et al. (2014) Inhibition 
of the central melanocortin system 
decreases brown adipose tissue activity. 
J Lipid Res 55, 2022-2032.
12.  Bartelt, A., Bruns, O. T., Reimer, R. et al. 
(2011) Brown adipose tissue activity 
controls triglyceride clearance. Nat Med 
17, 200-205.
13.  Refinetti, R. (2012) Integration of 
biological clocks and rhythms. Compr 
Physiol 2, 1213-1239.
14.  Hatori, M., Vollmers, C., Zarrinpar, A. 
et al. (2012) Time-restricted feeding 
without reducing caloric intake prevents 
metabolic diseases in mice fed a high-fat 
diet. Cell Metab 15, 848-860.
15.  Paschos, G. K., Ibrahim, S., Song, W. L. 
et al. (2012) Obesity in mice with 
adipocyte-specific deletion of clock 
component Arntl. Nat Med 18, 1768-1777.
16.  Turek, F. W., Joshu, C., Kohsaka, A. et al. 
(2005) Obesity and metabolic syndrome 
in circadian Clock mutant mice. Science 
308, 1043-1045.
17.  Yang, S., Liu, A., Weidenhammer, A. et al. 
(2009) The role of mPer2 clock gene in 
glucocorticoid and feeding rhythms. 
Endocrinology 150, 2153-2160.
18.  Coomans, C. P., van den Berg, S. A., 
Houben, T. et al. (2013) Detrimental 
effects of constant light exposure 
and high-fat diet on circadian energy 
metabolism and insulin sensitivity. 
FASEB J 27, 1721-1732.
19.  Coomans, C. P., van den Berg, S. A., 
Lucassen, E. A. et al. (2013) 
The suprachiasmatic nucleus controls 
circadian energy metabolism and 
hepatic insulin sensitivity. Diabetes 62, 
1102-1108.
20.  Dark, J. (2005) Annual lipid cycles in 
hibernators: integration of physiology 
and behavior. Annu Rev Nutr 25,  
469-497.
21.  Krol, E., Redman, P., Thomson, P. J. et al. 
(2005) Effect of photoperiod on body 
mass, food intake and body composition 
in the field vole, Microtus agrestis. J Exp 
Biol 208, 571-584.
22.  Baranowski, T., O’Connor, T., 
Johnston, C. et al. (2014) School year 
versus summer differences in child 
Kooijman.indd   104 30-9-2015   10:54:13
105
5
weight gain: a narrative review. Child 
Obes 10, 18-24.
23.  Deboer, T. & Tobler, I. (1996) 
Shortening of the photoperiod affects 
sleep distribution, EEG and cortical 
temperature in the Djungarian hamster. 
J Comp Physiol A 179, 483-492.
24.  Cailotto, C., La Fleur, S. E., Van, H. C. 
et al. (2005) The suprachiasmatic 
nucleus controls the daily variation of 
plasma glucose via the autonomic output 
to the liver: are the clock genes involved? 
Eur J Neurosci 22, 2531-2540.
25.  Buijs, R. M. & Kalsbeek, A. (2001) 
Hypothalamic integration of central and 
peripheral clocks. Nat Rev Neurosci 2, 
521-526.
26.  Tupone, D., Madden, C. J., & 
Morrison, S. F. (2014) Autonomic 
regulation of brown adipose tissue 
thermogenesis in health and disease: 
potential clinical applications for 
altering BAT thermogenesis. Front 
Neurosci 8, 14.
Kooijman.indd   105 30-9-2015   10:54:13
Kooijman.indd   106 30-9-2015   10:54:13
6
PERIPHERAL CANNABINOID 1 
RECEPTOR BLOCKADE ACTIVATES 








Robin C. van Aggele










FASEB J (2014) 28: 5361-75




The endocannabinoid system is an important player in energy metabolism by 
regulating appetite, lipolysis and energy expenditure. Chronic blockade of the 
cannabinoid 1 receptor (CB1R) leads to long-term maintained weight loss and 
reduction of dyslipidemia in experimental and human obesity. The molecular 
mechanism by which CB1R blockade reverses dyslipidemia in obesity has not been 
clarified yet. In this study, we showed that CB1R blockade with the systemic CB1R 
blocker rimonabant enhanced whole-body energy expenditure and activated brown 
adipose tissue (BAT) indicated by by increased expression of genes involved in BAT 
thermogenesis and decreased lipid droplet size in BAT. This was accompanied by 
selectively increased triglyceride (TG) uptake by BAT and lower plasma TG levels. 
Interestingly, the effects on BAT activation were still present at thermoneutrality 
and could be recapitulated by using the strictly peripheral CB1R antagonist AM6545, 
indicating direct peripheral activation of BAT. Indeed, CB1R blockade directly 
activated T37i brown adipocytes resulting in enhanced uncoupled respiration, most 
likely via enhancing cAMP/PKA signalling via the adrenergic receptor pathway. Our 
data indicate that selective targeting of the peripheral CB1R in BAT has therapeutic 
potential in attenuating dyslipidemia and obesity.




The endocannabinoid system regulates a broad range of physiological functions (1) 
and consists of G-protein coupled cannabinoid receptors, its endogenous lipid 
ligands (endocannabinoids) and the enzymes involved in the biosynthesis and 
degradation of endocannabinoids (2,3). The cannabinoid type 1 receptor (CB1R) is 
expressed at high levels in the brain but also at functionally relevant concentrations 
in various peripheral tissues (1). In contrast, the cannabinoid type 2 receptor 
is mainly expressed on immune cells (4). CB1R knockout mice display reduced 
adiposity and are resistant to diet-induced obesity (5). Moreover, overweight and 
obese humans exhibit an overactive endocannabinoid system (6,7), suggesting a role 
of the endocannabinoid system in energy metabolism.
Chronic systemic blockade of the CB1R with the inverse agonist rimonabant 
leads to long-term maintained weight loss and reduction of dyslipidemia in obese 
rodents  (8,9) and humans (10-13). Rimonabant was considered one of the most 
promising therapeutic drugs to treat obesity, until the appearance of central 
psychiatric side effects resulted in its removal from the market in 2008. Nevertheless, 
several lines of evidence indicate that the effect of CB1R blockade is not restricted 
to a central mode of action, especially since the CB1R has been shown to be present 
in peripheral tissues including the liver (14), skeletal muscle (15) and adipocytes (16). 
More specifically, Tam et al. (17) recently showed that the strictly peripheral CB1R 
antagonist AM6545 induced weight loss and diminished hepatic steatosis in a mouse 
model. Thus, it seems plausible that psychiatric side effects can be avoided by strict 
peripheral blockade of the CB1R, while retaining the beneficial anti-obesity and 
lipid-lowering effects.
Despite clear evidence that pharmacological CB1R antagonism improves 
dyslipidemia, the exact mechanisms and the peripheral tissues involved have not 
yet been elucidated. Recently, brown adipose tissue (BAT) emerged as an important 
player in triglyceride (TG) clearance (18). In contrast to white adipose tissue (WAT), 
which stores excess TG as fat, BAT dissipates energy into heat, a process mediated 
by the mitochondrial uncoupling protein-1 (UCP-1) (19). The best known trigger for 
activation of BAT is cold, which increases sympathetic outflow from the hypothalamic 
temperature centre towards BAT, leading to release of noradrenalin and increased 
thermogenesis (19). Metabolically active BAT stores exist in adult humans (20-22), 
and BAT volume and activity are lower in obese subjects (21). In addition, BAT volume 
and activity are lower in South Asians, a population prone to develop type 2 diabetes 
mellitus and cardiovascular disease (23). Together, these findings have increased 
interest in the therapeutic potential of BAT to combat obesity and related disorders, 
such as dyslipidemia.
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In this study, we aimed at elucidating the molecular mechanism by which CB1R 




Homozygous human cholesteryl ester transfer protein (CETP) transgenic mice were 
crossbred with hemizygous APOE*3-Leiden (E3L) mice at our Institutional Animal 
Facility to obtain E3L.CETP mice, as previously described (24). We chose to perform 
our studies in this specific mouse model, since these mice are a well-established 
model for human-like lipoprotein metabolism and respond to lipid-lowering 
pharmacological interventions (24-26). In all the studies described below, 10 week-
old E3L.CETP male mice were housed under standard conditions in conventional 
cages in a 12:12 h light: dark cycle with ad libitum access to food and water, and 
were fed a high-fat diet (HFD; Research diets, New Brunswick, USA, 60% lard fat) 
for 12 weeks to induce obesity. From the 7th week onwards, the drinking water was 
supplied with 10% fructose. All mouse experiments were performed in accordance 
with the Institute for Laboratory Animal Research Guide for the Care and Use of 
Laboratory Animals and have received approval from the Departmental Ethical 
Review Board (Leiden University Medical Center, Leiden, The Netherlands).
Pharmacological intervention
After 12 weeks of HFD, diet-induced obese (DIO) mice were randomised according to 
their body weight and plasma total cholesterol (TC) and triglyceride (TG) levels into 
four groups. Subsequently, mice were housed at either 21°C (subthermoneutral) or 
28°C (thermoneutral), and received 60% HFD with or without 10 mg/kg body weight/
day (0.00885%, w/w) rimonabant (Axon Medchem, Groningen, the Netherlands) or 
AM6545 (Sigma-Aldrich, St. Louis, USA) for 4 weeks.
Body weight and food intake
In all experiments, mice were housed individually during the 4 week treatment 
period. Food intake was recorded daily by weighing the food that was left in the cage 
or was recorded automatically in metabolic cages (see below). Body weight was 
measured twice a week.
Indirect calorimetry and physical activity
Indirect calorimetry was performed in fully automatic metabolic cages (LabMaster 
System, TSE Systems, Bad Homburg, Germany) during the fourth week of treatment. 
After 20 h acclimatization, oxygen uptake (V˙ O2), carbon dioxide production (V˙ CO2) 
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and caloric intake were measured for 5 consecutive days. Carbohydrate (CHO) and fat 
oxidation rates were calculated from V˙ O2 and V˙ CO2 as described previously (27). 
Total energy expenditure (EE) was calculated from V˙ O2 and V˙ CO2 using the Weir 
equation (28). Physical activity was measured using infrared sensor frames.
Dual-energy X-ray absorptiometry (DEXA) scan
After 4 weeks treatment, body composition was measured by DEXA using the Norland 
pDEXA Sabre X-ray Bone Densitometer. Mice were anaesthetized intraperitoneally 
with a combination of 6.25 mg⁄kg acepromazine (Alfasan), 6.25 mg⁄kg midazolam 
(Roche) and 0.31 mg⁄kg fentanyl (Janssen-Cilag). The total body of the mice was 
scanned, yet the heads were excluded from the analyses.
Plasma parameters
Blood was collected from the tail vein of 4-6 hour fasted mice into chilled capillaries 
that were coated with paraoxon (Sigma, St. Louis, MO) to prevent ongoing lipolysis (29). 
Capillaries were placed on ice and centrifuged, and plasma was assayed for TG, TC, 
and phospholipids (PL) using commercially available enzymatic kits from Roche 
Diagnostics (Mannheim, Germany for TG and TC) and Instruchemie (Delfzijl, the 
Netherlands for PL). Free fatty acids (FFA) were measured using NEFA C kit from 
Wako Diagnostics (Instruchemie, Delfzijl, The Netherlands).
Lipoprotein profiles
To determine lipid distribution over plasma lipoproteins, pooled plasma was used 
for fast performance liquid chromatography (FPLC). Plasma was injected onto a 
Superose 6 column (ÄKTA System, Amersham Pharmacia Biotech, Piscataway, NJ) 
and eluted at a constant flow rate of 50 µL/min with PBS pH 7.4. TG and TC were 
measured as described above in collected fractions of 50 µL.
In vivo clearance of labeled VLDL-like emulsion particles
VLDL-like TG-rich emulsion particles (80 nm) labeled with glycerol tri[3H]oleate 
(triolein, TO) were prepared and characterized as described previously (30). To 
study the in vivo clearance of the VLDL-like particles, mice were fasted for 4 h and 
injected (t = 0) via the tail vein with 200 μL of emulsion particles (1.0 mg TG per 
mouse). Blood samples were taken from the tail vein at 2, 10, 20 and 30 min after 
injection to determine the serum decay of [3H]TO. Plasma volumes were calculated 
as 0.04706  × body weight  (g) as determined from 125I-BSA clearance studies as 
described previously (31). After taking the last blood sample, mice were cervically 
dislocated and perfused with ice-cold PBS via the heart to remove blood from the 
organs. Subsequently, the liver, heart, spleen, hindlimb muscle, gonadal WAT (gWAT), 
subcutaneous WAT (sWAT) and brown adipose tissue (BAT) were collected. Organs 
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were dissolved overnight at 60°C in Tissue Solubilizer (Amersham Biosciences, 
Rosendaal, The Netherlands), and 3H activity was quantified. Uptake of [3H]TO-
derived radioactivity by the organs was expressed per gram wet tissue weight.
In vivo hepatic VLDL-TG and VLDL-apoB production
To measure VLDL production in vivo, mice were fasted for 4 h and anesthetized 
by intraperitoneal injection of 6.25 mg⁄kg acepromazine (Alfasan), 6.25 mg⁄kg 
midazolam (Roche) and 0.31 mg⁄kg fentanyl (Janssen-Cilag). Mice were injected 
intravenously with Tran[35S] label (150 μCi/mouse) (MP Biomedicals, Eindhoven, 
The Netherlands) to label newly produced apolipoprotein B (apoB). After 30 min, at 
t=0 min, Triton WR-1339 (Sigma-Aldrich) was injected intravenously (0.5 mg/g body 
weight, 10% solution in PBS) to block serum VLDL-TG clearance. Blood samples 
were drawn before (t = 0) and at 15, 30, 60, and 90 min after injection of Triton WR-
1339 and used for determination of plasma TG concentration as described above. 
After 90  min, mice were exsanguinated via the retro-orbital plexus. VLDL was 
isolated from serum after density gradient ultracentrifugation at d<1.006 g/mL by 
aspiration (32) and examined for incorporated 35S-activity.
RNA isolation and qRT-PCR analysis
Total RNA was isolated with the Nucleospin® RNA II Kit (Macherey-Nagel) according 
to the manufacturer’s instructions. 1 μg of total RNA was reverse-transcribed 
with iScript cDNA synthesis kit (Bio-Rad), and the obtained cDNA was purified with 
Nucleospin Extract II kit (Macherey-Nagel). Real-time PCR was carried out on the IQ5 
PCR machine (Bio-Rad) using the Sensimix SYBR Green RT-PCR mix (Quantace). Melt 
curve analysis was included to assure a single PCR product was formed. Expression 
levels were normalized using glyceraldehyde-3-phosphate dehydrogenase (Gapdh), 
β2-microglobulin and 36b4 as housekeeping genes. Primer sequences are listed in 
Table 1.
Histology
Interscapular BAT, liver and sWAT were removed and fixed directly in 4% 
paraformaldehyde, dehydrated and embedded in paraffin. For UCP-1 staining in 
BAT, sections (5 μm) were dewaxed in xylene, rehydrated in ethanol and treated with 
3% H2O2 (Sigma) in absolute methanol for 30 min. Next, sections were immersed 
in 10 mmol/L citrate buffer (pH 6.0), boiled for 10 min and cooled down at room 
temperature. Slides were blocked during 60 min with normal goat serum (1:75 in 
PBS) and incubated overnight at 4°C with rabbit monoclonal anti-UCP-1 antibodies 
(Abcam) diluted 1:400 in normal goat serum (1:75). Next, sections were incubated 
for 60 min with biotinylated goat α-rabbit secondary antibodies (Vector Labs) diluted 
1:600 in normal goat serum (1:75). Immunostaining was amplified using Vector 
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Laboratories Elite ABC kit (Vector Labs) and the immunoperoxidase complex was 
visualized with Nova Red (Vector Labs). Counterstaining was performed with Mayer’s 
hematoxylin (1:4). Haematoxylin and Eosin stainings of liver and sWAT sections were 
done using standard protocols. Intracellular lipid content in BAT was quantified by 
use of ImageJ (version 1.47).
Liver lipid extraction
Lipids were extracted from livers consistent with a modified protocol from Bligh 
and Dyer (33). Small liver samples (approx. 50 mg) were homogenized in 10 µL of 
ice-cold methanol per mg tissue. Lipids were extracted into an organic phase by 
adding 1800 μL of CH3OH: CHCl3 (3:1, vol/vol) to 45 μL of homogenate and subsequent 
centrifugation. The lower, organic phase was dried and suspended in 2% Triton 
X-100. Hepatic TG and TC concentrations were measured using commercial kits, as 
explained (see: Plasma parameters). Liver lipids were expressed per milligram of 
protein, which was determined using the BCA protein assay kit (Thermo Scientific, 
Rockford, IL, USA).
In vitro experiments with brown adipocytes
The murine brown preadipocyte cell line T37i (34) was cultured in HAM’S-F12 
medium (Gibco-Invitrogen) supplemented with 10% fetal calf serum, 2 mM HEPES, 
100 U/mL penicillin and 100 μg/mL streptomycin (Gibco-Invitrogen). For experiments, 
T37i cells were seeded in 6-wells plates and grown towards confluence. Two days 
after reaching confluence, cells were differentiated using normal culture medium 
supplemented with 2 nM triiodothyronine (T3) (Sigma) and 112 ng/mL bovine insulin 
(Sigma). The differentiation medium was replaced every 2 or 3 days. After 9 days of 
Table 1 – List of primer sequences for RT-PCR
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differentiation, cells were stimulated for 8 h with rimonabant (Axon Medchem) at 
0.1 μM or 1 μM or with vehicle (DMSO) in absence or presence of noradrenalin (1µM). 
Subsequent experiments were performed after pre-incubation for 1 h with and in 
the presence of PKA inhibitor H89 (25µM). Then, 500 µL of supernatant was collected 
and snap-frozen in liquid nitrogen. Cells were washed twice with ice-cold PBS and 
cells were harvested in ice-cold lysis buffer as described below.
Oxygen consumption measurements
A Seahorse Bioscience XF24 extracellular flux analyzer (Seahorse Biosciences, 
North Billerica, MA, USA) was used to measure oxygen consumption rate (OCR) 
in differentiated T37i cells. T37i cells were differentiated in T75 flasks. On day 9 
of differentiation, the cells were trypsinized and seeded in poly-D-lysine (Sigma 
Aldrich) coated 24-well-Seahorse-assay plates. The next day, the cells were 
treated with DMSO vehicle or rimonabant (1 μM). After 4 h, the cells were placed in 
freshly prepared seahorse medium comprising DMEM with 5 mM glucose and 1 mM 
pyruvate with pH 7 and incubated for 1 h in a 37°C incubator without supplemental 
CO2. The ATP synthetase inhibitor oligomycin and the β3-specific agonist CL316,243 
(Tocris) were preloaded in the reagent delivery chambers of the Seahorse sensor 
cartridge and then pneumatically injected into the wells to reach final working 
concentrations. Three baseline OCR measurements were performed, followed by 
injection with CL316,243 to a final concentration of 1 µM or oligomycin to a final 
concentration of 0.5 µM. Post exposure OCR was measured three times after 2 min 
of mixing. The averages of three baseline measurements and three post-exposure 
OCRs were used for data analyses.
In vitro experiments with white adipocytes
3T3-Ll cells (mouse embryonic fibroblast cells, ATCC CCL 92.1) were cultured at 
37 ºC under 5% CO in DMEM containing GlutaMAX (4.5 g/L L-D-Glucose and sodium 
pyruvate) (GIBCO) supplemented with 10% fetal calf serum (FCS, GIBCO), 100 U/mL 
penicillin and 100 μg/mL streptomycin (Gibco-Invitrogen). Confluent 3T3-Ll cells 
were induced to differentiate by treatment with a combination of 1.5 µM insulin, 
0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma) and 1 µM dexamethasone 
(Sigma). After 48 h of treatment the differentiation was maintained by addition of 
culture medium that contained 10 µM insulin. After 15 days of differentiation, cells 
were stimulated for 8 h with rimonabant (Axon Medchem) at 0.1 μM or 1 μM or with 
vehicle (DMSO). Then, 500 µL of supernatant was collected and snap-frozen in liquid 
nitrogen.
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Protein isolation and Western blot
T37i cells or snap-frozen tissue samples were lysed in ice-cold buffer containing 
50 mM Hepes (pH 7.6), 50 mM NaF, 50 mM KCl, 5 mM NaPPi, 1 mM EDTA, 1 mM 
EGTA, 1 mM DTT, 5 mM β-glycerophosphate, 1 mM sodium vanadate, 1% NP40 and 
protease inhibitors using cocktail tablets (Roche). Homogenates were centrifuged 
at 13,000 rpm for 15 min at 4°C and the protein content of the supernatant was 
determined using the BCA Protein Assay Kit from Thermo Scientific. Proteins 
(20 μg) were separated by 10% SDS-PAGE followed by transfer to a polyvinylidene 
fluoride transfer membrane (Merck, Amsterdam, The Netherlands). Membranes 
were blocked for 1 h at room temperature in Tris-buffered saline tween-20 buffer 
with 5% non-fat dry milk followed by an overnight incubation with specific primary 
antibodies. Primary antibodies specific for cannabinoid type 1 receptor (CB1R), 
E2-F, AMPK, P-AMPK, ACC, P-ACC, P-HSL (ser563), P-HSL (ser565) and tubulin 
were purchased from Cell Signaling (Leiden, The Netherlands). A primary antibody 
specific for uncoupling protein 1 (UCP1) was purchased from Sigma-Aldrich. All 
antibodies were diluted 1:1000. Blots were incubated with horseradish peroxidase-
conjugated secondary antibodies for 1 h at room temperature. Bands were visualized 
with SuperSignal West Pico Chemiluminescent Substrate (Pierce) and quantified 
using ImageJ (version 1.47).
Statistical analysis
All data are expressed as mean ± SEM. Statistical analysis using the unpaired 
two-tailed Student’s test was performed with the SPSS 20.0 software package for 
Windows (SPSS, Chicago, United States) to determine differences between vehicle- 
and compound-treated groups. A P-value < 0.05 was considered statistically 
significant.
RESULTS
Systemic CB1R blockade by rimonabant in DIO mice reduces obesity 
and dyslipidemia and increases energy expenditure
To investigate the effect of systemic CB1R blockade on body composition and energy 
balance, E3L.CETP transgenic mice were fed a HFD for 12 weeks to render them obese 
(mean body weight: 53.2 ± 0.9 g) and treated with rimonabant or vehicle for 4 weeks. 
Rimonabant elicited a profound decrease in body mass (-25%, p<0.001; Figure 1A) 
which was not due to a decrease in lean mass but rather to a massive decrease in fat 
mass (-32%, p<0.001; Figure 1B). Rimonabant decreased caloric intake transiently 
(i.e. until day 6) (Figure 1C), in accordance with previous observations (35,36), while 
it persistently induced weight loss throughout the treatment period (i.e. 4 weeks). 
Furthermore, rimonabant markedly diminished plasma TG levels (-59%, p<0.05) and 
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TC levels (-40%, p<0.01) (Figure 1D), which is in line with previous human studies 
(10-12). Rimonabant tended to reduce plasma phospholipid (PL) levels (-31%, p=0.05) 
and had no effect on plasma free fatty acid (FFA) levels. Lipoprotein profiling 
showed that the marked decrease in plasma TG mostly resulted from a reduction 
in VLDL-TG (AUC -62%) (Figure 1E). The persistent reduction in body weight despite 
the transient decrease in food intake following rimonabant treatment suggests 
increased energy expenditure. Indeed, rimonabant increased substrate utilization 
reflected by increased fat oxidation (+18%, p<0.05; Figure 1F), carbohydrate (CHO) 
oxidation (+18%, p<0.05; Figure 1G), and consequently total energy expenditure 
(+17%, p<0.05; Figure 1H), as measured via indirect calorimetry, without increasing 
locomotor activity (Figure 1I) or RQ values (data not shown).
Systemic CB1R blockade by rimonabant attenuates dyslipidemia by 
activating brown adipose tissue
Plasma VLDL-TG levels are determined by the balance between hepatic VLDL-TG 
production and VLDL-TG clearance by lipoprotein lipase (LPL)-expressing peripheral 
organs. Therefore, to gain insight into the mechanism by which systemic CB1R 
antagonism reduces plasma VLDL-TG, we first assessed the effect of rimonabant 
on VLDL production. DIO mice were treated with rimonabant or vehicle for 4 weeks 
and then sequentially injected with Trans35S and Triton WR1339 resulting in linear 
accumulation of VLDL in which newly synthesized apolipoproteins are radiolabeled. 
Rimonabant did not affect the time-dependent accumulation of plasma TG following 
Triton injection (Figure 2A). Therefore, the VLDL-TG production rate, as determined 
from the slope of the curve, was not significantly different. In addition, the rate of 
VLDL-apoB production did not change (Figure 2B). In line with these observations, 
hepatic expression of lipogenic genes such as fatty acid synthase (Fasn) and 
stearoyl-CoA desaturase (Scd1) was unchanged (Figure 2C). All together, these 
data demonstrate that global CB1R antagonism does not diminish dyslipidemia by 
lowering hepatic VLDL-TG production.
To investigate whether rimonabant increases VLDL-TG clearance, we determined 
the kinetics of i.v. injected [3H]TO-labeled TG-rich VLDL-like emulsion particles, 
which have been previously shown to mimic the metabolic behavior of TG-rich 
lipoproteins (30), and studied the plasma clearance and organ distribution of [3H]
TO-derived fatty acids (FA) in mice treated with rimonabant or vehicle for 4 weeks. 
Rimonabant accelerated clearance of [3H]TO from plasma (t½ =3.9 ± 0.6 vs. 6.4 ± 
0.4  min, p<0.05) (Figure 2D), as explained by increased uptake of [3H]TO-derived 
activity by energy-dissipating BAT (+53%, p<0.05; Figure 2E). Of note, rimonabant 
decreased the uptake of [3H]TO by the energy-storing sWAT depot (-42%, p<0.05).
To further investigate the mechanism by which systemic CB1R blockade 
increased FA uptake by BAT, we determined the mRNA expression of genes involved 
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Figure 1 – Systemic CB1R blockade by rimonabant in DIO mice reduces obesity and 
dyslipidemia and increases energy expenditure. Male E3L.CETP mice were fed a HFD for 
12 weeks to induce DIO and were then treated with rimonabant or vehicle for 4 weeks while 
housed at 21°C. (A) Body weight change (g) during the treatment period. (B) Lean and fat 
mass (g) as measured via DEXA-scan after 4 weeks of treatment. (C) Mean daily food intake (g) 
during the treatment period. (D) Plasma triglyceride (TG), total cholesterol (TC), phospholipid 
(PL), and free fatty acid (FFA) levels in 4-hour fasted mice after 4 weeks of treatment. (E) TG 
distribution over lipoproteins after separation from pooled plasma (n=9) by FPLC. (F) Fat 
oxidation, (G) carbohydrate (CHO) oxidation, (H) energy expenditure (EE), and (I) activity levels 
as measured during 5 consecutive days in the fourth week of treatment via fully automatic 
metabolic cages. (F-H) Measurements were corrected for lean mass. Values are means ± SEM 
(n=9) *p<0.05, **p<0.01, ***p<0.001 compared to the control group.
in both BAT differentiation, BAT activity, TG lipolysis and FA uptake. Rimonabant did 
not affect expression of genes involved in BAT differentiation (Pgc1α, Prdm16) and 
intracellular lipolysis (Hsl, Atgl) (data not shown). However, as shown in Figure 2F, 
rimonabant increased expression of Lpl (+30%, p<0.05) and Cd36 (+24%, p<0.05) that 
drive extracellular VLDL-TG lipolysis and subsequent uptake of FA by BAT (18). In 
addition, rimonabant increased expression of Ucp1, which encodes the uncoupling 
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Figure 2 – Systemic CB1R blockade by rimonabant in DIO mice attenuates dyslipidemia by 
activating brown adipose tissue. Male E3L.CETP mice were fed a HFD for 12 weeks to induce 
DIO and were then treated with rimonabant or vehicle for 4 weeks while housed at 21°C (A) 
After 4 weeks of treatment, 4-hour fasted mice were injected intravenously with Tran[35S] and 
TritonWR1339 and blood samples were drawn at the indicated time points. TG concentrations 
were determined and plotted as the increase in plasma TG relative to t=0.  (B)  ApoB 
production rate, as measured by counting 35S-activity in the VLDL fraction isolated after 
90 min. (C) Expression of Fasn and Scd1 in liver as measured by qRT-PCR. (D) After 4 weeks 
of treatment, 4-hour fasted mice were injected intravenously with [3H]TO-labeled VLDL-
like emulsion particles, blood was collected at the indicated time points and radioactivity 
was measured in plasma.  (E)  Uptake of [3H]TO-derived radioactivity by various organs was 
determined, and expressed as percentage of the injected dose per gram wet tissue weight. 
(F) Noradrenalin (NA) content in BAT was measured and expressed as pg/mg BAT (G) Expression 
of Lpl, Cd36, and Ucp1 in BAT as measured by qRT-PCR.  (H)  Representative pictures of 
immunohistochemical UCP-1 stainings of BAT in vehicle (top) and rimonabant (bottom) treated 
mice. Pictures were taken at 100x magnification (scale bar 100 μm). (I) Percentual lipid content 
in BAT tissue sections as quantified by use of ImageJ. Values are means ± SEM (n=9) and 
expression of genes was corrected for the housekeeping genes β2-microglobulin and 36b4. 
*p<0.05, ***p<0.001 compared to the control group. gWAT, gonadal white adipose tissue; sWAT, 
subcutaneous white adipose tissue.
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protein that mediates thermogenesis (+49%, p<0.05). Furthermore, histology 
showed a more intense immunohistochemical staining of UCP-1 in BAT (Figure 2G) 
as well as a decrease in intracellular lipid droplet size, reflected by a decrease in 
relative lipid area (-39%, p<0.001; Figure 2H), both pointing to more active BAT (37). 
Thus, these data provide strong evidence that systemic CB1R antagonism diminishes 
dyslipidemia and increases energy expenditure, by promoting VLDL-TG uptake and 
subsequent combustion by BAT.
Systemic CB1R blockade by rimonabant diminishes TG storage in 
WAT and liver
To investigate whether the increased flux of TG towards BAT reduces (ectopic) TG 
accumulation, we analyzed WAT and the liver in more detail. Indeed, from the VLDL-
TG clearance experiment it appeared that retention of [3H]TO-derived activity by 
the energy storing sWAT depot was diminished after rimonabant treatment (-42%, 
p<0.05; Figure 2E). In line with this, the cell size of white adipocytes was decreased 
in this depot as evident after H&E staining (Supplemental Figure 1A). In addition, 
rimonabant diminished expression of the lipogenic genes Fasn (-58%, p<0.05) and 
Scd1 (-54%, p<0.05), while it increased expression of the lipolytic enzyme hormone 
sensitive lipase (Hsl) (+126%, p<0.05) in WAT (Supplemental Figure 1B), suggesting 
net FA efflux from WAT. To investigate whether rimonabant may directly enhance 
intracellular lipolysis in WAT, we assessed its effect on glycerol release in 3T3-L1 
cells, an in vitro model of differentiated (white) adipocytes. Rimonabant did not affect 
glycerol release (Supplemental Figure 1C), suggesting that the enhanced FA efflux 
from WAT may occur secondary to the enhanced BAT activation.
In liver, rimonabant markedly decreased liver weight (Supplemental Figure 2A), 
which was accompanied by a reduction in liver TG content (-45%, p<0.01) (Supplemental 
Figure 2B) and smaller intracellular lipid vacuoles (Supplemental Figure 2C). 
Furthermore, rimonabant caused a (likely compensatory) downregulation of hepatic 
expression of genes involved in lipid oxidation, such as acyl-CoA synthetase long-
chain family member 1 (Acsl1) and acetyl-CoA carboxylase 2 (Acc2) (Supplemental 
Figure 2D), while genes involved in lipogenesis were not affected (Figure 2C). Thus, 
these data suggest that systemic CB1R blockade reduces storage of TG in WAT and 
liver, which may, at least in part, be a consequence of increased FA demand and flux 
towards BAT.
The anti-obesity and lipid-lowering effects of systemic CB1R 
blockade by rimonabant are not abrogated at thermoneutrality
BAT is densely innervated by the sympathetic nervous system (SNS) (19). Therefore, 
one of the mechanisms by which systemic CB1R blockade may lead to BAT activation 
could involve central CB1R blockade resulting in increased sympathetic outflow 
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towards BAT. To investigate whether rimonabant acts centrally by increasing 
sympathetic nervous system (SNS) activation towards BAT, we next evaluated the 
effects of rimonabant in DIO mice that were housed at thermoneutral temperature 
(28°C). At thermoneutrality, rimonabant still markedly reduced obesity (Figure 3A,B) 
without affecting lean mass. This was accompanied by a transient decrease in food 
intake (i.e. until day 6) (Figure 3C). Importantly, at thermoneutrality rimonabant still 
lowered plasma TG (-70%, p<0.05; Figure 3D), which was mainly due to a reduction 
in VLDL-TG (AUC -52%; Figure 3E). Furthermore, rimonabant still increased 
whole-body fat and carbohydrate oxidation (Supplemental Figure 3A,B), resulting 
in increased total energy expenditure (+21%, p<0.05; Figure 3F), accompanied by 
increased markers of BAT activation both on mRNA (Figure 3G) and histological 
levels (Figure 3H). Thus, these data suggest that the reduction in dyslipidemia, 
increase in energy expenditure and activation of BAT by systemic CB1R blockade 
occurs at least in part independent of SNS activation of BAT.
In vitro CB1R blockade by rimonabant induces activation of brown 
adipocytes which is at least in part mediated by PKA signaling
To explore the possibility that direct blockade of a CB1R in BAT may be responsible 
for the anti-obesity and lipid-lowering effect induced by systemic CB1R blockade, 
we first investigated whether the CB1R is expressed on BAT. Indeed, western 
blots on protein from tissues derived from untreated mice showed that the CB1R 
is highly expressed in BAT (Figure 4A), even when compared to the expression in 
hypothalamus and liver. In vitro treatment of T37i brown adipocytes with rimonabant 
(1 μM) enhanced UCP-1 protein content (Figure 4B). In line with this, we found a 
significantly elevated oxygen consumption rate in the cells upon 5 h of treatment 
with rimonabant (+23%, p<0.05; Figure 4C). Furthermore, under these conditions 
oligomycin was less capable to suppress oxygen consumption rate (OCR) (Figure 4D), 
pointing to enhanced uncoupling of oxidative phosphorylation. Enhanced uncoupling 
may be the result of enhanced intracellular lipolysis resulting in allosteric activation 
of UCP-1 (19). Indeed, we found that rimonabant dose-dependently increased glycerol 
release (Figure 4E), pointing to increased intracellular lipolysis.
AMP-activated protein kinase (AMPK) serves as an intracellular energy sensor 
and activation of AMPK by means of phosphorylation results in enhanced fatty 
acid and glucose oxidation in a variety of tissues as well as controls lipolysis in 
white adipocytes (38). Of note, CB1R blockade has been shown to increase AMPK 
phosphorylation in both liver cells (39) and white adipocytes (40). In line with this, 
we found that in vitro treatment of cultured T37i brown adipocytes with rimonabant 
for 8 h induced AMPK phosphorylation (Figure 4F) as well as phosphorylation of 
ACC (Figure 4G), the downstream effector of AMPK. Of note, the induction of AMPK 
phosphorylation was not yet present after 30 min of incubation with rimonabant (data 





































































































































Figure 3 – The anti-obesity and lipid-lowering effects of systemic CB1R blockade by 
rimonabant in DIO mice are not abrogated at thermoneutrality. Male E3L.CETP mice were fed 
a HFD for 12 weeks to induce DIO and were then treated with rimonabant or vehicle for 4 weeks 
while housed at 28°C (A) Body weight change (g) during the treatment period. (B) Lean and fat 
mass (g) as measured via DEXA-scan after 4 weeks of treatment. (C) Mean daily food intake 
(g) during the treatment period. (D) Plasma triglyceride (TG) levels in 4-hour fasted mice after 
4 weeks of treatment. (E) TG distribution over lipoproteins after separation from pooled plasma 
(n=9 per group) by FPLC. (F) Energy expenditure (EE) as measured during 5 consecutive days 
in the fourth week of treatment via fully automatic metabolic cages, corrected for lean mass. 
(G)  Expression of Lpl, Cd36, and Ucp1 in BAT as measured by qRT-PCR (H) Representative 
pictures of immunohistochemical UCP-1 stainings of BAT in vehicle (left) and rimonabant 
(right) treated animals. Pictures were taken at 100x magnification (scale bar 100 μm). Values 
are means ± SEM (n=9) *p<0.05, **p<0.01, ***p<0.001 compared to the control group.
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not shown). Furthermore, rimonabant did not affect phosphorylation of Ser565-HSL 
(Figure 4H), which is presumably the regulatory site by which the kinase controls 
HSL activity.
In contrast, rimonabant increased the phosphorylation of the PKA target residue 
on HSL (Ser563) (Figure 4I). As the Ser563 residue is phosphorylated by protein 
kinase  A  (PKA), which is itself activated by cAMP, this suggests that the cAMP/
PKA pathway at least in part mediates the enhanced intracellular lipolysis in brown 
adipocytes upon CB1R blockade. Indeed, as shown in Figure 4I, the combination 
of noradrenalin (which also signals through the cAMP/PKA pathway in brown 
adipocytes) and rimonabant even further enhanced p-HSL563 content (+200%, p<0.01). 
Moreover, in the presence of the PKA inhibitor H89 the enhanced pHSL563 content 
induced upon rimonabant was blunted (Figure 4J).
Altogether, these data indicate that direct blockade of the CB1R on brown 
adipocytes directly stimulates intracellular lipolysis, UCP-1 protein content as well 
as uncoupling, which may at least in part be mediated by cAMP-PKA signaling.
◄ Figure 4 – Rimonabant directly stimulates BAT activity in T37i brown adipocytes in vitro.
(A) CB1R protein content was measured via Western blot in BAT, hypothalamus, and liver 
derived from DIO E3L.CETP transgenic mice with elongation factor 2 (EF-2) as housekeeping 
protein. (B) T37i cells were treated with rimonabant (0, 0.1, or 1 µM) for 8 h, and UCP-1 was 
measured via Western blot. (C) T37i cells were treated with rimonabant (1 µM) for 5 h, and OCR 
was measured via Seahorse in the basal state, as well as after addition of oligomycin (arrow 
A) and the 3-adrenergic agonist CL316243 (arrow B). (D) Percentage inhibition of OCR after 
addition of oligomycin. (E) T37i cells were treated with rimonabant (0, 0.1, or 1 µM) for 8 h, and 
glycerol release was measured in the supernatant. (F) T37i cells were treated with rimonabant 
(0, 0.1, or 1 µM) for 8 h, and p-AMPK/AMPK was measured via Western blot. (G) T37i cells were 
treated with rimonabant (0, 0.1, or 1 µM) for 8 h, and p-ACC/ACC was measured via Western 
blot. (H) T37i cells were treated with rimonabant (0, 0.1, or 1 µM) for 8 h and p-HSL565 was 
measured via Western blot. (I) T37i cells were treated with rimonabant (1 µM) with or without 
noradrenalin (NA; 1 µM), and protein content of p-HSL563 was measured via Western blot. (J) 
T37i brown adipocytes were treated with rimonabant (1 µM), H89 (25 µM) or a combination. 
Protein content of pHSL563 was measured via Western blot. Values are means ± SD (n=3–4). 
*p<0.05, **p<0.01, ***p<0.001 vs. control group.
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Strictly peripheral CB1R blockade by AM6545 reduces obesity and 
dyslipidemia and increases energy expenditure in DIO mice
To investigate whether peripheral CB1R blockade is sufficient to induce weight loss 
and reverse dyslipidemia in vivo, we treated DIO mice for four weeks with vehicle or 
AM6545, a peripherally restricted CB1R antagonist that has been previously shown 
not to elicit central side effects (17). AM6545 markedly reduced body weight (-19%, 
p<0.001; Figure 5A) and fat mass (-23%, p<0.01; Figure 5B), without altering lean 
mass. AM6545 did not induce the initial transient decrease in food intake as seen with 
rimonabant, although a slight decrease was evident later during the treatment period 
(Figure 5C). However, total caloric intake was not affected. Furthermore, AM6545 
substantially decreased plasma TG levels (-49%, p<0.05; Figure 5D), which mostly 
resulted from a reduction in VLDL-TG (AUC -73%; Figure 5E). In addition, AM6545 
increased total energy expenditure (Figure 5F), which was due to an increase in both 
fat and carbohydrate oxidation (Figure 5G,H). Thus, these data demonstrate that 
peripheral CB1R blockade is sufficient to diminish obesity and dyslipidemia in DIO.
Strictly peripheral CB1R blockade by AM6545 attenuates dyslipidemia 
by activating brown adipose tissue
To investigate whether peripheral CB1R blockade also diminished dyslipidemia by 
increasing FA uptake by BAT, we again assessed VLDL-TG production and clearance. 
Just like rimonabant, AM6545 did not affect the production rates of VLDL-TG and 
VLDL-apoB (Figure 6A,B) or hepatic expression of lipogenic genes (Figure 6C). 
Instead, AM6545 also accelerated clearance of [3H]TO-labeled VLDL-like emulsion 
particles from plasma (Figure 6D), accompanied by a marked increase of 3H retention 
by BAT (+235%, p<0.01; Figure 6E), and a decrease in 3H uptake by sWAT (-51%, p<0.01). 
In BAT, AM6545 increased expression of Lpl (+67%, p<0.05), Cd36 (+59%, p<0.05) and 
Ucp1 (+32%, p<0.05; Figure 6F) and decreased lipid content (Figure 6G), all pointing to 
increased BAT activity. AM6545 also decreased white adipocyte size (Supplemental 
Figure 4A) and liver weight (-24%, p<0.001; Supplemental Figure 4B) accompanied 
by a reduction in liver TG content (-17%, p<0.05) (Supplemental Figure 4C) and lipid 
vacuole size (Supplemental Figure 4D). Thus, peripheral CB1R blockade is sufficient 
to diminish dyslipidemia, and probably also obesity, by promoting VLDL-TG uptake 
and subsequent combustion of engulfed FA by BAT.
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Figure 5 – Strictly peripheral CB1R blockade by AM6545 reduces obesity and dyslipidemia 
and increases energy expenditure in DIO mice. Male E3L.CETP mice were fed a HFD for 
12 weeks to induce DIO and were then treated with AM6545 or vehicle for 4 weeks while housed 
at 21°C. (A) Body weight change (g) during the treatment period. (B) Lean and fat mass (g) as 
measured via DEXA-scan after 4 weeks of treatment. (C) Mean daily food intake (g) during 
the treatment period. (D) Plasma triglyceride (TG) levels in 4-hour fasted mice after 4 weeks 
of treatment. (E) TG distribution over lipoproteins after separation from pooled plasma (n=9 
per group) by FPLC. (F-H) energy expenditure, fat oxidation and carbohydrate (CHO) oxidation 
as measured during 5 consecutive days in the fourth week of treatment via fully automatic 
metabolic cages, corrected for lean mass. Values are means ± SD (n=9) *p<0.05, ***p<0.001 
compared to the control group.











































































































































Figure 6 – Strictly peripheral CB1R blockade by AM6545 attenuates dyslipidemia in DIO mice 
by activating brown adipose tissue. Male E3L.CETP mice were fed a HFD for 12 weeks to 
induce DIO and were then treated with AM6545 or vehicle for 4 weeks while housed at 21°C. (A) 
After 4 weeks of treatment, 4-hour fasted mice were injected intravenously with Tran[35S] and 
TritonWR1339 and blood samples were drawn at the indicated time points. TG concentrations 
were determined and plotted as the increase in plasma TG relative to t=0. (B) ApoB production 
rate, as measured by counting [35S]-activity in the VLDL fraction after 90 min. (C) Expression of 
Fasn and Scd1 in liver as measured by qRT-PCR. (D) After 4 weeks of treatment, 4-hour fasted 
mice were injected intravenously with [3H]TO-labeled VLDL-like emulsion particles. Blood was 
collected at the indicated time points and radioactivity was measured in plasma. (E) Uptake of 
[3H]TO-derived radioactivity by various organs, and expression per gram wet tissue weight. (F) 
Expression of Lpl, Cd36, and Ucp1 in BAT as measured by qRT-PCR. (G) Representative pictures 
of immunohistochemical UCP-1 stainings of BAT in vehicle (left) and rimonabant (right) treated 
animals. Pictures were taken at 100x magnification (scale bar 100 μm). (H) Noradrenalin (NA) 
content in BAT was measured and expressed as pg/mg BAT. Values are means ± SEM (n=9) 
and expression of genes was corrected for the housekeeping genes β2-microglobulin and 36b4. 
*p<0.05, **p<0.01, ***p<0.001 compared to the control group.




Systemic CB1R blockade by the inverse CB1R agonist rimonabant alleviates the 
excess body weight and dyslipidemia that are associated with obesity, both in 
mice and in humans (8,9,11-13). In this study, we demonstrate that systemic CB1R 
blockade reverses DIO and reduces plasma VLDL-TG by selectively increasing 
VLDL-TG clearance by metabolically active BAT followed by combustion. Of note, the 
mechanism involves peripheral activation of BAT since the effects were still present 
at thermoneutrality and could be recapitulated by using the strictly peripheral (17) 
CB1R antagonist AM6545. Accordingly, cultured brown adipocytes could be activated 
by blockade of the CB1R with rimonabant.
Systemic CB1R blockade by rimonabant resulted in massive activation of BAT, as 
evidenced by reduced lipid content and increased UCP-1 expression, accompanied by 
increased energy expenditure, which is in accordance with previous studies (35,41). 
Of note, by performing kinetic studies with radioactively labeled VLDL-TG we provided 
clear evidence that the TG-lowering effect of rimonabant is due to increased uptake 
of TG-derived FAs by BAT. Since metabolically active BAT has been shown to be 
present and active in human adults (20-23), it is tempting to speculate that the body 
weight-reducing and TG-lowering effects of rimonabant previously found in obese 
subjects might be due to activation of BAT, although the precise role of BAT in TG 
metabolism in humans remains to be established.
Previous studies suggested central CB1R blockade as the main mechanism 
by which rimonabant induces BAT activation, resulting in increased sympathetic 
outflow towards BAT and increased energy expenditure (35,41). For instance, Bajzer 
and colleagues (36) reported that denervation of BAT in mice blunted the effect 
of rimonabant on insulin-mediated glucose uptake. However, in their study, the 
increase in energy expenditure and the reduction in body weight and fat mass were 
not blunted by BAT denervation, suggesting that a peripheral mechanism is at least 
in part involved in these beneficial effects. Indeed, we found that treatment of DIO 
mice with the strictly peripheral CB1R antagonist AM6545 still resulted in increased 
energy expenditure accompanied by increased uptake of TG-derived FAs by BAT 
as well as significant weight loss and reduction in dyslipidemia. Furthermore, we 
showed that the CB1R is highly expressed in BAT. It is important to realize that this 
does not exclude the possibility that presynaptic CB1R on peripheral sympathetic 
nerve terminals innervating BAT may be the peripheral target whose blockade 
enhances BAT activation through enhanced noradrenalin release. However, the fact 
that we found that noradrenalin content in BAT was only increased upon treatment 
with rimonabant at 21°C and not at thermoneutrality or upon AM6545 treatment 
(data not shown), makes this mechanism less likely. In line with this, we found that 
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rimonabant directly activated brown adipocytes in vitro, further supporting the 
possibility of a peripheral mode of action of CB1R blockade in BAT.
We found that systemic blockade of the CB1R by rimonabant did not affect VLDL-
TG production following either systemic or selective peripheral CB1R blockade. In 
contrast, a study by Tam and colleagues (17) reported that blocking the peripheral 
CB1R by AM6545 treatment resulted in a marked increase in the production of VLDL-
TG in both DIO C57Bl/6 and leptin-deficient ob/ob mice. This might be explained 
by differences in study set-up, since Tam and colleagues measured VLDL-TG 
production after 1 week of treatment while in the present study VLDL-TG production 
was measured after 4 weeks. Likely, CB1R blockade transiently increases VLDL-
TG production, leading to a fast initial reduction in hepatic steatosis as was also 
observed in their study. The subsequent normalization in VLDL production that we 
found in our study after 4 weeks of treatment may then be the consequence of a 
lower supply of FFAs towards the liver for incorporation into VLDL-TG, since these 
are efficiently cleared by BAT.
While we provide clear evidence that the TG-lowering effect of CB1R blockade 
is due to peripheral activation of BAT, the mechanism by which CB1R blockade 
lowers body weight and fat mass is less clear and no consistent mechanism has 
been reported up to date. Although BAT activation has been repeatedly shown to 
decrease body weight and fat mass (18,42,43), we cannot exclude that CB1R blockade 
on peripheral tissues other than BAT may contribute to the weight-reducing effect. 
For instance, the CB1R has been shown to be present on white adipocytes (16) and 
treatment of mice with rimonabant and AM6545 increased lipolysis (17,44,45). 
Accordingly, we also found that rimonabant increased mRNA expression of Hsl in 
subcutaneous WAT. The question remains whether the effect of rimonabant on WAT 
lipolysis is a primary effect or occurs as a consequence of enhanced BAT activation. 
As we did not observe a direct effect of rimonabant on glycerol release in 3T3L1 
white adipocytes it is more likely that the enhanced WAT lipolysis occurs secondary 
to BAT activation. Furthermore, the weight-reducing effect of global CB1R blockade 
is also at least in part due to an initial transient decrease in food intake induced 
by rimonabant. The greater efficacy of rimonabant over AM6545 in reducing body 
weight is then likely explained by the fact that AM6545 did not affect total caloric 
intake over the treatment period, as has been shown before (17). Thus, future studies 
are needed to elucidate the specific contribution of BAT in the weight-reducing effect 
of (peripheral) CB1R blockade.
It is interesting to speculate on the possible intracellular mechanisms by which 
CB1R blockade enhances BAT activity. One of the hallmarks of brown adipocyte 
activation is enhanced intracellular lipolysis, resulting in release of FA that can 
subsequently allosterically activate UCP-1 (19). In search for the pathway that is 
connected to induction of intracellular lipolysis by CB1R blockade, we measured 
the phosphorylation state of HSL on various regulatory residues in T37i cells 
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upon treatment with rimonabant. We found that rimonabant selectively enhanced 
p-HSL563, the residue that is phosphorylated by PKA, and that this effect could be 
blocked by addition of the PKA inhibitor H89. As PKA is itself activated by enhanced 
intracellular cAMP levels, this suggests that rimonabant enhances the cAMP/
PKA pathway in brown adipocytes. This mechanism is not surprising as the major 
mediators in CB1R signaling are in fact G-proteins of the G(i/o) family that inhibit 
adenylyl cyclases (46). Moreover, CB1R agonism in a variety of cell types inhibits 
adenylyl cyclase activity and thus cAMP levels (46). In addition, we found that CB1R 
blockade resulted in increased AMPK phosphorylation in brown adipocytes, which 
is in accordance with previous studies performed in hepatocytes (39) and white 
adipocytes (40). However, as AMPK may be activated in case of low intracellular 
ATP levels, the effect of rimonabant on the kinase might be secondary to enhanced 
uncoupling of oxidative phosphorylation induced by rimonabant. Indeed, we found 
that p-AMPK was only enhanced in brown adipocytes after chronic and not acute 
stimulation with rimonabant. Thus, we propose a mechanism (Figure 7) by which 
CB1R blockade on the brown adipocyte membrane results in enhanced cAMP/PKA 
signalling and phosphorylation of HSLser563. This results in enhanced intracellular 
lipolysis and release of FA that subsequently activate UCP1 resulting in enhanced 
uncoupling. As a secondary mechanism, uptake of VLDL-TG derived FA is enhanced 
through an increase of expression of Lpl and Cd36.
Together, our study shows that CB1R blockade diminishes dyslipidemia by 
inducing BAT-mediated VLDL-TG uptake and BAT thermogenesis via a peripheral 
mode of action. Our data suggest that blockade of the peripheral CB1R in BAT may 
be a promising therapy to combat obesity and to lower cardiovascular risk without 
inducing centrally mediated side effects.
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Figure 7 – Proposed mechanism by which CB1R antagonism enhances activation of BAT. 
CB1R antagonism abrogates the inhibition of ß3 adrenergic signaling, and thereby enhances 
adenylyl cyclase activity, resulting in enhanced cAMP levels and activation of protein kinase 
A (PKA). PKA phosphorylates HSL on Ser563, leading to enhanced intracellular lipolysis and 
release of FA. FA can either undergo β oxidation or can allosterically activate UCP-1, resulting 
in enhanced uncoupling. In addition, PKA phosphorylates CREB, enhancing Ucp1 transcription. 
The consequently decreasing triglyceride (TG) pool within the intracellular lipid droplets is 
replenished by enhanced uptake of TG-derived fatty acids (FA) from TG-rich lipoproteins 
through lipolysis by LPL followed by uptake of FA from the plasma through CD36 eventually 
resulting in lowering of plasma TG levels. ATGL, adipose triglyceride; CB1R, cannabinoid 
1 receptor; DG, di-glyceride; FA, fatty acid; HSL, hormone sensitive lipase; LPL, lipoprotein 
lipase; MGL, monoacylglycerol lipase; MG, monoglyceride; TAG, triacylglycerol lipase; UCP-1, 
uncoupling protein-1.
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Supplemental Figure 1 – Effect of systemic CB1R blockade by rimonabant on subcutaneous 
WAT. Male E3L.CETP mice were fed a HFD for 12 weeks to induce diet-induced obesity and were 
then treated with rimonabant or vehicle for 4 weeks while being housed at an environmental 
temperature of 21°C. (A) Representative pictures of H&E stainings of sWAT in vehicle (left) 
and rimonabant (right) treated animals. Sections were enlarged 100x (scale bar 100 μm). (B) 
Expression of Fasn, Scd1, and Hsl in sWAT as measured by qRT-PCR. (C) 3T3L1 white adipocytes 
were treated with rimonabant (0, 0.1 or 1 μM) for 8 hours and glycerol release was measured 
in the supernatant. Values are means ± SEM (n=9 for in vivo study and n=4 for in vitro study) 
and expression of genes was corrected for the housekeeping genes β2-microglobulin and 36b4. 
*p<0.05 compared to the control group.

































































Supplemental Figure 2 – Effect of systemic CB1R blockade by rimonabant on hepatic 
steatosis. Male E3L.CETP mice were fed a HFD for 12 weeks to induce diet-induced obesity 
and were then treated with rimonabant or vehicle for 4 weeks while being housed at an 
environmental temperature of 21°C. (A) Liver weight (g). (B) Liver content of triglycerides (TG), 
total cholesterol (TC) and phospholipids (PL). (c) Representative pictures of H&E stainings 
of livers from vehicle (left) and rimonabant (right) treated animals. Pictures were taken at 
100x magnification (scale bar 100 μm). (D) Expression of Acsl1 and Acc2 in liver as measured 
by qRT-PCR. Values are means ± SEM (n=9) and expression of genes was corrected for the 













































Supplemental Figure 3 – Systemic CB1R blockade increases fat and carbohydrate oxidation 
at thermoneutrality. Male E3L.CETP mice were fed a HFD for 12 weeks to induce diet-induced 
obesity and were then treated with rimonabant or vehicle for 4 weeks while being housed at an 
environmental temperature of 28°C. (A,B) Fat and carbohydrate (CH) oxidation as measured 
during 5 consecutive days in the fourth week of treatment via fully automatic metabolic cages, 
corrected for lean body mass. Values are means ± SEM (n=9). *p<0.05 compared to the control 
group.












































Supplemental Figure 4 – Effect of strictly peripheral CB1R blockade by AM6545 on lipid 
storage in sWAT and liver. Male E3L.CETP mice were fed a HFD for 12 weeks to induce diet-
induced obesity and were then treated with AM6545 or vehicle for 4 weeks while being housed 
at an environmental temperature of 21°C. (A) Representative pictures of H&E stainings of sWAT 
in vehicle (left) and AM6545 (right) treated animals. Pictures were taken at 100x magnification 
(scale bar 100 μm). (B) Liver weight (g). (C) Liver content of triglycerides (TG), total cholesterol 
(TC) and phospholipids (PL). (D) Representative pictures of H&E stainings of liver in vehicle 
(left) and AM6545 (right) treated animals. Pictures were taken at 100x magnification (scale 
bar 100 μm). Sections were enlarged 100x (scale bar 100 μm). Values are means ± SEM (n=9). 
*p<0.05, ***p<0.001 compared to the control group.
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HEMATOPOIETIC α7 NICOTINIC 
ACETYLCHOLINE RECEPTOR DEFICIENCY 
INCREASES INFLAMMATION AND 
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The autonomic nervous system attenuates inflammation through activation of the 
α7 nicotinic acetylcholine receptor (α7nAChR), a pathway termed the cholinergic 
anti-inflammatory reflex. Interestingly, α7nAChR is expressed on immune cells and 
platelets, both of which play a crucial role in the development of atherosclerosis. To 
investigate the role of hematopoietic α7nAChR in inflammation and platelet function 
in atherosclerotic ldlr -/- mice and to identify its consequences for atherosclerotic 
lesion development. Bone marrow from α7nAChR-/- mice or wild-type littermates 
was transplanted into irradiated ldlr -/- mice. After a recovery period of 8 weeks, 
the mice were fed an atherogenic Western-type diet for 7 weeks. Hematopoietic 
α7nAChR deficiency clearly increased the number of leukocytes in the peritoneum 
(2.6-fold, p<0.001), blood (2.9-fold; p<0.01), mesenteric lymph nodes (2.0-fold; 
p<0.001) and spleen (2.2-fold; p<0.01), indicative of an increased inflammatory 
status. Additionally, expression of inflammatory mediators was increased in 
peritoneal leukocytes (TNFα, 1.6-fold, p<0.01; CRP, 1.8-fold; p<0.01) as well as in the 
spleen (TNFα, 1.6-fold, p<0.01). The lack of α7nAChR on platelets from these mice 
increased the expression of active integrin αIIbβ3 upon stimulation by ADP (1.9-fold, 
p<0.01), indicating increased activation status, while incubation of human platelets 
with an α7nAChR agonist decreased aggregation (-35%, p<0.05). Despite the large 
effects of hematopoietic α7nAChR deficiency on inflammatory status and platelet 
function, it  did not affect atherosclerosis development or composition of lesions. 
Hematopoietic α7nAChR is important for attenuation of inflammatory responses and 
maintaining normal platelet reactivity, but loss of hematopoietic α7nAChR does not 
aggravate atherosclerosis development.




Accumulating evidence indicates a prominent role of the autonomic nervous system 
in the regulation of inflammation via the so-called ‘cholinergic anti-inflammatory 
pathway’. This pathway relies upon direct activation of the afferent vagus nerve 
by pro-inflammatory cytokines and subsequent activation of efferent nerve fibers 
resulting in the release of acetylcholine in peripheral organs (1-4). Acetylcholine 
stimulates α7 nicotinic acetylcholine receptors (α7AChR) which is highly expressed 
on immune cells, resulting in decreased NF-κB-mediated gene expression of pro-
inflammatory cytokines (5,6). In addition to immune cells, α7nAChR is expressed on 
a variety of cells including neuronal cells (7), endothelial cells (8) and platelets (9).
Despite its widespread expression, mice deficient for α7nAChR are viable, 
develop normally and show no physical or neurological defects (10). However, 
upon endotoxin administration, α7nAChR-/- mice have significantly increased TNFα 
levels in the serum and spleen compared with wild-type mice (4). Serum IL-6 and 
C-reactive protein (CRP) are increased in α7nAChR-/- mice compared to control mice 
on an atherosclerosis-prone background (11). Accordingly, in vitro studies show that 
acetylcholine attenuates the release of pro-inflammatory cytokines (i.e. TNFα, IL-
1β, and IL-6) by macrophages conditioned by exposure to endotoxin (1). Additionally, 
cholinergic stimulation of α7nAChR inhibits endothelial cell activation and leukocyte 
recruitment during inflammation (8) and modulates platelet function (9). Together, 
these data suggest an attenuating effect for α7nAChR signaling on inflammation.
Atherosclerosis is a chronic inflammatory disease and the main cause of 
cardiovascular events. Atherosclerotic plaque development is initiated by trapping 
of lipids in the intima of the arterial wall, which stimulates vascular cells to produce 
inflammatory molecules and recruit monocytes and T cells to the vessel wall (12). 
Interestingly, the spleen is the most important source of acetylcholine (13) and 
splenic monocytes contribute largely to atherosclerotic lesion development  (14). 
Additionally, circulating inflammatory markers that are under control of the 
cholinergic anti-inflammatory pathway, such as CRP and IL-6, have been implicated 
in the pathogenesis of atherosclerosis (15,16). Furthermore, recruitment, 
transmigration and activation of leukocytes, as well as platelet function contribute 
to atherogenesis (15-17).
We thus hypothesized that α7nAChR activity exhibits an inhibitory effect on 
atherosclerotic lesion development. As the cholinergic anti-inflammatory pathway 
exerts its function through hematopoietic α7nAChR, the aim of this study was to 
assess the stimulatory effect of hematopoietic α7nAChR deficiency on inflammation 
and platelet function, and their consequences for atherosclerotic lesion development. 
Because wild-type (WT) mice do not develop atherosclerosis due to rapid hepatic 
(V)LDL clearance resulting in low (V)LDL-cholesterol levels (~2 mM), we used LDL 
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receptor deficient mice as recipients of α7nAChR-deficient or WT bone marrow. LDL 
receptor deficient mice have increased cholesterol levels on a chow diet that are 




α7nAChR +/- and α7nAChR -/- mice obtained from Charles River Laboratories 
(L’Arbresle, France) were used to generate α7nAChR-/- and α7nAChR+/+ (wild-type, WT) 
mice (both C57Bl/6J background). Homozygous LDL receptor knockout (ldlr -/-) mice 
(C57Bl/6J background) were obtained from The Jackson Laboratory (Bar Harbor, USA) 
as mating pairs and bred at the Gorlaeus Laboratories (Leiden, The Netherlands). 
Mice were housed in sterilized filter-top cages in a temperature-controlled room 
with a 12-h light/dark cycle and food and water were provided ad libitum. Mice were 
maintained on sterilized regular chow, containing 4.3% (w/w) fat and no cholesterol 
(RM3, Special Diet Services, Witham, UK). To induce atherosclerosis, they were fed 
a Western-type diet (WTD), containing 15% (w/w) cacao butter, 1% (w/w) corn oil 
and 0.25% (w/w) cholesterol (Diet W, Abdiets, Woerden, The Netherlands). Drinking 
water was supplied with antibiotics (83 mg/L ciprofloxacin and 67 mg/L polymyxin B 
sulfate) and 6.5 g/L sucrose. Animal experiments were performed at the Gorlaeus 
Laboratories of the Leiden Academic Centre for Drug Research in accordance 
with the National Laws (ID 10161.1). All animal experiments were approved by the 
Ethics Committee for Animal Experiments of Leiden University and carried out in 
compliance with the Dutch government guidelines.
Bone marrow transplantation (BMT)
To induce bone marrow aplasia, female ldlr -/- recipient mice (10-12 weeks old), 
which represent an established model for the development of atherosclerosis, were 
exposed to a single dose of 9 Gy (0.19 Gy/min, 200 kV, 4 mA) total body irradiation 
using an Andrex Smart 225 Röntgen source (YXLON International, Hamburg, 
Germany) with a 6-mm aluminum filter 1 day before the transplantation. At the day 
of transplantation, bone marrow from female donor WT and α7nAChR-/- mice was 
isolated by flushing the femurs and tibias with phosphate-buffered saline (PBS) (n=3 
per group). Single-cell suspensions were obtained by passing the cells through a 
70 µm cell strainer (Falcon, The Netherlands). Irradiated ldlr -/- recipients received 
5x106 bone marrow cells by intravenous injection into the tail vein. After a recovery 
period of 8 weeks mice were fed the WTD for 7 weeks, after which animals were 
sacrificed. Body mass was recorded weekly throughout the study.
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Assessment of successful bone marrow reconstitution
At the end of the study, bone marrow was isolated from the transplanted ldlr -/- mice, 
and hematologic chimerism was determined using genomic DNA by PCR at 15 weeks 
after BMT. The relative presence of the α7nAChR in bonemarrow was assessed using 
primers for murine α7nAChR (forward: 5’-CCTGGTCCTGCTGTGTTAAACTGCTTC-3’; 
reverse: 5’-CTGCTGGGAAATCCTAGGCACACTTGAG-3’) and for the neomycin gene 
neocassette (forward: 5’-TGCTCCTGCCGAGAAAGTAT-3’; reverse: 5’-AATATCACGG 
GTAGCCAACG-3’).
Plasma lipid and lipoprotein analysis
Blood was drawn after a 4 h fast at the start of WTD feeding and after 4 weeks of diet 
via tail-bleeding. At the end of the study, mice were anesthetized by subcutaneous 
injection of a mixture of xylazine (5 mg/mL), ketamine (40 mg/L) and atropine (0.05 mg/
mL) before blood was collected by bleeding via the eye. Plasma was isolated by 
centrifugation and stored frozen at -80°C until further analyses. The concentrations 
of total cholesterol (TC) and triglycerides (TG) in plasma were determined using 
commercially available enzymatic colorimetric kits according to the manufacturer’s 
protocols (236691 and 1488872; Roche Molecular Biochemicals, Indianapolis,  IN, 
USA). The plasma concentration of phospholipids (PL) was determined using 
another enzymatic colorimetric kit (3009; Instruchemie, Delfzijl, The Netherlands). 
The distribution of lipids over the various lipoproteins in plasma was determined by 
fractionation of 50 μL of pooled plasma using a Superose 6 HR 10/30 column (Äkta 
System; Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Analysis of leukocytes
For analysis of leukocytes, at the end of the study, mice were anesthetized by 
subcutaneous injection of a mixture of xylazine (5 mg/mL), ketamine (40 mg/L) 
and atropine (0.05 mg/mL) before blood was collected by bleeding via the eye. 
The peritoneal cavities of the transplanted mice were lavaged with 10 mL ice-cold 
PBS to collect peritoneal leukocytes. Spleen and mesenteric lymphnodes were take 
out for quantification of cell composition, using an automated Sysmex XT-2000iV 
analyzer (Sysmex Europe GMBH, Norderstedt, Germany), and for gene expression 
analysis.
Gene expression analysis
Total RNA was isolated using the Nucleospin RNA II kit (Macherey-Nagel, Düren, 
Germany) according to manufacturer’s instructions. One microgram of total RNA 
was converted to cDNA with iScript cDNA Synthesis kit (Biorad) and purified with 
Nucleospin Extract II kit (Macherey-Nagel). RT-PCR was conducted on a IQ5 PCR 
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machine (Biorad) using Sensimix SYBR Green RT-PCR mix (Quantace, London, UK). 
mRNA levels were normalized to mRNA levels of Hprt, Gapdh and Cyclo.
Analysis of murine platelet function
For analysis of murine platelet function, blood was collected into 0.1 volume 
130 mmol/L trisodium citrate via cardiac puncture. Platelet count and mean platelet 
volume (MPV) were analyzed in whole blood using a Sysmex XT-2000iV Hematology 
Analyzer. The platelet count was corrected for the volume of anti-coagulant present.
To investigate platelet activation, we measured the ability of platelets to convert 
integrin αIIbβ3 to its active high-affinity open conformation (αIIbβ3*) upon stimulation 
by different agonists. For this purpose, 25 µL diluted whole blood (1:20 (v/v) in Hepes-
Tyrode buffer (145 mM NaCl, 5 mM KCl, 0.5 mM Na2HPO4, 1 mM MgSO4, 10 mM Hepes, 
5 mM D-glucose, pH 7.2)) was recalcified (1 mM CaCl2) and stimulated by ADP (0.5 
and 5 µM; Sigma, St. Louis, MO, USA), PAR-4 peptide (0.1 and 1.0 mM; Bachem, Weil 
am Rhein, Germany) or the Ca2+ ionophore A23187 (1 µM; Sigma) for 15 min at 20°C in 
the presence of 5 µL RPE-conjugated anti-active integrin αIIbβ3 (clone JON/A; Emfret 
Analytics, Eibelstadt, Germany). Samples were fixed in 1% formaldehyde in PBS, 
and integrin αIIbβ3 in its active high affinity open confirmation was determined by 
flow cytometry. The total expression level of integrin αIIbβ3 (both active and inactive 
integrin αIIbβ3) was also assessed by flow cytometry in whole blood. Whole blood 
(25 µL) was diluted (1:20 (v/v) in Hepes-Tyrode buffer (pH 7.2)), recalcified (1 mM 
CaCl2), incubated with 5 µL RPE-conjugated anti-integrin αIIbβ3 (clone Leo.F2; Emfret 
Analytics) for 15 min at 20°C and analyzed by flow cytometry after fixation. The ratio 
of active integrin αIIbβ3* / total integrin αIIbβ3 protein was appointed as a marker for 
platelet activation.
Analysis of human platelet activation
For human platelet activation studies, platelets were isolated from freshly drawn 
venous blood from healthy volunteers, who claimed not to have taken any medication 
10 days prior to blood collection. These studies were approved by the Medical Ethics 
Committee of University Medical Center Utrecht and informed consent was obtained 
for blood sampling from all donors. Blood was collected into 3.2% tri-sodium citrate 
and was centrifuged (156 x g, 15 min, 20°C) to prepare platelet-rich plasma. Tri-
sodium citrate was used instead of EDTA to ensure presence of sufficient calcium 
for platelet activation. After addition of 0.1 volume ACD (2.5% (w/v) trisodium citrate, 
1.5% (w/v) citric acid, 2% (w/v) D-glucose) to lower the pH of the plasma to pH 
6.5, platelets were further purified by centrifugation (400 x g, 15 min, 20°C). After 
resuspension of the platelet pellet in Hepes-Tyrode buffer (pH 6.5), prostacyclin 
(PGI2; Cayman Chemical, Ann Arbor, MI, USA) was added to a final concentration 
of 10 ng/mL and the washing procedure was repeated once. The platelet pellet was 
Kooijman.indd   144 30-9-2015   10:54:27
145
7
resuspended in Hepes-Tyrode buffer (pH 7.2) and the platelet count was adjusted to 
2.0x1011 platelets/L. Platelets were left for 30 min at 37°C to ensure a resting state.
For aggregation experiments, platelets were pre-incubated for 30 minutes at 
room temperature with the α7nAChR agonist PNU282987 (10 µM) or vehicle (DMSO). 
Platelet aggregation was initiated by addition of ADP (10 µM) in the presence of 
fibrinogen (0.5 mg/mL; Kordia Life Sciences, Leiden, The Netherlands) and was 
monitored in a Chrono-Log lumiaggregometer (Chrono-Log Corporation, Haverford, 
PA, USA) at 37°C and a stirring speed of 1000 rpm. Additionally, surface expression 
of P-selectin was determined as another marker of platelet reactivity and was 
measured by flow cytometry in citrated whole blood, treated with PNU282987 (10 µM) 
or vehicle prior to stimulation with ADP (serial dilutions ranging from 0-125 µM) for 
20 min in the presence of RPE-conjugated anti-CD62P (BD Pharmingen, Franklin 
Lakes, NJ, USA).
Atherosclerosis quantification
Atherosclerotic mean lesion area (in µm2) was quantified in cross-sections (5 μm) 
throughout the aortic root area starting from the appearance of open aortic 
valve leaflets. Per mouse, four sections with 50-μm intervals were used for 
atherosclerosis measurements. Sections were stained with hematoxylin-phloxine-
saffron for histological analysis. Lesions were categorized for severity according to 
the guidelines of the American Heart Association adapted for mice(18,19). Various 
types of lesions were discerned: no lesions, mild lesions (types 1–3) and severe 
lesions (types 4–5). Immunohistochemistry for determination of lesion composition 
was performed as described previously(20). Rat anti-mouse antibody MAC3 
(1:1000; BD Pharmingen, The Netherlands) was used to quantify macrophage area. 
Monoclonal mouse antibody M0851 (1:800; Dako, Heverlee, the Netherlands) against 
smooth muscle cell (SMC) actin was used to quantify SMC area. Sirius Red staining 
was used to quantify collagen area. Lesion area and composition were determined 
using ImageJ.
Statistical analysis
Data are presented as means ± SEM unless indicated otherwise. To compare 
differences among groups T-tests were performed. A P-value <0.05 was considered 
statistically significant.




Hematopoietic α7nAChR deficiency does not affect body weight and 
plasma lipid levels
Ldlr -/- mice were transplanted with bone marrow from α7nAchR -/- mice or WT 
littermates. After a recovery period of 8 weeks on regular murine chow diet, the 
transplanted mice were challenged with an atherogenic Western-type diet (WTD) for 
7 weeks. Mice transplanted with α7nAchR-/- bone marrow showed a modest temporary 
drop in body weight compared to mice transplanted with WT bone marrow at week 
3 and 4 after BMT, but the weight curves were not different while feeding the WTD 
(Figure 1A). Reconstitution of the recipient ldlr -/- mice with bone marrow of donor 
mice was successful as assessed by α7nAChR transcript analysis in bone marrow 
(>90% chimerism; Supplemental Figure 1).
To evaluate whether hematopoietic α7nAChR deficiency affects lipid metabolism, 
plasma total cholesterol (TC), phospholipids (PL) and triglycerides (TG) were 
assessed at the start of WTD feeding and after 4 and 7 weeks of diet intervention. No 
differences in plasma lipid concentrations were found between α7nAChR -/- and WT 
transplanted mice at the start of the diet (not shown), after 4 weeks (not shown), nor 
after 7 weeks (Figure 1B). In addition, the distribution of cholesterol over lipoproteins 
of the α7nAChR -/- transplanted mice did not differ from that of the WT transplanted 
mice (Figure 1C).
Hematopoietic α7nAChR deficiency increases inflammatory status
As a measure of inflammatory status, the leukocyte count within the peritoneal 
cavity was quantified after lavage. Remarkably, disruption of hematopoietic α7nAChR 
significantly increased peritoneal leukocyte count by 2.6-fold (12.3±3.4 x109/L vs. 
4.8±0.9 x109/L; p<0.05) (Figure 2A). This was due to a significant increase in multiple 
leukocyte cell types within the α7nAChR-/- vs. control transplanted mice, i.e. monocytes 
(6.3±1.6 x109/L vs. 2.9±0.5 x109/L; p<0.05) (Figure 2B), lymphocytes (3.9±1.3 x109/L vs. 
1.7±0.4 x109/L; p<0.05) (Figure 2C), and neutrophils (0.41±0.14 x109/L vs. 0.16±0.04 
x109/L; p<0.05) (Figure 2D), suggesting an increased pro-inflammatory status of the 
body. In line with these observations, in peritoneal leukocytes of α7nAChR-/- vs. control 
transplanted mice, mRNA expression of the pro-inflammatory cytokines TNFα (1.6-
fold; p<0.01) and CRP (1.8-fold; p<0.01) was increased, while mRNA expression 
of IL-1β (1.6-fold; p=0.26) and IL-6 (1.2-fold; p=0.45) was not affected (Figure 2E). 
Interestingly, not only the number of leukocytes in the peritoneum was increased 
upon hematopoietic α7nAChR deficiency, but also in the blood (2.9-fold; p<0.01), 
mesenteric lymph nodes (2.0-fold; p<0.001) and spleen (2.2-fold; p<0.01) (Figure 2F). 
Analysis of subsets by flow cytometry revealed, comparable to the sysmex analysis 
on peritoneal leukocytes, an increase in all leukocyte subpopulations (not shown). 































































Figure 1 – Effect of hematopoietic α7nAChR deficiency on body weight, plasma lipid levels 
and cholesterol distribution over lipoproteins. ldlr -/- mice were transplanted with bone 
marrow of α7nAChR-/- (n=11) or WT mice (n=20) (t=-8 wks), allowed to recover for 8 weeks 
and subsequently (t=0 wks) fed a Western-type diet (WTD) during 7 weeks. Body weight was 
monitored during the whole experiment (A). After 7 wks of WTD feeding, blood samples were 
drawn and the concentrations of cholesterol, phospholipid and triglycerides in plasma were 
determined (B). The distribution of cholesterol over the different lipoproteins was determined 
by fractionation of pooled plasma by FPLC. VLDL, LDL and HDL were collected in fractions 1-6, 
7-14, and 15-24, respectively (C). Values represent means ± SEM.









































































































































































Figure 2 – Effect of hematopoietic α7nAChR deficiency on inflammation. After 7 weeks of 
WTD, the number of peritoneal leukocytes was determined (A) and their composition was 
analyzed, i.e. monocytes (B), lymphocytes (C) and neutrophils (D) in hematopoietic α7nAChR-/- 
(n=11) or WT mice (n=20). Total RNA was extracted from peritoneal leukocytes and mRNA 
expression of the pro-inflammatory cytokines TNFα, CRP, IL-6, and IL-1β was determined (E). 
Leukocytes in blood, lymph nodes and spleen were counted (F). The spleen was isolated and 
weighed (G), after which mRNA expression of the pro-inflammatory cytokines TNFα, IL-6, and 
IL-1β was determined (H) Values represent means ± SEM. **p<0.01 and ***p<0.001 denote 
statistical difference vs. controls.
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As the cholinergic anti-inflammatory pathway is known to act via the spleen (13), the 
spleen was further analysed. The spleen of α7nAChR-/- and WT transplanted mice did 
not differ in weight (90±4 mg vs. 86±4 mg; p=0.47) (Figure 2G), but mRNA expression 
of TNFα was increased in the spleen of α7nAChR-/- transplanted mice compared to 
controls (1.6-fold; p<0.01) (Figure 2H), similar as observed for peritoneal leukocytes.
Overall, these findings show an increased inflammatory status of α7nAChR-/- 
transplanted mice compared to control transplanted mice.
Hematopoietic α7nAChR deficiency increases platelet reactive status
Functional α7nAChR is expressed on platelets and modulates activation of 
platelets  (9), which may represent an important linkage between inflammation, 
thrombosis and atherosclerosis (17). Integrin αIIbβ3 is an integrin complex found on 
the surface of platelets, and is essential for platelet aggregation upon binding of 
fibrinogen. Upon platelet activation, integrin αIIbβ3 changes its conformation to an 
active high affinity state in which it is able to bind its ligands, including fibrinogen. 
Using flow cytometry, the expression of active integrin αIIbβ3 was measured after 
platelet activation by the agonists ADP and PAR-4 peptide. The lack of α7nAChR on 
platelets did not affect baseline expression of active integrin αIIbβ3 (not shown), but 
increased its expression upon stimulation by ADP compared to control platelets (2.0-
fold for 0.5 µM, p<0.05 and 1.9-fold for 5 µM, p<0.01), and induced a non-significant 
increase of integrin αIIbβ3 after stimulation by PAR-4 peptide (1.5-fold for 0.1 mM, 
p=0.12 and 1.3-fold for 1 mM, p=0.19) (Figure 3A). The expression of total integrin 
αIIbβ3 (both active and inactive integrin αIIbβ3) on platelets did not differ between both 
groups (Figure 3B,C). These data indicate that α7nAChR signaling is not only involved 
in diminishing pro-inflammatory cytokine production by immune cells, but also in 
reducing the reactive state of circulating platelets.
For platelet activation, an increased intracellular Ca2+ concentration is essential. 
To study the contribution of platelet receptor signaling in activation of integrin αIIbβ3 
in the absence of functional α7nAChR, the Ca2+ ionophore A23187 was used to directly 
induce Ca2+ entry without the activation of platelet receptors. After stimulation 
with A23187, no differences were observed in the expression of active integrin 
αIIbβ3 between both groups (Figure 3D). These results indicate that the differences 
in reactive state of the platelets are likely due to interactions between α7nAChR 
signaling and signaling upstream of Ca2+ mobilization. However, it should be noted 
that A23187 is a potent activator of platelets, which may have blunted the effects of 
α7nAChR deficiency.
As aggregation experiments were unfeasible to perform on platelets of these 
mice, human platelets from healthy individuals were incubated with the α7nAChR-
selective agonist PNU-282987 to investigate the effects of α7nAChR signaling on 
platelet aggregation. Incubation with 10 µM PNU-282987, prior to stimulation with 














































































































































































Figure 3 – Effect of hematopoietic α7nAChR deficiency on platelet reactivity. After 7 weeks 
of WTD, platelets were isolated from whole blood from hematopoietic α7nAChR -/- (n=4) or 
WT mice (n=4), stimulated with the platelet agonists ADP and PAR-4 peptide, and the ratio 
of the active form of integrin αIIbβ3* relative to total integrin αIIbβ3 protein was analyzed by 
flow cytometry (A). The expression of total integrin αIIbβ3 protein (both active and inactive 
form) was determined by flow cytometry (B). Integrin αIIbβ3 activation (*αIIbβ3 = active form of 
integrin) without activation of platelet receptors was determined by using the Ca2+ ionophore 
A23187 (C). In human platelets (n=3), aggregation was assessed upon ADP activation after 
pre-incubation with the α7nAChR agonist PNU-282987 (D) and maximal aggregation after 
750 sec was determined (E). P-selectin expression, a marker for human platelet activation, 
was measured after activation by ADP (F). Values represent means ± SEM. *p<0.05 denotes 
statistical difference vs. controls.
ADP, inhibited platelet aggregation (Figure 3E), and reduced the maximal aggregation 
response by 35% (p<0.05) (Figure 3F). Additionally, the expression of P-selectin, 
another marker for platelet reactivity, tended to decrease after treatment with PNU-
282987 prior to stimulation with increasing concentrations of ADP (Figure 3G). Pre-
incubation with a physiological concentration of PNU-282987 (100 nM; Supplemental 
Figure 2) or shorter pre-incubation of 5 min instead of 30 min (Supplemental 
Figure  3) did not reduce P-selectin expression nor decrease platelet-bound 
fibrinogen, which is another marker for platelet aggregation. Together, these data 
indicate that stimulation of the α7nAChR reduces platelet activation and aggregation, 
while α7nAChR deficiency results in an increased platelet reactive state.
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Hematopoietic α7nAChR deficiency does not affect atherosclerotic 
lesion development
An increased inflammatory status and increased platelet activation status, 
observed in hematopoietic α7nAChR deficient mice, may be expected to accelerate 
the development of atherosclerosis. To study the role of hematopoietic α7nAChR in 
atherosclerosis development, α7nAChR-/- and WT transplanted mice were sacrificed 






































































Figure 4 – Effect of hematopoietic α7nAChR deficiency on atherosclerotic lesion 
development.  After 7 weeks of WTD, hearts were isolated of hematopoietic α7nAChR-/- 
(n=11) or WT mice (n=20), and cross-sections (5 μm) with 50-μm intervals throughout the 
aortic root area starting from the appearance of open aortic valve leaflets were used for 
atherosclerosis measurements. Sections were stained with hematoxylin-phloxine-saffron 
(HPS) for histological analysis. Representative images of HPS staining (A). Atherosclerotic 
mean lesion area (in µm2) was quantified in four subsequent cross-sections (B). The same four 
sections per mouse were categorized according to lesion severity (C). Immunohistochemistry 
for determination of lesion composition; MAC3 for macrophages and actin for smooth muscle 
cells (SMC) or Sirius Red staining for collagen content (D). Comparable to lesion size, the 
composition of the lesions was determined in four subsequent cross-sections (E). Values 
represent means ± SEM per group.
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determined in the valve area of the aortic root. However, α7nAChR deficiency in mice 
did not affect atherosclerotic lesion size (Figure 4A,B) and lesion severity, classified 
as mild (type 1-3) and severe (type 4-5) lesions (Figure 4C). In addition, no significant 
differences could be observed between the lesion composition of α7nAChR-/- and 
WT transplanted mice, with respect to the relative area of macrophages (MAC3 
staining), smooth muscle cells (SMC; actin staining) and collagen (Sirius Red 
staining) (Figure 4D,E).
Discussion
In the present study, we determined the effect of the absence of hematopoietic 
α7nAChR on the inflammatory status and platelet function, and the consequences 
for atherosclerotic lesion development in hyperlipidemic ldlr -/- mice. We showed 
that hematopoietic disruption of α7nAChR clearly increased inflammatory status 
as indicated by an increased number of peritoneal leukocytes and an increased 
expression of inflammatory mediators by both peritoneal leukocytes (TNFα, CRP) and 
the spleen (TNFα). Apparently, hematopoietic α7nAChR deficiency recapitulates the 
pro-inflammatory phenotype of total body α7nAChR-deficient mice (4). Of note, in our 
study hematopoietic α7nAChR-/- mice were subjected to a WTD containing 16% fat and 
0.25% cholesterol, a diet known to evoke only mild inflammation (21). Still the number 
of leukocytes in the blood, lymph nodes, spleen and peritoneum all increased by at 
least 2-fold, consistent with a role for the cholinergic anti-inflammatory pathway 
in prevention of inflammation during diet-induced hyperlipidemia. The increased 
number of leukocytes was explained by an increase in various leukocyte cell types 
(i.e., monocytes, lymphocytes and neutrophils).
In addition to leukocytes, the α7nAChR is also expressed on platelets (9). 
Therefore, we evaluated the effect of α7nAChR deficiency as well as specific α7nAChR 
activation on platelet reactivity by determining active integrin αIIbβ3 expression and 
platelet aggregation, respectively. Murine α7nAChR deficiency in platelets increased 
active integrin αIIbβ3 expression induced by classical platelet agonists. Accordingly, 
in human platelets, ADP-induced platelet aggregation was inhibited by the α7nAChR-
selective agonist PNU-282987. As activation of platelets induces inflammation (17), 
these data are in line with the immunosuppressive function of the cholinergic anti-
inflammatory pathway. Furthermore, these results indicate that activation of α7nAChR 
signaling is involved in normal platelet function as α7nAChR deficiency resulted in 
increased platelet reactivity in response to agonists. In seeming contrast to our 
findings, Schedel et al. (9) reported that stimulation of the α7nAChR with increasing 
concentrations of PNU-282987 (100 nM up to 10 µM) results in increased ADP-
induced Ca2+ entry into human platelets, suggesting increased platelet activation. 
However, as platelet aggregation was not affected in these studies, the functional 
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relevance of those observations is unclear. Of note, PNU-282987 at a concentration 
of 1 µM also acts as an antagonist for 5-HT(3) receptors (22) that are expressed on 
platelets (23), which may thus have contributed to the observed effects in human 
platelets. Evaluation of the amount of platelet-leukocyte complexes in vivo, as well as 
direct platelet aggregation measurements, would have given valuable information 
on the enhanced platelet activation in response to ADP in the α7nAChR deficient mice 
and the diminished platelet response after α7nAChR activation on human platelets. 
Unfortunately, aggregation experiments were unfeasible to perform on platelets of 
these mice and therefore remain to be addressed.
In the present study the enhanced inflammation in hematopoietic α7nAChR -/- 
mice did not increase plasma lipids, although previous studies have shown that 
pro-inflammatory signaling in pre-clinical models does affect lipid metabolism (24). 
Furthermore, it has been shown that serum CRP and IL-6, which are markers in the 
pathogenesis of atherosclerosis (15,16), were increased in α7nAChR deficient mice 
on an apoE-deficient background, a highly inflammatory and oxidative stress mouse 
model (25), but not on a WT background (11). Together, these data indicate that the 
contribution of α7nAChR signaling to lipid metabolism may become apparent only 
under higher inflammatory conditions.
Hematopoietic α7nAChR deficiency increased the inflammatory status and 
caused increased platelet reactivity, both considered as important risk factors in 
atherosclerotic lesion development (16,17,26). Nonetheless, hematopoietic α7nAChR 
deficiency did not aggravate WTD-induced atherosclerotic lesion development in ldlr -/- 
mice. As the impact of the of circulating pro-inflammatory cells on plaque infiltration 
is best observed during early lesion development, we assessed atherosclerotic lesion 
development already at 7 weeks of Western-type diet feeding, which resulted in early 
lesions as reflected by the relatively small lesion area (~1x105 µm2) and low lesion 
severity (~80% mild lesions), comparable to previous studies (27). The macrophage 
content of the plaque was not affected by hematopoietic α7nAChR deficiency, even in 
these early lesions, suggesting comparable leukocyte infiltration. It should be noted 
that the α7nAChR is also present on endothelial cells and that stimulation of the 
endothelial α7nAChR inhibits leukocyte recruitment during inflammation (8), which 
is a crucial step in atherosclerotic lesion development  (12). Possibly, a potential 
aggravating effect of hematopoietic α7nAChR deficiency on inflammation and 
platelet activation may thus become apparent only when α7nAchR is also absent in 
endothelial cells. However, the contribution of endothelial cells to the cholinergic 
anti-inflammatory pathway is unknown, as well as the effects of whole-body α7nAchR 
deficiency on the development of atherosclerosis. Alternatively, it is possible that 
the diet used was too mild to evoke sufficient inflammation as addition of 0.25% 
cholesterol to the WTD only slightly increases liver inflammation in APOE*3-Leiden.
CETP mice (21).
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In conclusion, hematopoietic α7nAChR deficiency increases inflammatory status 
and platelet activation status, but does not affect atherosclerotic lesion development 
in ldlr -/- mice.
Acknowledgements
We acknowledge the support from ‘the Netherlands CardioVascular Research 
Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical 
Centers, the Netherlands Organisation for Health Research and Development and 
the Royal Netherlands Academy of Sciences’ for the GENIUS project ‘Generating the 
best evidence-based pharmaceutical targets for atherosclerosis’ (CVON2011-19). 
P.C.N. Rensen is an Established Investigator of the Netherlands Heart Foundation 
(grant 2009T038). S.J.A. Korporaal and M. van der Stoep are supported by the 
Landsteiner Foundation for Blood Transfusion Research (grant 0912F).




1.  Borovikova, L. V., Ivanova, S., Zhang, M. 
et al. (2000) Vagus nerve stimulation 
attenuates the systemic inflammatory 
response to endotoxin. Nature 405,  
458-462.
2.  Pavlov, V. A., Wang, H., Czura, C. J. 
et al. (2003) The cholinergic anti-
inflammatory pathway: a missing link 
in neuroimmunomodulation. Mol Med 9, 
125-134.
3.  Tracey, K. J. (2002) The inflammatory 
reflex. Nature 420, 853-859.
4.  Wang, H., Yu, M., Ochani, M. et al. (2003) 
Nicotinic acetylcholine receptor alpha7 
subunit is an essential regulator of 
inflammation. Nature 421, 384-388.
5.  Blanchet, M. R., Langlois, A., Israel-
Assayag, E. et al. (2007) Modulation 
of eosinophil activation in vitro by a 
nicotinic receptor agonist. J Leukoc Biol 
81, 1245-1251.
6.  Yoshikawa, H., Kurokawa, M., 
Ozaki, N. et al. (2006) Nicotine inhibits 
the production of proinflammatory 
mediators in human monocytes 
by suppression of I-kappaB 
phosphorylation and nuclear factor-
kappaB transcriptional activity through 
nicotinic acetylcholine receptor alpha7. 
Clin Exp Immunol 146, 116-123.
7.  Steinlein, O. (1998) New functions for 
nicotinic acetylcholine receptors? Behav 
Brain Res 95, 31-35.
8.  Saeed, R. W., Varma, S., Peng-
Nemeroff, T. et al. (2005) Cholinergic 
stimulation blocks endothelial cell 
activation and leukocyte recruitment 
during inflammation. J Exp Med 201, 
1113-1123.
9.  Schedel, A., Thornton, S., Schloss, P. 
et al. (2011) Human platelets express 
functional alpha7-nicotinic acetylcholine 
receptors. Arterioscler Thromb Vasc Biol 
31, 928-934.
10.  Orr-Urtreger, A., Goldner, F. M., 
Saeki, M. et al. (1997) Mice deficient in the 
alpha7 neuronal nicotinic acetylcholine 
receptor lack alpha-bungarotoxin 
binding sites and hippocampal fast 
nicotinic currents. J Neurosci 17, 9165-
9171.
11.  Wilund, K. R., Rosenblat, M., 
Chung, H. R. et al. (2009) Macrophages 
from alpha 7 nicotinic acetylcholine 
receptor knockout mice demonstrate 
increased cholesterol accumulation 
and decreased cellular paraoxonase 
expression: a possible link between the 
nervous system and atherosclerosis 
development. Biochem Biophys Res 
Commun 390, 148-154.
12.  Libby, P., Ridker, P. M., & Hansson, G. K. 
(2011) Progress and challenges 
in translating the biology of 
atherosclerosis. Nature 473, 317-325.
13.  Huston, J. M. (2012) The vagus nerve and 
the inflammatory reflex: wandering on 
a new treatment paradigm for systemic 
inflammation and sepsis. Surg Infect 
(Larchmt) 13, 187-193.
14.  Robbins, C. S., Chudnovskiy, A., 
Rauch, P. J. et al. (2012) Extramedullary 
hematopoiesis generates Ly-6C(high) 
monocytes that infiltrate atherosclerotic 
lesions. Circulation 125, 364-374.
15.  Libby, P. (2002) Inflammation in 
atherosclerosis. Nature 420, 868-874.
16.  Ross, R. (1999) Atherosclerosis--an 
inflammatory disease. N Engl J Med 340, 
115-126.
17.  Gawaz, M., Langer, H., & May, A. E. 
(2005) Platelets in inflammation and 
atherogenesis. J Clin Invest 115,  
3378-3384.
18.  Gijbels, M. J., van der Cammen, M., van 
der Laan, L. J. et al. (1999) Progression 
and regression of atherosclerosis 
in APOE3-Leiden transgenic mice: 
an immunohistochemical study. 
Atherosclerosis 143, 15-25.
19.  Volger, O. L., Mensink, R. P., Plat, J. 
et al. (2001) Dietary vegetable oil and 
wood derived plant stanol esters reduce 
atherosclerotic lesion size and severity 
in apoE*3-Leiden transgenic mice. 
Atherosclerosis 157, 375-381.
20.  Hu, L., Boesten, L. S., May, P. et al. (2006) 
Macrophage low-density lipoprotein 
receptor-related protein deficiency 
enhances atherosclerosis in ApoE/
LDLR double knockout mice. Arterioscler 
Thromb Vasc Biol 26, 2710-2715.
21.  Kleemann, R., Verschuren, L., van 
Erk, M. J. et al. (2007) Atherosclerosis 
and liver inflammation induced by 
increased dietary cholesterol intake: 
a combined transcriptomics and 
metabolomics analysis. Genome Biol 8, 
R200.
Kooijman.indd   155 30-9-2015   10:54:31
156
7
22.  Bodnar, A. L., Cortes-Burgos, L. A., 
Cook, K. K. et al. (2005) Discovery 
and structure-activity relationship of 
quinuclidine benzamides as agonists of 
alpha7 nicotinic acetylcholine receptors. 
J Med Chem 48, 905-908.
23.  Stratz, C., Trenk, D., Bhatia, H. S. et al. 
(2008) Identification of 5-HT3 receptors 
on human platelets: increased surface 
immunoreactivity after activation with 
adenosine diphosphate (ADP) and 
thrombin receptor-activating peptide 
(TRAP). Thromb Haemost 99, 784-786.
24.  van Diepen, J. A., Berbee, J. F., 
Havekes, L. M. et al. (2013) Interactions 
between inflammation and lipid 
metabolism: relevance for efficacy 
of anti-inflammatory drugs in 
the treatment of atherosclerosis. 
Atherosclerosis 228, 306-315.
25.  Palinski, W., Ord, V. A., Plump, A. S. et al. 
(1994) ApoE-deficient mice are a model 
of lipoprotein oxidation in atherogenesis. 
Demonstration of oxidation-specific 
epitopes in lesions and high titers of 
autoantibodies to malondialdehyde-
lysine in serum. Arterioscler Thromb 14, 
605-616.
26.  Reinhart, W. H. (2013) Platelets in 
vascular disease. Clin Hemorheol 
Microcirc 53, 71-79.
27.  Meurs, I., Lammers, B., Zhao, Y. et al. 
(2012) The effect of ABCG1 deficiency 
on atherosclerotic lesion development 
in LDL receptor knockout mice 
depends on the stage of atherogenesis. 
Atherosclerosis 221, 41-47.






Supplemental Figure 1 – Hematologic chimerism of α7nAChR-/- mice. At the end of the study, 
bone marrow was isolated from the transplanted ldlr -/- mice, and hematologic chimerism was 
determined using genomic DNA by PCR at 15 weeks after BMT. The relative presence of the 
α7nAChR was assessed for murine α7nAChR, diluted up to 10% for hematopoietic α7nAChR+/+ 
to determine chimerism (A), and for the neomycin gene neocassette (B). Figure include 
three  representative hematopoietic α7nAChR+/+ and α7nAChR-/- mice. Controls include DNA 
from α7nAChR+/+ and α7nAChR-/- mice.


































l) 100 nM PNU



























Supplemental Figure 2 – Effects of low dose α7nAChR agonist PNU282987 on human 
platelets. Human platelets were isolated from freshly drawn venous blood from healthy 
volunteers. Surface expression of P-selectin (A) and fibrinogen-binding (B) were determined 
by flow cytometry in citrated whole blood, treated with α7nAChR agonist PNU282987 (100 nM 
or 10 µM) or vehicle for 30 min prior to stimulation with ADP (serial dilutions ranging from 
0-125 µM) for 20 min. Values represent means ± SEM.





























































Supplemental Figure 3 – Effects of short incubation with α7nAChR agonist PNU282987 on 
human platelets. Human platelets were isolated from freshly drawn venous blood from healthy 
volunteers. Surface expression of P-selectin (A) and fibrinogen-binding (B) were determined 
by flow cytometry in citrated whole blood, treated with α7nAChR agonist PNU282987 (100 nM 
or 10 µM) or vehicle for 5 min prior to stimulation with ADP (serial dilutions ranging from 
0-125 µM) for 20 min. Values represent means ± SEM.
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The brain plays a prominent role in the regulation of inflammation. Immune cells 
are under control of the so-called cholinergic anti-inflammatory reflex, mainly 
acting via autonomic innervation of the spleen. Activation of this reflex inhibits 
the secretion of pro-inflammatory cytokines and may reduce the development 
of atherosclerosis. Therefore, the aim of this study was to evaluate the effects of 
selective parasympathetic (Px) and sympathetic (Sx) denervation of the spleen on 
inflammatory status and atherosclerotic lesion development. Female APOE*3-
Leiden.CETP mice, a well-established model for human-like lipid metabolism and 
atherosclerosis, were fed a cholesterol-containing Western-type diet for 4 weeks 
after which they were sub-divided into three groups receiving either splenic Px, 
splenic Sx or sham surgery. The mice were subsequently challenged with the 
same diet for an additional 15 weeks. Selective Px increased leukocyte counts (i.e. 
dendritic cells, B cells and T cells) in the spleen and increased gene expression of 
pro-inflammatory cytokines in the liver and peritoneal leukocytes as compared to Sx 
and sham surgery. Both Px and Sx increased circulating pro-inflammatory cytokines 
IL-1β and IL-6. However, the increased pro-inflammatory status in denervated mice 
did not affect atherosclerotic lesion size or lesion composition. Predominantly 
selective Px of the spleen enhances the inflammatory status, which however does 
not aggravate diet-induced atherosclerotic lesion development.




Atherosclerosis is a chronic inflammatory disease initiated by innate and adaptive 
immune responses to endogenously modified structures, in particular oxidized 
lipoproteins, within the arterial wall (1). The autonomic nervous system may 
enhance innate immune responses by sympathetic activity (2), while it suppresses 
inflammation via the vagus nerve, a mechanism termed the cholinergic anti-
inflammatory pathway (3,4). In response to circulating pro-inflammatory cytokines 
afferent vagal nerves are directly activated. Subsequent efferent vagal activity 
results in the release of acetylcholine which activates the α7 nicotinic acetylcholine 
receptor (α7nAChR) on resident tissue macrophages and other immune cells, thereby 
inhibiting the production and release of pro-inflammatory cytokines (e.g. TNFα, 
IL-6, IL-1β) (5). α7nAChR is integral to the cholinergic anti-inflammatory pathway, 
as vagus nerve stimulation fails to inhibit TNFα production in pharmacologically 
α7nAChR inhibited or α7nAChR-deficient mice (5,6). Recently, we demonstrated 
that hematopoietic α7nAChR deficiency in dyslipidemic mice enhances systemic 
inflammation as evidenced by increased leukocytes in the blood, lymph nodes, 
spleen and peritoneum (all by at least 2-fold) and increased gene expression of TNFα 
in peritoneal leukocytes and spleen (7).
As the spleen contains half of the body’s monocyte population, it is not surprising 
that the cholinergic anti-inflammatory pathway acts mainly via the spleen. Indeed, 
Huston et al. (8) reported that vagus nerve stimulation fails to inhibit TNFα production 
in splenectomised animals during endotoxemia, indicating an essential role for the 
spleen in the cholinergic anti-inflammatory pathway. Furthermore, splenectomy 
reduces the production of antibodies directed against oxidized LDL in apoE-deficient 
mice and was associated with increased atherosclerotic lesion development (9). 
Trauma patients who undergo splenic removal are more prone to develop coronary 
heart disease, in which enhanced atherosclerotic lesion development may be 
causal (10).
Taken together, these findings suggests that autonomic innervation of the spleen 
and the development of atherosclerosis may be closely interrelated. Therefore, 
the aim of this study was to determine the effect of selective parasympathetic 
denervation (Px), as compared to sympathetic denervation (Sx) of the spleen and 
sham surgery, on systemic inflammation and atherosclerotic lesion development in 
female APOE*3-Leiden.CETP mice, a well-established mouse model for human-like 
lipoporotein metabolism.





APOE*3-Leiden mice were crossbred with mice expressing human cholesteryl ester 
transfer protein (CETP) under control of its natural flanking regions to generate 
heterozygous APOE*3-Leiden.CETP mice (11). Mice were housed under standard 
conditions with a 12:12h light:dark cycle and had free access to food and water. At the 
age of 10-12 weeks, female APOE*3-Leiden.CETP mice received a Western-type diet 
(WTD) containing 0.1% cholesterol (w/w), 1% (w/) corn oil and 15% (w/w) cacao butter 
(AB diets, Woerden, the Netherlands). After a run-in period of 4 weeks, mice (n=45) 
were randomized based on plasma lipid levels and body weight into three groups 
(n=15 each) receiving either splenic parasympathetic denervation (Px), splenic 
sympathetic denervation (Sx) or sham surgery. A schematic representation of the 
innervation of the spleen and the sites of denervation can be found in Figure  1A. 
For all surgeries, mice were anesthetized by an intraperitoneal (i.p.) injection of 
a mixture of fentanylcitrate/fluanisone (Hypnorm; Janssen, Beerse, Belgium), 
midazolam (Dormicum; Roche, Mijdrecht, The Netherlands), and H2O (1: 1: 2, v/v). 
All animal experiments had been approved by the Institutional Ethics Committee on 
Animal Care and Experimentation.
Selective parasympathetic denervation of the spleen
Since parasympathetic nerves enter the spleen at both tips, these tips were 
sequentially exposed during surgery to allow cutting of the nerves. After a midline 
abdominal incision the spleen was pulled gently towards the site of the incision, 
and the nerve at the tip of the spleen was cut. The connective tissue between the 
tip and the first hilus was also removed, as some parasympathetic input reaches 
the spleen via this connective tissue. Subsequently, the spleen was further pulled 
towards the midline to reach the lower tip of the spleen. After following back the 
nerve to the plexus, the connective tissue from this plexus back to the spleen was 
removed. The  wound was closed with novosyn suture (B. Braun Medical, Oss, 
The Netherlands) (12).
Selective sympathetic denervation of the spleen
A midline abdominal incision was performed along the linea alba and the stomach 
was pushed up and to the right to reveal the blood vessels to and from the spleen. 
After the arterial branch to the stomach a bifurcation indicates the first branching 
point of the arterial supply to the spleen. From this bifurcation on the arteries will 
split many times and end at the hili of the spleen. Sympathetic nerves run along 
and around these arteries to reach the spleen. The area just before and after the 
bifurcation was chosen to remove the sympathetic nerves. The wound was closed 





Figure 1 – Confirmation of splenic denervations and gating strategy. Schematic 
representation of the innervation of the spleen (A). The sympathetic input (pink) reaches the 
spleen via the arteries, the parasympathetic input (green) reaches the spleen via both tips of 
the spleen. The location at which denervations were performed are shown by the dashed lines. 
Gating strategy for flow cytometry analysis (B). Confirmation of sympathetic denervation (C) by 
measurement of tyrosine hydroxylase protein content of the spleen. As controls, TH content 
for the brain and (denervated) brown fat are included.
with novosyn suture (B. Braun Medical, Oss, The Netherlands) (12). Sympathetic 
denervation was confirmed 15 weeks after surgery by measurement of Tyrosine 
hydroxylase (TH) content Western blotting (anti-TH antibody; AB-112; Abcam).
Gene expression analysis in spleen, liver and peritoneal leukocytes
After surgery, the mice were fed the WTD for another 15 weeks. Subsequently, 
mice were sacrificed and organs were collected and peritoneal leukocytes isolated 
by lavage of the peritoneum with ice-cold PBS. Total RNA from spleen, liver and 
peritoneal leukocytes was isolated using the Nucleospin RNA II kit (Macherey-Nagel, 
Düren, Germany) according to manufacturer’s instructions. One microgram of total 
RNA was converted to cDNA with iScript cDNA Synthesis kit (Biorad) and purified with 
Nucleospin Extract II kit (Macherey-Nagel). Real-time polymerase chain reaction 
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(RT-PCR) was conducted on the IQ5 PCR machine (Biorad) using the Sensimix SYBR 
Green RT-PCR mix (Quantace, London, UK). mRNA levels were normalized to mRNA 
levels of β2 microglobulin, cyclophilin, and acidic ribosomal phosphoprotein P0 
(36B4).
Flow cytometry analysis
From five randomly selected animals per group, peripheral blood and spleens 
were processed for flow cytometry. Thereto, single cell suspensions were obtained 
by mashing the cells trough a 70 µm cell strainer (Falcon, The Netherlands). 
Subsequently, cells were counted and 2x106 cells were stained with appropriate 
antibodies (Table 1) to determine immune cell subsets: Live immune cells were 
selected from the forward and sideward scatter, and populations of B-cells (CD19+), 
dendritic cells (CD11c+CD14-), T-cells (CD3+), neutrophils (CD11b+Ly6Ghigh), and 
macrophages (CD14+CD11b+) were identified. Specific T cell subsets were determined 
within the CD3+ fraction as T helper cells (CD4+), cytotoxic T cells (CD8+), activated 
T cells (CD25+), naïve T cells (CD62L+). Data were acquired on a FACSAria or a 
FACSCanto II (BD Biosciences). Analyses were performed using FlowJo software 
(Treestar, Ashland, OR, USA). Gating strategy is shown in Figure 1B.
Table 1 – Detailed information of antibodies used for flow cytometry analysis
Antibody Conjugate Clone Source Dilution
CD19 PE ID3 BD 1,600
CD14 FITC Sa14-2 eBioscience 500
CD11c Biotin HL3 BD 200
CD3 APC 145-2C11 BD 300
CD3 FITC 145-2C11 BD 400
CD11b PerCP M1/70 BD 800
Ly6G Ef450 RB6-8C5 eBioscience 800
CD4 PE L3T4 GK1.5 BD 1,000
CD8 biotin 53-6.7 BD 400
CD62L APC MEL-14 Biolegend 1,600
CD25 PerCP PC61 BD 500
Second step: Sav-PE-Cy7 BD 500
Serum measurements
Serum was isolated and stored frozen at -80°C until further analyses. The cytokines 
TNFα, IL-1β and IL-6 were determined using V-PLEX Proinflammatory Panel1 (mouse) 
Kit (Meso Scale Discovery, Rockville, ML, USA) according to the manufacturer’s 
instructions. In 50x diluted serum samples, E-selectin concentrations were 
measured according to the manufacturer’s instructions (DY575, R&D systems, 
Minneapolis, MN, USA).
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Plasma lipid and lipoprotein analyses
Blood was collected after a 4-h fast into EDTA-containing cups by tail bleeding, 
and plasma was isolated by centrifugation and stored frozen at -80°C until further 
analyses. The concentrations of total cholesterol (TC) and triglycerides (TG) in 
plasma were determined using commercially available enzymatic colorimetric kits 
according to the manufacturer’s protocols (236691 and 1488872; Roche Molecular 
Biochemicals, Indianapolis, IN, USA). The concentrations of phospholipids (PL) in 
plasma were determined using a commercially available enzymatic colorimetric kit 
(3009; Instruchemie, Delfzijl, The Netherlands). The distribution of lipids over the 
different lipoproteins in plasma was determined after fractionation of pooled plasma 
(14-15 mice per pool) by FPLC using a Superose 6 HR 10/30 column (Äkta System; 
Amersham Pharmacia Biotech, Piscataway, NJ).
Atherosclerosis quantification
From all mice, hearts were isolated and fixed in phosphate-buffered 4% 
formaldehyde, dehydrated and embedded in paraffin. Cross-sections (5 μm) were 
made throughout the aortic root area and stained with hematoxylin-phloxine-
saffron for histological analysis. Lesions were categorized for severity according 
to the guidelines of the American Heart Association adapted for mice (13). Various 
types of lesions were discerned: no lesions, mild lesions (types 1-3) and severe 
lesions (types 4-5). Immunohistochemistry for determination of lesion composition 
was performed as described previously (14). Rat anti-mouse antibody MAC3 (1:1000; 
BD Pharmingen, Breda, The Netherlands) was used to quantify macrophage area. 
Monoclonal mouse antibody M0851 (1:800; Dako, Heverlee, the Netherlands) against 
smooth muscle cell (SMC) α-actin was used to quantify SMC area. Sirius Red was 
used to quantify collagen area. Lesion area was quantified in the aortic root starting 
from the appearance of open aortic valve leaflets in four subsequent sections with 
50 μm intervals. In ImageJ the lesions were delineated to determine mean lesion 
area (in µm2) and a color threshold was set to determine the area percentage of 
MAC3, SMC or collagen staining in a consistent manner across the different slides.
Statistical analysis
Data are presented as means ± SEM unless indicated otherwise. To compare 
differences among groups one-way ANOVA with Turkey’s post-test was performed 
using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, 
CA, USA, www.graphpad.com). Differences at a P-value <0.05 were considered 
statistically significant.




Female APOE*3-Leiden.CETP mice were fed a WTD during 4 weeks, and were 
randomized into three groups receiving either parasympathetic denervation (Px) 
of the spleen, sympathetic denervation (Sx) of the spleen (Figure 1A), or sham 
surgery. After surgery, the mice received WTD feeding for 15 additional weeks to 
induce atherosclerotic lesion development. To confirm that Sx was successful and 
that sympathetic nerves did not regenerate, tyrosine hydroxylase (TH) content of 
the spleen was determined (Figure 1C), showing the absence of TH still 15 weeks 
after Sx. Upon sacrification of the mice, the tips of the spleen were gently exposed 
to confirm that the re-innervation of the parasympathetic nerves was not the case.
Splenic parasympathetic denervation increases immune cell count 
in spleen
The spleen plays an important role in the immune system and, therefore, contains a 
wide range of immune cell types, including monocytes, macrophages, dendritic cells, 
neutrophils, T cells and B cells. To define the effect of the selective denervations on 
immune cell composition, flow cytometry analyses were performed. Total splenic 
immune cell count was increased (+49%, p<0.01) in Px mice (200±10 x106 cells) 
compared to sham operated mice (134±10 x106 cells), while Sx denervation did not 
affect immune cell count (156±25 x106 cells) (Figure 2A). In a fraction of immune 
cells (i.e. 2.0x106 cells), percentages of each cell type were analyzed using flow 
cytometry and multiplied with total immune cell counts (see Figure 1B for the gating 
strategy). This revealed an increase in the number of various immune cell subtypes, 
including B cells (98±7 x106 cells vs. 61±5 x106 cells, p<0.01) (Figure 2B), T cells (63±4 
x106 cells vs. 41±4 x106 cells, p<0.01) (Figure 2C) and dendritic cells (DCs; 10±1 x106 
cells vs. 7±1 x106 cells, p<0.05) (Figure 2D). Neutrophils (Figure 2E) and monocytes/
macrophages (Figure 2F) only showed a non-significant increase upon Px.
As T cells are integral to the cholinergic anti-inflammatory pathway (15), the 
phenotype of the T cells (i.e naivity or activation status of the T helper or cytotoxic 
T cells) was further studied. In accordance to the general increase in various immune 
cells, Px increased both T-helper (TH; +60%, p<0.01) (Figure 2G) and cytotoxic T cells 
(Tcyt; +49%, p<0.01) (Figure 2H). Further subdivision revealed that Px increased naïve 
(Figure 2I) as well as activated (Figure 2J) TH cells, and increased naïve Tcyt  cells 
(Figure 2K) without increasing activated Tcyt cells (Figure 2L). Thus, splenic Px 
resulted in an overall increase in immune cells in the spleen, while Sx did not affect 
immune cell count compared to sham surgery, indicating the importance of the 
parasympathetic nerve in regulation of the immune system.





















































































































































































Figure 2 – Effect of splenic denervation on immune cell composition of the spleen. APOE*3-
Leiden.CETP mice were fed a WTD during 4 weeks, were randomized into three groups 
receiving either splenic parasympathetic denervation (Px), sympathetic denervation (Sx), or 
sham surgery (t=0). Mice were fed a WTD during 15 additional weeks before spleens were 
isolated and cellular composition was analyzed by flow cytometry. Immune cells were counted 
based on FSC (A) and further subdivided into B-cells (CD19+) (B), T-cells (CD3+) (C), dendritic 
cells (CD11c+CD14-) (D), neutrophils (CD11b+Ly6Ghigh) (E) and monocytes/macrophages 
(CD14+CD11b+) (F). Specific T cells subsets were identified as TH (CD4+) (G), TCyt (CD8+) (H), naïve 
TH (CD4+CD62L+) (I), activated TH (CD4+ CD25+ (J), naïve TCyt (CD8+CD62L+) (K) and activated 
TCyt (CD8+ CD25+ (L). Values represent means ± SEM of 5 mice per group. *p<0.05, **p<0.01 
compared to sham surgery.























































































































































Figure 3 – Effect of splenic denervation on the gene expression of inflammatory genes. 
During the course of the experiment body weight was monitored (A). At 15 weeks after Px, Sx 
or sham surgery, spleens were weighed (B) and splenic weight was expressed as percentage 
of body weight (C), total RNA was extracted and expression levels of TNFα, IL-1β and IL-6 were 
determined by real-time PCR (D). Similarly, livers were weighed (E) and hepatic expression 
of these genes was determined (F). Peritoneal leukocytes were isolated and gene expression 
was quantified (G). Values represent means ± SEM of 15 mice per group *p<0.05, **p<0.01, 
***p<0.01 compared to sham surgery.
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Splenic parasympathetic denervation increases expression of 
inflammatory cytokines
During the course of the experiment, body weight gain was slightly lower in both Px 
and Sx mice. At the end of the experiment, body weight of sham operated mice was 
31.6 ±1.1 g, compared to 27.3 ±1.1 g (p<0.05) and 27.4 ±1.2 g (p<0.05) for Px and Sx mice, 
respectively (Figure 3A). Splenic weight tended to be increased in Px (Figure 3B) and 
was different when expressed as percentage of the body weight for Px (0.52 ±0.02 %; 
p<0.001) and Sx (0.47 ±0.02 %; p<0.05) compared to sham (0.41 ±0.01 %) (Figure 3C). 
Gene expression analyses revealed that Px only caused a trend towards an increase 
of the inflammatory cytokines IL-1β and IL-6 within the spleen (Figure 3D). Further 
analysis of other organs showed no difference in liver weight when expressed 
as percentage of the body weight (Figure 3E). Interestingly, Px increased gene 
expression of IL-6 in the liver (+80%; p<0.01) (Figure 3F) and increased gene 
expression of TNFα, IL-1β and IL-6 in isolated peritoneal leukocytes, which reached 
significance for IL-1β (3.3-fold; p<0.05) (Figure 3G). Next we determined the effect 
of Px on white blood cell count in peripheral blood and further analysed subsets by 
flow cytometry. Px tended to increase total immune cell count albeit significance 
was not reached (+41%; p=0.18) (Figure 4A). Subdivision of leukocytes into B cells 
(Figure 4B), T cells (Figure 4C), dendritic cells (Figure 4D), neutrophils (Figure 4E) 
or monocytes (Figure 4F) did not reveal differences. However, as the number of 
immune cells per se does not reflect activity of these cells, we measured serum 
levels of TNFα (Figure 4G), IL-1β (Figure 4H) and IL-6 (Figure 4I) in serum. While 
TNFα levels remained unaffected, both IL-1β and IL-6 serum concentrations were 
increased by Px. Interestingly, in contrast to our gene expression in liver, spleen and 
peritoneal leukocytes, also Sx increased inflammatory status as IL-1β and IL-6 levels 
compared to sham operated mice.
Splenic parasympathetic denervation does not affect atherosclerotic 
lesion development
Since inflammation can influence lipid metabolism (16), we next evaluated whether 
selective splenic denervations had an effect on lipid metabolism. Plasma total 
cholesterol (TC), phospholipids (PL) and triglycerides (TG) were assessed at 2, 4, 
6 and 15 weeks after surgery. No differences in plasma lipid concentrations were 
found between the Px, Sx and sham operated mice at weeks 2, 4, 6 (not shown) 
and 15 weeks (Figure 4J). Likewise, the distribution of cholesterol over the various 
lipoproteins did not differ between Px, Sx or sham control mice (Figure 4K). Serum 
E-selectin as marker for vascular inflammation, was increased in Px as well as in 
Sx compared to sham, suggesting that immune cell infiltration into atherosclerotic 
lesions might be enhanced by the selective denervations (Figure 4L).






























































































































































































Figure 4 – Effect of splenic denervation on white blood cell composition, serum cytokines 
and plasma lipids. At 15 weeks after Px, Sx or sham surgery, blood was drawn and analyzed by 
flow cytometry. Immune cells were counted (A) and further subdivided into B-cells (CD19+) (B), 
T-cells (CD3+) (C), dendritic cells (CD11c+CD14-) (D), neutrophils (CD11b+Ly6Ghigh)  (E) and 
monocytes (CD14+CD11b+) (F). Serum cytokine levels of TNFα (G), IL-1β (H) and IL-6 (I) were 
measured. Plasma concentrations of total cholesterol (TC), phospholipids (PL) and triglycerides 
(TG) were determined (J). The distribution of cholesterol over the different lipoproteins was 
determined by fractionation of pooled plasma by FPLC (K). Serum E-selectin  (L). Values 
represent means ± SEM of 5 (A-F) or 15 (G-L) mice per group.










































































































Figure 5 – Effect of splenic denervation on atherosclerotic lesion size and composition. 
At 15 weeks after Px, Sx or sham surgery, hearts were isolated and cross-sections (5 μm) 
with 50 μm intervals throughout the aortic root area starting from the appearance of open 
aortic valve leaflets were used for atherosclerosis measurements. Sections were stained 
with hematoxylin-phloxine-saffron for histological analysis and representative images 
are shown (A). Atherosclerotic mean lesion area (in µm2) was quantified in four subsequent 
cross-sections (B). The same four sections per mouse were categorized according to lesion 
severity (C). Lesion composition was determined by immunohistochemistry in four subsequent 
cross-sections using α-actin for smooth muscle cells (SMC) (D), Sirius Red staining for 
collagen content (E) and MAC3 for macrophages (F). Values represent means ± SEM of 15 mice 
per group.
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To study the effect of splenic denervation on atherosclerosis development, mice 
were sacrificed after 15 weeks after surgery, and atherosclerotic lesion size and 
lesion severity were determined in the valve area of the aortic root. Both Px and 
Sx did neither affect atherosclerotic lesion size (Figure 5A,B) nor lesion severity, 
when classified as mild (type 1-3) and severe (type 4-5) lesions (Figure 5C). However, 
also no significant differences were observed in lesion composition between Px, Sx 
and sham operated mice, with respect to the relative area of smooth muscle cells 
(SMC; α-actin staining; Figure 5D), collagen (Sirius Red staining; Figure 5E) and 
macrophages (MAC3 staining; Figure 5F).
Discussion
In the current study, we tested the hypothesis that the brain plays a prominent role 
in modulating the activity of immune cells and may therefore affect atherosclerosis 
development. We determined the effect of selective splenic parasympathetic 
denervation (Px), sympathetic denervation (Sx) on the inflammatory status and 
examined the potential consequences for plasma lipids and the development of 
atherosclerosis in APOE*3-Leiden.CETP mice. We showed that predominantly 
splenic Px increased the inflammatory state of the body as indicated by increased 
leukocyte counts within the spleen and increased pro-inflammatory cytokine 
expression. However, splenic Px as well as Sx did not affect atherosclerotic lesion 
development.
Interestingly, we found increased circulating levels of the pro-inflammatory 
cytokines IL-1β and IL-6 upon both Px and Sx. Classically, the parasympathetic 
and sympathetic nerves system act in opposite direction to facilitate control over 
physiological responses to maintain homeostasis. However, for the spleen, it has 
been suggested that both systems in fact act together to restrain inflammation by 
projection of the vagus nerve also onto the sympathetic splenic nerve (6,17). Previous 
studies even suggested absence of direct parasympathetic innervation of the 
spleen as neither choline acetyltransferase nor vesicular acetylcholine transporter 
producing nerve endings could be detected within the spleen (6,18). However the 
absence of the classical vagus transmitter acetylcholine is not sufficient proof for 
the absence of direct input from the vagus. In previous studies we identified neuronal 
connections between the spleen and both the intermedio lateral column of the spinal 
cord (IML) and the dorsal motor nucleus of the vagus nerve (DMV) by retrograde 
tracing using pseudorabies virus (PRV) and cholera toxin-b (CTB) (12,19), suggesting 
sympathetic as well as parasympathetic neuronal connectivity. Surgical ablation 
of the nerves along the splenic arteries (similar to Sx) resulted in undetectable 
retrograde tracer in the IML and absence of TH in the spleen. In contrast, surgical 
ablation of the nerve branches at the splenic ends (similar to Px) resulted in a loss 
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of detectability of the tracers in the DMV and can therefore most likely be allocated 
to the parasympathetic nerves system. In addition, Px severely diminished (-70%) 
LPS-induced antibody production, clearly indicating functional involvement of these 
nerve branches in the control of the immune response (12). In contrast, Sx did not 
affect the production of specific antibodies. While absence of sympathetic input 15 wk 
after Sx was confirmed by measuring TH content, confirmation of Px was limited to 
visual inspection due to the lack of specific markers for these neurons. However, 
consistent with the notion that vagal activation suppresses the immune response (5), 
we found that Px enhances the number of leukocytes and increases expression of 
proinflammatory cytokines. It may seem contradictive that Px results in diminished 
LPS-induced antibody production (12), while here we report enhanced inflammatory 
responses. However, one should consider the dual challenge for the brain during 
inflammation, namely to contain the inflammation by for example reducing cytokine 
production and subsequently to induce memory within the immune system to prevent 
new infections by inducing antibody production.
Despite that Px increased the number of immune cells in the spleen in the 
current study, no differences in splenic TNFα gene expression or circulating TNFα 
were found. Possibly stronger inflammatory stimuli are required to attenuate TNFα 
production by spleen macrophages via stimulation of the vagus nerve, as has been 
shown for LPS-induced endotoxemia (6). Compatible with the notion that TNFα is 
crucially involved in the pathogenesis and progression of atherosclerosis (20,21), 
Px and Sx did not aggravate WTD-induced atherosclerotic lesion development 
and did not affect lesion composition in APOE*3-Leiden.CETP mice. Similarly, we 
previously showed that hematopoietic α7nAChR deficiency in ApoE-/- mice does 
increase inflammatory status of the body and enhances platelet reactivity, but does 
not aggravate atherosclerosis as lesion size and plaque composition remained 
unaffected (7). In contrast, Johansson et al. (22) recently reported an increase in 
atherosclerotic lesion development upon hematopoietic α7nAChR deficiency in 
Ldlr -/- mice, indicating that the genetic and environmental context are important to 
determine the outcome of disrupted anti-inflammatory reflexes. Despite conflicting 
outcomes, interfering with inflammatory reflexes might be an interesting target in 
the prevention of atherosclerosis. Several animal studies report beneficial effects of 
low dose β-blockers on atherogenesis (23,24), mainly via reducing of inflammatory 
responses rather than changes in lipid metabolism. Also in humans, the use of 
metoprolol slows progression of intima-media thickness (25,26).
While the role of the autonomic splenic nerves in human physiology is unclear, 
splenectomy in trauma patients has been associated with frequency of ischemic 
coronary diseases, probably explained by increased plasma lipids (10). Rodent 
studies confirmed the role of the spleen in lipid metabolism as splenectomized rats 
showed reduced HDL-cholesterol and increased plasma triglycerides. Complete 
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removal of the spleen in ApoE-deficient mice increased plaque development, 
although the underlying mechanism remained elusive (9). In the current study, no 
differences in plasma lipids were found upon splenic denervations, suggesting that 
regulation of lipid metabolism via the spleen is probably not mediated via innervation 
of the splenic nerves, which may explain why atherosclerosis development was not 
aggravated in this study. Interestingly, splenectomized trauma patients do display 
increased infection rates and have increased leukocyte counts (27), corresponding 
with the data presented in the current study, however the exact contribution of an 
isolated increased inflammatory status without effects on plasma lipid levels to 
atherosclerosis development is unclear.
In conclusion, selective disruption of mainly the splenic parasympathetic nerve 
increases splenic immune cell counts and the systemic inflammatory status, but 
does not contribute to atherosclerotic lesion development.
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One of the first studies confirming a crucial role of the nervous system in homeostasis 
dates back to 1942 when Hetherington and Ranson described that hypothalamic 
lesioning of rats frequently causes obesity by increasing food intake and decreasing 
energy expenditure (1). In following fascinating experiments, Hervey surgically 
connected the circulatory system of hypothalamic lesioned rats via subcutaneous 
tissues to normal rats. In these parabiotic experiments, the normal rats that were 
connected to the obese rats decreased their food intake and lost weight (2). About 
35 years later, leptin was isolated and identified as the satiety signal (3) that was 
overproduced in obesity but to which hypothalamic lesioned rats could not respond.
Today, the hypothalamus and autonomic nervous system (ANS) are increasingly 
recognized as the regulators of body homeostasis and as possible treatment target 
in obesity and related disorders including type II diabetes (T2D) and cardiovascular 
disease (CVD). This thesis further revealed the role of the ANS in the control of lipid 
metabolism and inflammation, and identified pathological consequences of disturbed 
regulation. We found that mainly the parasympathetic nervous system (PNS) is 
required for maintaining anti-inflammatory reflexes, while the sympathetic nervous 
system (SNS) is highly important for energy expenditure and lipid metabolism, 
largely via regulating brown adipose tissue (BAT) activity.
Hypothalamic multi-tasking to maintain energy balance
Leptin was initially discovered as the satiety signal lacking in genetically obese 
ob/ob mice (3). More recent studies specified the central melanocortin system as 
main target of leptin (4). Leptin and other anorexigenic peptides including insulin, 
glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and cholecystokinin (CCK) act 
by activation of cocaine- and amphetamine-regulated transcript (CART)/pro-
opiomelanocortin (POMC)-expressing neurons and suppression of neuropeptide Y 
(NPY)/Agouti-related protein (AgRP)-expressing neurons, resulting in activation of 
melanocortin 4 receptor (MC4R) signalling (Figure 1). Probably because of MC4R’s 
integral role, MC4R deficiency is the most common form of monogenic obesity (5) and 
associated with increased risk of cardiovascular disease. In addition to increased 
food intake in MC4R deficient individuals, energy expenditure is lower and nutrient 
usage shifts from fatty acid oxidation towards carbohydrate oxidation (6). Similarly, 
we (Chapter 2) and others (6) have shown that inhibition of MC4R signalling in mice 
by intracerebroventricular (ICV) administration of the synthetic antagonist SHU9119 
increases food intake and weight gain, and also reduces fat oxidation. Interestingly, 
we observed that the increase in adiposity was also present in mice receiving ICV 
SHU9119 that were limited in food intake to the amount consumed by the control 
group, indicating that the reduction in fat oxidation contributes to the increase in fat 
mass. Apparently, the central melanocortin system exerts a dual-role in maintaining 
energy balance, namely by regulating energy intake as well as by regulating energy 













Figure 1 – The melanocortin system as central regulator of food intake and energy 
expenditure. See text for details. AgRP, agouti-related protein; CART, cocaine- and 
amphetamine-regulated transcript; GLP-1, glucagon-like peptide-1; MC4R, melanocortin 
4 receptor; NPY, neuropeptide Y; POMC, pro-opiomelanocortin. Red arrow, inhibition; green 
arrow, stimulation.
expenditure. Indeed, ICV administration of leptin (7), insulin (8) and GLP-1 (Chapter 3) 
result in both reduced food intake and an increase in energy expenditure, while 
ghrelin that is produced by the stomach upon fasting exerts opposing effects (9). By 
performing dedicated mechanistic experiments as described in this thesis, we now 
identifi ed regulation of BAT activity as mechanism underlying the changes in energy 
expenditure (Chapters 2 and 3).
Considering the importance of energy balance for survival, in addition to the 
response to satiety hormones, the brain also directly monitors energy status of the 
body. High energy availability drives de novo lipogenesis not only in metabolic organs 
but also in the hypothalamus, yielding increased levels of malonyl coenzyme A (CoA) 
and long-chain fatty acyl-CoAs that signal the need to reduce food intake. 
Correspondingly, ICV administration of long-chain fatty acids, e.g. oleic acid, reduces 
food intake (10). Conversely, ICV administration of inhibitors of fatty acid synthase 
(FAS) has a profound orexigenic effect (11). Interestingly, fatty acid synthesis is tightly 
regulated/inhibited by 5’ adenosine monophosphate-activated protein kinase (AMPK), 
that is a cellular energy sensor by itself being active upon low energy availability 
(high AMP/ATP). This mechanism also mediates at least part of the GLP-1-mediated 
reduction in food intake. GLP-1 signalling lowers hypothalamic AMPK activity 
thereby increasing neuronal fatty acid synthesis resulting in decreased expression 
of orexigenic peptides and increased expression of anorexigenic peptides and fi nally 
reduced food intake. Consistent with this pathway, both ICV administration of AICAR 
(potent AMPK activator) and an adenoviral vector overexpressing constitutively 
active AMPK diminish weight loss induced by the GLP-1 analogue liraglutide (12).
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So far, we have discussed that the hypothalamus monitors the body’s energy status 
directly (e.g. by fatty acid synthesis and AMPK activity) and indirectly (e.g. signaling 
induced by anorexigenic and orexigenic peptides) and responds by regulating both 
food intake and energy expenditure. This dual mode of action makes the hypothalamus 
and more specifically the melanocortin system an attractive target in the treatment 
of obesity and related disorders. In fact, GLP-1 analogues (e.g. exenatide, liraglutide 
and dulaglutide) and DPP-4 inhibitors (e.g. sitagliptin, saxagliptin and aloglipitin) that 
prevent the breakdown of GLP-1, are already implemented in the treatment of T2D. 
The potential of these drugs to prevent CVD remains to be determined and future 
studies may focus on combinations of drugs targeting multiple aspects of the central 
melanocortin system thereby enhancing efficacy.
Hypothalamic (dys)regulation of circadian rhythms
Via several pathways, feeding provides negative feedback to the hypothalamus in 
order to enhance satiety thereby reducing food intake. In addition, feeding behavior 
is a so-called Zeitgeber for the central clock, located in the suprachiasmatic nucleus 
(SCN) of the hypothalamus, and for peripheral clocks that drive circadian rhythms. In 
general, disturbed circadian rhythmicity leads to adiposity. For example, dim light at 
night (13) shifts circadian rhythmicity and increases body fat mass. When we exposed 
mice to more hours of light per day (i.e. 16 h or 24 h compared to regular 12  h), 
we observed increased adiposity (Chapter 4). Genetic mouse models of circadian 
dysfunction, among others Clockmt/mt mice (14) and Per2-/- mice (15), are also prone to 
develop obesity. Lesioning of the central circadian clock in the SCN in mice results 
in disturbed rhythmicity and an acute induction of weight gain (16). The underlying 
mechanism may include timing of feeding that is disturbed in these animal models. 
This is reflected by mouse studies showing that feeding restricted to the light phase 
(i.e. the inactive period) leads to increased body weight gain compared to dark phase 
restricted feeding (17,18). Conversely, restricting food intake to the active period of 
mice was shown to prevent diet-induced obesity (19,20).
In humans, plasma levels of lipids display diurnal variations independent of 
food intake (21), suggesting that the circadian clock is an important determinant 
of lipid levels. Consequently, disturbed rhythmicity may lead to dyslipidemia and 
eventually CVD. In fact, already in 1949 a Scandinavian observational study among 
factory workers reported an association between shift-work and cardiovascular 
mortality  (22). The underlying mechanism remained elusive. Meanwhile, the 
behavioral patterns of human activity, especially in industrialized countries, have 
undergone dramatic changes with respect to adherence to day and night rhythms. 
For example, 1) electrical light has uncoupled behavioral active period from the 
natural occurring day, 2) aircraft travel has resulted in jet-lag phenomenon, and 
3) the 24-hour economy necessitates working at night and social activities are 
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shifted, simultaneously affecting sleep duration. Notably, the increasing prevalence 
of obesity is associated with disrupted sleep-wake pattern (23) and coincides with 
the availability of artificial light (24,25). However, for these association studies, it 
is rather difficult to identify causality. For example, shift-work leads to changes in 
locomotor activity, food intake and light exposure that all potentially affect circadian 
rhythmicity, adiposity and the development of CVD. Randomized clinical trials and 
animal studies are needed to determine the contribution of the different factors to 
metabolic health and to design specific intervention strategies.
Circadian rhythms are not limited to energy metabolism but are also present 
in other factors involved in the development of CVD, including blood pressure (26), 
thrombotic factors (27) and the immune system (28). Maintenance of circadian 
rhythmicity may be an additional strategy to prevent and treat human dyslipidemia 
and CVD. This could be achieved by for example providing advice on life style changes 
regarding sleep and food intake behavior. Currently, the feasibility of extending sleep 
duration by giving sleep advice is being explored in randomized controlled trials. 
Pilot data show that sleep duration of obese individuals may be extended by from 
less than 6 hours to more than 7 hours for more than 20 nights out of 28 nights, 
resulting in body weight loss, appetite loss and improvement of sleep quality (29).
Sympathetic activation of brown fat to protect against dyslipidemia 
and CVD
Retrograde tracing in Syberian hamsters identified neuroanatomical connections 
between the SCN and BAT (30), indicating possible involvement of BAT in the 
associations between disturbed circadian rhythm and obesity. Indeed, we now 
showed that prolonging day light exposure not only changes circadian rhythmicity 
but also reduces sympathetic outflow towards BAT accompanied by decreased BAT 
activity and increased body fat mass in mice (Chapter 4). Recent evidence suggests 
that in humans, BAT activity is also physiologically regulated by the circadian clock. 
The detectability of BAT by [18F]fluorodeoxyglucose (FDG)-PET-CT imaging at room 
temperature follows a circannual cycle (31,32), with low detectability of BAT in 
summer (i.e. short day) as compared to winter (i.e. long day). Although differences in 
outside temperature over the year would be a likely explanation for this phenomenon, 
the detectability of BAT showed a stronger correlation with day length than with 
outside temperature (31). Likewise, we demonstrated that exposure of mice to short 
day length of 8 h enhances BAT activity reflected by the total daily uptake of lipids 
from the circulation when compared to 12 and 16 h of light (Chapter 5). It is tempting 
to speculate that this seasonal adaptation of BAT activity to day length precedes 
changes in temperature and thereby prepares the body for upcoming changes in 
ambient temperature. Future studies should reveal the contribution of prolonged 
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light exposure, shift-work and other circadian disturbances on human BAT function 
and metabolism.
The importance of the SNS for BAT function is reflected by the number of nerve 
endings in the tissue. Each brown adipocyte is in close proximity to a nerve ending 
that releases norepinephrine upon sympathetic activity initiated by for example 
cold exposure. In addition to its crucial role in non-shivering thermogenesis, BAT is 
probably required for maintaining energy balance and is activated upon overeating, 
a process called diet-induced thermogenesis (DIT). Although the existence of DIT is 
under debate (33), we and others have identified the central melanocortin system, 
crucial in the regulation of food intake and energy expenditure as described above, 
as an important determinant of BAT activity. Inhibition of MC4R receptor signaling 
reduces BAT activity (Chapter 2), while activation of the melanocortin system by ICV 
administration of GLP-1 (Chapter 3), insulin (34) and leptin (35) results in enhanced 
sympathetic outflow and activation of BAT. These studies suggest that reduced 
BAT activity may underlie at least part of the obese phenotype in MC4R deficient 
individuals, and underscore the potency of targeting the melanocortin system as 
therapeutic target for obesity and related disorders.
In humans, BAT activity, as quantified by [18F]FDG PET-CT scan, inversely correlates 
with body mass index and body fat mass (36-39). BAT activation by cold exposure 
alleviates hypertriglyceridemia through its large potential to take up and combust 
TG-derived fatty acids, at least in mice (40,41) and likely also in humans (37). Other 
potent BAT activators that act via the SNS are thyroid hormone (42), estradiol (43), 
nicotine (44) and bone morphogenetic protein-8 (45). Alternatively, BAT can be 
activated directly by for example metformin (46), irisin (47), salsalate (48) or CB1R 
inhibitors (Chapter 6), the latter being dependent on sympathetic signaling. Central 
and peripheral contributors to BAT activity as described within this thesis are 
summarized in Figure 2. SNS-mediated activation of BAT and subsequent lowering 
of plasma TG can be pharmacologically mimicked by β3-adrenergic receptor (β3-AR) 
agonists in mice (49,50). Interestingly, a recent study showed that the β3-AR agonist 
mirabregon acutely increases BAT activity in human volunteers. Future chronic 
studies are evidently needed to illuminate the role of β3-AR agonism in human 
obesity and hyperlipidemia.
The primacy of BAT activation on hypertriglyceridemia is clear, however, 
the effect on hypercholesterolemia, which especially underlies development 
of atherosclerosis, is less well known. Experimental studies report either 
reduced (46,51) or increased (52) levels of plasma cholesterol after BAT activation. 
Dong et al. (52) were the first to document an effect BAT activation on atherosclerosis 
development, and unexpectedly found that cold BAT activation via exposure 
aggravates atherosclerosis development in Ldlr -/- and Apoe-/- mice. However, it should 
be noted that BAT activation increases lipolytic processing of (V)LDL particles (41), 


















F igure 2 – Regulation of brown adipose tissue by central systems and peripheral 
pharmaceutical compounds. See text for details. CB1R, cannabinoid 1 receptor; 
GLP-1, glucagon-like peptide-1; MC4R, melanocortin 4 receptor; NE, norepinephrine; 
SCN, suprachiasmatic nucleus.
leading to enhanced formation of cholesterol-rich remnants that are normally taken 
up by the liver, mainly through ApoE-LDLR interactions, both of which obviously 
do not occur in Ldlr -/- and Apoe-/- mice. Strikingly, we recently showed that β3-AR 
agonism in APOE*3-Leiden.CETP mice, with functional ApoE-LDLR interactions, not 
only alleviates hypercholesterolemia but also reduces atherosclerotic lesion area 
and lesion severity (49).
The effect of BAT activation on hypercholesterolemia and atherosclerosis 
development in humans is still largely unknown as only few studies investigated the 
effect of BAT activation on plasma cholesterol levels. One study reported that subjects 
with detectable BAT have lower plasma total cholesterol and LDL-cholesterol 
levels as compared to subjects without detectable BAT (53). De Lorenzo et al. (54) 
showed that daily cold exposure of 20 min for 90 days reduced total cholesterol, LDL-
cholesterol and body mass in hypercholesterolemic patients. These data show that 
SNS-mediated BAT activation may also improve hypercholesterolemia in humans 
and underscore its potential as anti-atherogenic treatment as well.
Modulation of the immune response by the autonomic nervous 
system
Metabolic regulation and infl ammatory responses are highly integrated. Salsalate and 
its derivative salicylate not only activate BAT, but also reduce NF-κB activity thereby 
lowering infl ammation (48) and atherosclerosis (55). Anti-infl ammatory processes 
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allow skewing of macrophages from M1 macrophages to norepinephrine-producing 
M2 macrophages in BAT, thereby inducing similar responses as via SNS-mediated 
BAT activation (56). The ANS itself exerts a complex control on inflammation, which 
depends on bidirectional communication between the brain and the immune system. 
Lymphoid organs such as bone marrow and the spleen are mainly innervated by 
sympathetic noradrenergic neurons. Primary afferent visceral neurons are often 
not labelled parasympathetic or sympathetic but do form reflex circuits with the 
autonomic pathways. Neuroanatomical evidence is limited for the involvement of 
the parasympathetic nerves in immune organs and its functional existence is highly 
under debate (57). However, electrical stimulation of the vagus nerve does inhibit 
pro-inflammatory responses (58) and recent studies indicate evidence for presence 
and functional activity of parasympathetic branches in the spleen (59,60). We now 
observed that surgical dissection of these splenic parasympathetic nerves enhanced 
inflammation in mice (Chapter 8), consistent with disruption of the cholinergic anti-
inflammatory reflex as proposed by Tracey et al. (61) and the pro-inflammatory 
effects of hematopoietic α7nAChR deficiency (Chapter 7). In addition, hematopoietic 
α7nAChR deficiency resulted in a higher activation status of platelets. Regulation 
of the immune response by autonomic reflexes as described within this thesis are 
summarized in Figure 3.
As the ANS mainly responds to pro-inflammatory cytokines, pharmaceutical 
targeting of these systems to reduce inflammation does not seem feasible. 
Surprisingly, training of the ANS by meditation, breathing techniques, and exposure 
to cold (i.e. immersions in ice cold water) results in increased plasma epinephrine 
levels and reduced inflammation upon endotoxemia (62). However, it remains to be 
determined whether such an intervention can be used to prevent or treat chronic 
inflammation as is often the case in obesity or during atherosclerosis development. 












Figure 3 – Regulation of the immune response by autonomic reflexes and pharmaceutical 
compounds. See text for details. α7nAChR, α7 nicotinic acetylcholine receptor; ACh, 
acetylcholine; IL-1β, interleukin-1β; IL-6, interleukin-6; TNFα, tumor necrosis factor α.
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Currently large-scale phase III trials with cardiovascular events as end-
point are underway for drug agents that reduce IL-6 and C-reactive protein (e.g. 
canakinumab and low dose methotrexate). Pre-clinical studies suggest that at 
least part of the anti-inflammatory and atheroprotective effects of methotrexate in 
mouse models result from increased adenosine release and subsequent activation 
of the A2A-receptor leading to enhanced reverse-cholesterol transport and reduced 
foam-cell formation (63). Combined with the observation that A2A-receptor agonists 
activate BAT (64), these studies indicate that A2A-receptor agonism is a potential 
treatment target for CVD. Unfortunately, many A2A-receptor ligands are known to 
alter cardiac function.
Concluding remarks
The central nervous system is an important regulator of lipid metabolism and 
inflammation. The fact that many of the systems involved, including the melanocortin 
system, exert multiple modes of action, makes these systems attractive and 
powerful targets for obesity and related disorders. Although pharmaceutical 
targeting of the brain appears to be difficult in humans, one may circumvent this 
by improving circadian rhythmicity, training the ANS by cold exposure, or the use 
of sympathomimetic compounds. Additionally, several unique approaches have 
been developed including combinatorial compounds (65) and nanoparticles (66) to 
specifically target hypothalamic sites.
Since its (re-)discovery in 2009, BAT became a hot research topic in the field of 
metabolism. Pre-clinical studies, including those described in this thesis, have shown 
that BAT activation protects against obesity, dyslipidemia and even atherosclerosis. 
So far only a couple of studies explored the metabolic benefits of BAT activation 
in humans. Future studies should elucidate to what extent the promising results 
obtained in animal studies can be extrapolated to the treatment of human obesity 
and related disorders.
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Cardiovascular disease (CVD) is currently the leading cause of morbidity and 
mortality in our Western society. The main cause of CVD is atherosclerosis, for 
which dyslipidemia and inflammation are major risk factors. The autonomic nervous 
system (ANS) is known to innervate key organs involved in lipid metabolism and 
immune responses, and is therefore a potential target to prevent or treat CVD. 
In Chapter 1 we provide an overview of the autonomic control of energy homeostasis, 
inflammatory reflexes and the potential interactions.
The hypothalamus, particularly the melanocortin system, integrates nutritional 
information originating from peripheral organs mediated through circulating 
hormones and metabolites.  It responds by regulating food intake and energy 
expenditure. In Chapter 2 we set out to investigate the underlying mechanism of 
the association between melanocortin 4 receptor (MC4R) deficiency and reduction in 
energy expenditure. We continuously infused the MC4R antagonist SHU9119 or vehicle 
into the lateral ventricle of mice for two weeks. We found that SHU9119 increased 
food intake and body weight, and markedly diminished fat oxidation and the uptake 
of [3H]oleate from glycerol tri[3H]oleate-labeled lipoprotein-like emulsion particles 
by brown adipose tissue (BAT). In BAT, SHU9119 decreased uncoupling protein-1 
(UCP1) protein levels resulting in a lower core body temperature. All of these effects 
were independent of the increased food intake as mice that received SHU9119 while 
being pair-fed to the vehicle treated group still exhibited these effects. We concluded 
that inhibition of the MC4R signalling impairs BAT function accompanied by reduced 
energy expenditure thereby promoting adiposity.
Next, in Chapter 3, we determined the potential beneficial metabolic effects 
of activation of the melanocortin system by the glucagon-like peptide-1 (GLP-1) 
analogue exendin-4. Chronic central infusion of exendin-4 enhanced sympathetic 
outflow towards BAT and increased the UCP1 content in BAT in both lean and diet-
induced obese mice. This activation of BAT was accompanied by enhanced uptake 
of fatty acids from glycerol tri[3H]oleate-labeled lipopoprotein-like emulsion 
particles and [14C]deoxyglucose by BAT, resulting in lower plasma TG and glucose 
concentrations, and reduced body weight. Pair-fed animals were included during 
all experiments to confirm that regulation of BAT by the central melanocortin 
system was independent of food intake. Collectively, these data suggest that 
BAT is a major contributor in the regulation of energy expenditure by the central 
melanocortin system and we anticipate that activation of this system, e.g. by GLP1 
receptor activation, is a promising strategy to combat obesity and related disorders 
by increasing BAT activity.
Another brain region that is highly involved in regulation of lipid metabolism is the 
suprachiasmatic nucleus (SCN) that drives circadian rhythms. In general, disturbed 
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circadian rhythmicity is associated with obesity and related disorders such as CVD. 
Specifically, prolonged artificial light exposure associates with obesity in humans. 
In Chapter 4 we aimed to investigate the underlying mechanism in an experimental 
mouse study. Mice were exposed to prolonged 16 h or 24 h of light per day and effects 
were compared to exposure to 12 h of light per day. Increasing the daily light exposure 
for 5 weeks increased body fat mass without affecting food intake or locomotor 
activity. Mechanistically, we demonstrated that prolonged light exposure decreases 
sympathetic input into BAT, reduces β3-adrenergic intracellular signalling as well as 
the uptake of fatty acids from glycerol tri[3H]oleate-labeled lipoprotein-like emulsion 
particles and [14C]deoxyglucose by BAT. Surgical sympathetic denervation of BAT 
completely abolished effects of light exposure on the uptake of [3H]oleate by BAT, 
indicating a crucial role for the sympathetic nervous system (SNS). We concluded 
that impaired BAT activity is an important mediator in the association between 
disturbed circadian rhythm and adiposity and anticipate that activation of BAT may 
overcome the adverse metabolic consequences of disturbed circadian rhythmicity.
Activity of the SCN adapts to seasonal changes in light exposure. Interestingly, 
detectability of human BAT by [18F]fluorodeoxyglucose (FDG) PET-CET scans at room 
temperature follows a circannual cycle, with low detectability of BAT in summer 
as compared to winter. Although differences in outside temperature over the year 
would be a likely explanation for this phenomenon, the detectability of BAT showed 
a stronger correlation with daily light exposure than with outside temperature. 
In Chapter 5, we evaluated this relationship in mice that were exposed to 8 h, 
12 h or 16 h of light per day. The uptake of [3H]oleate by BAT from glycerol tri[3H]
oleate-labeled lipoprotein-like emulsion particles showed a strong daily rhythm. 
Additionally, expression of genes involved in thermogenesis revealed comparable 
patterns, mostly the expression being highest at the end of the resting phase. 
Strikingly, compared to 12 h, the rhythmicity of BAT was highest in mice exposed to 
8 h of light per day, accompanied by an increased overall uptake of [3H]oleate by BAT 
while 16 h of light per day markedly flattened the rhythm and lowered overall uptake 
of [3H]oleate by BAT.
Rimonabant is a systemic cannabinoid 1 receptor (CB1R) blocker that induces 
sustained weight loss and lowering of plasma TG levels in obese patients. 
In Chapter 6, we determined whether the beneficial metabolic effects of rimonabant 
were due to activation of BAT. Diet-induced obese mice were treated with rimonabant, 
resulting in lowered body weight and enhanced energy expenditure accompanied 
by increased uptake of [3H]oleate from glycerol tri[3H]oleate-labeled lipoprotein-
like emulsion particles by BAT. Of note, these results could be fully recapitulated at 
thermoneutral temperature, which reduces symnpathetic outflow to BAT, suggesting 
that the mechanism involves direct rather than SNS-mediated activation of BAT. 
Indeed, we demonstrated that the CB1R is expressed in BAT and that blockade of the 
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CB1R in cultured brown adipocytes in vitro increases UCP1 content and intracellular 
lipolysis. Furthermore, treatment of mice with the peripheral CB1R antagonist 
AM6545 resulted in comparable lowering of body weight and activation of BAT. Taken 
together we concluded that the TG-lowering effect of rimonabant is due to peripheral 
blockade of the CB1R on BAT.
Part II of this thesis describes studies on the regulation of inflammation by the ANS, 
with focus on the cholinergic anti-inflammatory reflex. In this reflex, acetylcholine 
is released upon ANS activity and stimulates α7AChR, which is highly expressed 
on immune cells and platelets, resulting in attenuation of NF-κB-mediated gene 
expression of pro-inflammatory cytokines. In Chapter 7, we studied the effects 
of hematopoietic α7 nicotinic acetylcholine receptor (α7nAChR) deficiency on 
inflammation, platelet activation status and atherosclerosis in Ldlr -/- mice. To this 
end, bone marrow from α7nAChR-/- or wildtype mice was transplanted into Ldlr -/- 
mice. Hematopoietic α7nAChR deficiency increased the number of leukocytes in the 
peritoneum, lymph nodes, spleen and blood accompanied by increased expression 
of pro-inflammatory cytokines in spleen and peritoneal leukocytes. Additionally, 
we found increased activation status of platelets. Likewise, incubation of human 
platelets with an a7nAChR agonist decreased aggregation. Despite the large effects 
of hematopoietic α7nAChR deficiency on inflammatory status and platelet function, it 
did not affect atherosclerosis development or composition of lesions.
The cholinergic anti-inflammatory reflex is proposed to act mainly via the spleen. 
Therefore, in Chapter 8, we assessed the effects of selective parasympathetic and 
sympathetic denervation of the spleen on inflammation and atherosclerotic lesion 
development in APOE*3-Leiden.CETP mice. Selective parasympathetic denervation 
increased leukocyte counts in the spleen and increased gene expression of pro-
inflammatory cytokines in the liver and in peritoneal leukocytes as compared to 
sympathetic denervation and sham surgery. Further, plasma levels of IL-6 and IL-
1β were increased in parasympathetically denervated mice. However, the increased 
pro-inflammatory status in parasympathetically denervated mice did not affect 
atherosclerotic lesion size or lesion composition.
Finally, we evaluated the results of this thesis in Chapter 9 and discussed the potency 
of targeting the ANS for treatment of obesity and CVD, with special attention for BAT 
activation as a highly relevant and emerging pharmaceutical target. Collectively, the 
studies described in this thesis have increased our insight into regulation of energy 
metabolism and inflammation by the ANS.
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Hart- en vaatziekten zijn de voornaamste doodsoorzaak in de wereld op het moment 
van schrijven. Zij zijn vaak het gevolg van vernauwing van bloedvaten door plaatselijke 
ontstekingen en ophopingen van vetten. Dit proces noemen ook wel aderverkalking of 
‘atherosclerose’. Onderzoek in de afgelopen jaren heeft aangetoond dat de hersenen, 
ofwel het ‘centrale zenuwstelsel’, een belangrijke rol spelen bij het aansturen van 
de verwerking van vetten door het lichaam en het moduleren van ontstekingen. Deze 
processen vinden onbewust plaats en worden gecontroleerd door het autonome 
zenuwstelsel, een onderdeel van het centrale zenuwstelsel. In dit proefschrift werd 
de manier waarop het autonome zenuwstelsel dit doet bestudeerd, wat mogelijk 
resulteert in nieuwe aangrijpingspunten in de preventie en behandeling van hart- en 
vaatziekten.
Hoofdstuk 1 geeft een algemene introductie op de onderwerpen die besproken 
worden in dit proefschrift. Hierin wordt onder andere beschreven dat obesitas 
een belangrijke risicofactor vormt voor het ontwikkelen van hart- en vaatziekten. 
Obesitas ontstaat door een ‘positieve energiebalans’, waarbij de voedselinname 
groter is dan het energieverbruik. Onderzoek aan systemen die voedselinname 
en energieverbruik regelen kan daarom belangrijke informatie opleveren die niet 
alleen gebruikt kan worden in de strijd tegen obesitas, maar ook in de strijd tegen 
hart- en vaatziekten. Daarnaast wordt de functie van bruin vet beschreven. Bruin vet 
is een uniek orgaan dat in pasgeboren kinderen en in kleine zoogdieren een cruciale 
rol speelt bij het handhaven van de lichaamstemperatuur. Omdat baby’s een relatief 
groot lichaamsoppervlak hebben waardoor relatief veel warmte wordt afgegeven 
aan de omgeving dient bruin vet warmte te genereren. Bruin vet heeft de unieke 
eigenschap om energie die opgeslagen is in vet en suiker te verbranden tot warmte, 
ofwel ‘thermogenese’. Hiertoe bevatten bruine vetcellen het ontkoppelingseiwit 
UCP1. Pas recent is ontdekt dat bruin vet ook aanwezig én actief is in volwassen en 
geactiveerd wordt door blootstelling aan een lage omgevingstemperatuur.
Obesitas is in sommige gevallen erfelijk. Mutaties in het gen dat codeert voor de 
melanocortine 4 receptor (MC4R), wat leidt tot deficiënte voor dit eiwit, vormen de 
meest voorkomende erfelijke oorzaak van obesitas. Het niet goed functioneren of 
ontbreken van de MC4R in mensen resulteert niet alleen in verhoogde eetlust maar 
vermindert ook het energieverbruik. In Hoofdstuk 2 onderzochten we in muizen 
het mechanisme waardoor MC4R-deficiëntie het energieverbruik vermindert door 
een remmer van de MC4R te infunderen in de hersenen. Infusie van de remmer 
resulteerde in snelle gewichtstoename wat gepaard ging met een toename van 
de voedselinname en een afname in het energieverbruik. We toonden aan dat de 
verlaging in het energieverbruik veroorzaakt werd door verminderde activiteit van 
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het sympathische zenuwstelsel, onderdeel van het autonome zenuwstelsel, vanuit 
de hersenen richting het bruin vet. Dit heeft tot gevolg dat het bruin vet minder actief 
is, wat bleek uit minder expressie van UCP1 en een ophoping van vet in het bruin 
vet weefsel, waardoor het minder vetten kon opnemen vanuit de bloedbaan. Om 
specifiek de bijdrage van het bruin vet in de gewichtstoename te onderzoeken hebben 
we muizen die behandeld werden met de MC4R remmer op dieet gezet waarbij de 
muizen precies evenveel aten als de muizen in de controlegroep. Uit dit experiment 
konden bleek dat remming van de MC4R gewichtstoename gaf onafhankelijk van 
de voedselinname, wat zeer waarschijnlijk werd veroorzaakt door een verlaagde 
activiteit van het bruin vet. We concludeerden dat het melanocortinesysteem, 
waarvan MC4R deel uitmaakt, een dubbele rol vervult: enerzijds reguleert het de 
eetlust en anderzijds reguleert het energieverbruik door de activiteit van bruin vet 
te moduleren.
Deze dubbele rol van het melanocortinesysteem maakt dit systeem een 
aantrekkelijk aangrijpingspunt voor medicatie. Het melanocortinesysteem wordt 
geactiveerd door onder andere hormonen die vrijkomen bij voedselinname, namelijk 
leptine, insuline en het zogenaamde glucagon-like peptide 1 (GLP-1). Momenteel 
worden analoga van GLP-1 zoals ‘exenatide’ ofwel ‘exendin-4’ ontwikkeld voor 
de behandeling van type 2 diabetes (T2D). Het was al bekend dat deze middelen 
gewichtsafname geven, maar het precieze mechanisme was nog onbekend. Vanuit 
de resultaten die beschreven zijn in hoofdstuk 2 was onze hypothese dat exendin-4 
bruin vet zou kunnen activeren. Om dit te onderzoeken hebben we in Hoofdstuk 3 
exendin-4 direct in de hersenen van muizen geïnfundeerd. Dit resulteerde in een 
afname van lichaamsgewicht wat veroorzaakt werd door een selectieve afname van 
lichaamsvet, en ging gepaard met verlaging van de voedselinname en een toename 
in energieverbruik. Mechanistisch onderzoek toonde aan dat de sympathische 
signalering vanuit de hersenen naar bruin vet was verhoogd. Dit leidde tot een 
verhoogde aanwezigheid van UCP1 in bruin vet en verhoogde de opname van vetten 
en glucose uit het bloed door bruin vet. Deze gunstige resultaten vonden we niet 
alleen in slanke muizen, maar ook in obese muizen die insulineresistent zijn. Deze 
studie geeft aan dat de gunstige effecten van GLP-1 analoga op de stofwisseling in 
T2D patiënten deels verklaard zouden kunnen worden door activatie van het bruin 
vet.
Een ander belangrijk systeem in de hersenen, de centrale biologische klok, regelt 
het dag- en nachtritme van het lichaam dat ook wel het ‘circadiane ritme’ wordt 
genoemd. Verstoringen van dit ritme als gevolg van bijvoorbeeld ploegendiensten, 
zijn geassocieerd met de ontwikkeling van obesitas en hart- en vaatziekten. Mogelijke 
oorzaken hiervoor zijn het verstoren van het slaap-, activiteits-, en eetpatroon, dan 
wel blootstelling aan licht op ongebruikelijke tijdstippen. Een recent onderzoek 
heeft laten zien dat er een relatie is tussen blootstelling aan licht in de nacht en 
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het lichaamsgewicht van mensen, maar een oorzakelijk verband en onderliggende 
mechanismen waren nog niet aangetoond. Om dit te onderzoeken hebben we in 
Hoofdstuk 4 muizen blootgesteld aan een verschillend aantal uren licht per etmaal: 
12 uur, 16 uur of 24 uur. We toonden aan dat met een langere lichtperiode per etmaal 
de hoeveelheid lichaamsvet toeneemt terwijl de muizen niet meer aten of minder 
bewogen. Ook hier bleek activiteit van bruin vet een cruciale factor. Hoe langer 
de lichtperiode, hoe lager de sympathische signalering vanuit de hersenen naar 
het bruin vet en hoe minder het bruin vet in staat is om vetten en glucose uit de 
bloedbaan op te nemen en te verbranden. We concludeerden dat een optimaal dag- 
en nachtritme cruciaal is voor een hoge activiteit van bruin vet.
In mensen kan bruin vet zichtbaar gemaakt worden door opname van een 
radioactief glucose-analoog te detecteren met PET-CT scans die ook worden 
uitgevoerd voor diagnostische doeleinden in de oncologie. Interessant is dat, 
wanneer men PET-CT scans over het jaar heen bekijkt, bruin vet vaker detecteerbaar 
is in de winter- dan in de zomermaanden. Dit kan natuurlijk veroorzaakt worden 
door de lage temperatuur in deze maanden. Echter, de detecteerbaarheid van bruin 
vet bleek beter overeen te komen met de lengte van de lichtperiode dan met de 
buitentemperatuur. In Hoofdstuk 5 onderzochten we de effecten van blootstelling 
aan een korte lichtperiode (8 uur per etmaal, overeenkomend met de winter) en 
een lange lichtperiode (16 uur per etmaal, overeenkomend met de zomer) op de 
activiteit van bruin vet in muizen. Terwijl blootstelling aan een lange lichtperiode de 
functie van bruin vet verminderde, overeenkomend met bevindingen uit Hoofdstuk 4, 
resulteerde blootstelling aan een korte lichtperiode in een verhoogde activiteit van 
het bruin vet. Deze observaties suggereren dat het korter worden van de dagen bij 
het naderen van de winter de activiteit van het bruin vet verhoogt om het organisme 
voor te bereiden op een lagere omgevingstemperatuur. Daarnaast onderzochten we 
de activiteit van bruin vet over de dag in de muizen en toonden aan we dat bruin vet 
het meest actief is als de muizen ontwaken aan het einde van de rustperiode.
Naast lichaamseigen eiwitten en de biologische klok werd onderzoek gedaan 
naar stoffen die bruin vet kunnen activeren. Rimonabant is een geneesmiddel dat op 
de markt was voor patiënten met sterk overgewicht en T2D. Rimonabant verlaagde 
niet alleen het lichaamsgewicht maar verbeterde ook risicofactoren voor hart- 
en vaatziekten. Binnen een jaar is rimonabant echter weer van de markt gehaald 
doordat het ernstige bijwerkingen had waaronder depressie. Desalniettemin is 
het interessant om te achterhalen hoe rimonabant deze gunstige effecten op de 
stofwisseling teweegbrengt. Hiertoe behandelden we obese muizen met rimonabant 
zoals beschreven in Hoofdstuk 6. Ook in muizen induceerde rimonabant een 
aanzienlijk gewichtsverlies en verbeterde het de bloedwaardes van vetten. Dit 
bleek het gevolg van een verhoogde opname van vetten door bruin vet weefsel. 
Deze  effecten bleven zelfs aanwezig wanneer de signalering tussen hersenen en 
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bruin vet minimaal was: een zogenaamde ‘thermoneutrale’ omgevingstemperatuur 
waarbij bruin vet in principe geen warmte hoeft te genereren voor het handhaven 
van de lichaamstemperatuur. Deze bevinding suggereerde dat rimonabant bruin 
vet direct zou kunnen activeren. Inderdaad konden we aantonen dat het eiwit waar 
rimonabant aan bindt, de cannabinoid 1 receptor (CB1R), niet alleen in de hersenen 
voorkomt maar ook in bruin vet. Om nog een stap verder te gaan gebruikten we in 
een nieuwe experiment een ander middel dat op rimonabant lijkt maar de hersenen 
niet kan binnendringen. Ook dit middel activeerde bruin vet en veroorzaakte 
gewichtsverlies. We concludeerden dan ook dat het eiwit waar rimonabant aan 
bindt een veelbelovend farmacologisch aangrijpingspunt is voor de behandeling van 
obesitas en mogelijk ook hart- en vaatziekten.
In het tweede deel van dit proefschrift wordt dieper ingegaan op de controle 
van ontstekingsprocessen door het autonome zenuwstelsel. De α7 nicotinerge 
acetylcholine receptor (α7nAChR) is een eiwit dat aanwezig is op verschillende cellen 
van het immuunsysteem en dat geactiveerd kan worden door signalen vanuit het 
autonome zenuwstelsel. Activatie van dit eiwit onderdrukt ontstekingsprocessen. 
In Hoofdstuk 7 onderzochten we de gevolgen van het ontbreken van deze receptor op 
immuuncellen voor de ontwikkeling van aderverkalking in muizen. We toonden aan 
dat het aantal witte bloedcellen in verschillende organen verhoogd was en dat die 
cellen ook actiever waren. Daarnaast waren bloedplaatjes ook in een hogere staat 
van paraatheid. Ondanks deze effecten op het immuunsysteem, vonden we geen 
nadelige gevolgen voor aderverkalking.
De milt is een belangrijk orgaan waar signalen vanuit het autonome zenuwstelsel 
bestemd voor immuuncellen vrijkomen. Deze signalen bereiken de milt via 
twee typen zenuwbanen, namelijk sympathische zenuwbanen en parasympatische 
zenuwbanen. In de studie beschreven in Hoofdstuk 8 onderzochten we de effecten 
van het chirurgisch verbreken van deze zenuwbanen op het immuunsysteem en 
de ontwikkeling van aderverkalking. Terwijl het verbreken van sympathische 
signalering nauwelijks effect had op immuuncellen, resulteerde het verbreken 
van parasympatische signalering in een verhoogd aantal immuuncellen in de milt. 
Verder resulteerde het verwijderen van zowel sympathische als parasympathische 
zenuwbanen tot een verhoogde productie van inflammatoire moleculen, zogenaamde 
cytokines. Echter, ook deze ingreep bleek geen gevolgen te hebben voor het ontstaan 
van aderverkalking.
Tot slot worden in Hoofdstuk 9 alle resultaten bediscussieerd en de mogelijkheden 
besproken van nieuwe therapieën voor de preventie en behandeling van obesitas 
en verwante ziektebeelden als T2D en hart- en vaatziekten. Samenvattend hebben 
we aangetoond dat de hersenen, en meer specifiek het autonome zenuwstelsel, een 
belangrijke rol spelen bij de verwerking van vetten in het lichaam en de modulatie 
van ontstekingsreacties. Wanneer dergelijke processen verstoord worden kan 
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dit resulteren in obesitas en mogelijk in hart- en vaatziekten. Daarnaast laten we 
zien dat activatie van bruin vet een veelbelovend aangrijpingspunt kan zijn om het 
energieverbruik te verhogen en obesitas tegen te gaan. Recent hebben we ook in 
muizen aangetoond dat activatie van bruin vet aderverkalking kan voorkomen. 
Momenteel wordt zowel door anderen als door onze groep veel onderzoek gedaan 
naar de mogelijk gunstige effecten van activatie van bruin vet op de stofwisseling in 
de mens.
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UITNODIGING
U bent van harte welkom 
voor het bijwonen van de 








Op woensdag 18 november 
2015 om 13.45 uur in het 
Groot Auditorium van het 
Academiegebouw, 
Rapenburg 73 te Leiden
Geïnteresseerden zijn 
van harte welkom om het 
‘lekenpraatje’ bij te wonen dat 
zal aanvangen om 12.45 uur 
in het Klein Auditorium van 
het Academiegebouw.
Na afloop van de promotie 
bent u van harte welkom op de 
receptie, deze zal plaatsvinden 
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